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Carbohydrate – receptor interactions are often involved in the attachment of viruses to host cells, 
and this docking is a necessary step in the virus life cycle that precedes infection and, ultimately, 
replication. Despite the conserved structures of the glycans involved in docking, they are still 
considered “undruggable”, meaning these glycans are beyond the scope of conventional 
pharmacological strategies. Recent advances in the development of synthetic carbohydrate 
receptors (SCRs) – small molecules that bind carbohydrates – could bring carbohydrate-receptor 
interactions within the purview of druggable targets. Here we discuss the role of carbohydrate-
receptor interactions in viral infection, the evolution of SCRs, and recent results demonstrating 
their ability to prevent viral infections in vitro. Common SCR design strategies based on boronic-
ester formation, metal chelation, and noncovalent interactions are discussed. The benefits of 
incorporating the idiosyncrasies of natural glycan binding proteins – including flexibility, 
cooperativity, and multivalency – into SCR design to achieve non-glucosidic specificity are 
shown. These studies into SCR design and binding could lead to new strategies to mitigate the 
grave threat to human health posed by enveloped viruses, which are heavily glycosylated viroids 
that are the cause of some of the most pressing and untreatable diseases, including HIV, Dengue, 
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Small Molecule Synthetic Carbohydrate Receptors 
Chapter 1:  
 
Contents of this chapter are adapted from the submitted paper: “Flexible Synthetic 
Carbohydrate Receptors as Inhibitors of Viral Attachment” 
 





1.1. The Role of Surface Glycans in Disease                     
Binding events occurring on the glycocalyx1-3 – the layer of glycolipids, glycoproteins, and 
glycopolymers on the surface of all eukaryotic cells as well as many bacteria and viruses – are involved in 
cell-cell communication,4-5 cell differentiation,6 cell-pathogen interactions,7 immune response,4, 7 disease 
progression,7 and many other essential biological processes.8 Glycan expression and composition in the 
glycocalyx have been correlated to developmental status,9-10 cell type,11 and the disease state of a cell.12-13 
For example, α-mannose is overexpressed on the surface of human liver,14 lung,15 and prostate16 cancer 
cells, while β-galactose and N-acetylglucosamine are overexpressed on the surface of skin malignant 
melanoma cells,17-18  as well as human testicular,19 brain,20 and white blood21 cancer cells. In other words, 
each cell type displays a specific glycosylation pattern that communicates information about the cell to the 
biological milieu, like a cell-specific fingerprint. These cell-, tissue-, and species-specific inventories of 
glycans comprise the “sugar code”,3 but much of this encoded information remains undeciphered, leaving 
critical gaps in knowledge about biological processes and networks that could be exploited to treat disease. 
Thus, there remains a need for new tools to analyze and utilize the information buried within the glycocalyx. 
Small molecule receptors that bind these fingerprint glycocalyx glycans could be one such tool for 
identifying cell or virus type, revealing fundamental aspects of glycan binding, or be used for disease 
diagnosis, as drug-delivery agents, or as therapeutics that operate by competitively inhibiting glycan 
interactions.22 
A topic that is the subject of rapidly increasing research interest is viral glycobiology,23-25 where 
the focus is on recognition events between glycans and receptors that have a central role in the viral life 
cycle. The interaction between the virus and the host occur through the association between glycans with 
glycan binding proteins (GBPs), which include lectins, periplasmic binding proteins, and 
glycosaminoglycan-binding proteins.10 A unique aspect of GBPs is that they often possess multiple 
individual glycan-binding domains26 that typically recognize a glycan substructure of 2 – 5 
monosaccharides. The binding affinity and specificity for a given glycan-binding domain to a glycan 
substructures is typically weak in solution (Kd values in the high micromolar to low millimolar range),10 
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but avidity is enhanced through multivalency that occurs the cell or viral surface or within the dense 
glycocalyx, where multiple sugar units bind to different sites on the GBP.26-27 
Understanding how these binding processes are involved in pathogen infection and reproduction 
could lead to new and desperately needed antiviral agents to counter the threat of viral outbreaks, especially 
those posed by enveloped viruses (EnV). EnV constitute a broad class of viruses that include retroviruses 
(HIV, hepatitis B), flaviviruses (dengue, hepatitis C, yellow fever, Japanese encephalitis, Zika), 
orthomyxoviruses (influenza A – C), filoviruses (Ebola, Marburg fever), and coronaviruses (SARS-COV-
2, SARS, MERS), among others.28 The glycans can be either on proteins on the viral envelope or on the 
cell of the host. Host membrane glycans that serve as attachment factors for viral glycoprotein receptors in 
several well-known diseases include N-linked glycans terminated by α2,3 or α2,6-linked sialic acid that are 
targets for influenza virus GBPs29 and sulfated glucosaminoglycans, such as heparin sulfate, that are co-
receptors for the herpes simplex,30 dengue,31-32 hepatitis C,33 and foot-and-mouth disease viruses.34 In 
addition, viral entry can be facilitated by binding between receptor domains in the host cell protein DC-
SIGN to oligomannosides on the viral envelope with α(1,6) linked backbones and α(1,2) and α(1,3) linked 
branches (Figure 1.1.A).35-36 Examples of diseases where DC-SIGN facilitates viral entry include HIV-1,37-
39 Ebola,37 Zika,40 and Dengue.39, 41-42 Other classic examples of glycan recognition include the interaction 
between the foot-and-mouth-disease virus αvβ6 integrin protein and  biomimetic heparan sulfate (HS) 
(Figure 1.1.B).43 Glycan expression determines the ability of viruses and bacteria to infect a specific cell-
type. For example, sialic acids on the surface of tracheal epithelial cells are correlated with the influenza 
receptor binding preference, as such the glycan display of the cells determines which of those cell-types in 
the upper respiratory tract host the virus.44 For example, avian influenza A viruses bind preferentially to 
α2,3 sialic acid, whereas human influenza A preferentially binds α2,6 sialic acids,45 (Figure 1.1.C and 
1.1.D, respectively), and this difference determines the species affected by the virus, as well as the tissue 
preference.46-47 Some bacteria also take advantage of glycan recognition to infect different tissues. The 
uropathogenic E. coli, for example, recognizes galactose in the urinary track epithelium,48 whereas the 





Figure 1.1. Examples of receptor-glycan interactions that account for viral docking. A) Dengue virus 
mannoside binding to the dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin 
(DC-SIGN) (PDB:1K9I).50 B) Binding of foot-and-mouth-disease virus αvβ6 integrin to biomimetic 
heparan sulfate (PDB:1QQP).43 C) Receptor-binding pocket of H5N1 Y161A influenza virus 
hemagglutinin binding to α2,3 sialic acid (PDB:6E7H).51 D) Receptor-binding pocket of H1 influenza virus 
hemagglutinin binding to α2,6 sialic acid (PDB: 1RVZ).52  
 
In the context of their role in the viral life-cycle, these binding events between host glycans and 
viral proteins, or vice-versa, precede membrane fusion, viral entry, and, ultimately, replication.53 During 
replication, EnV harness the membrane from the infected host cell in a process called "budding off", where 
newly formed virus particles become "enveloped" or wrapped in an outer coat that is made from a fragment 
of the cell's glycosylated lipid bilayer.54 This envelope is believed to play a role in helping EnV evade the 
host immune response, as a consequence of the EnV displaying to the milieu components that originate 
from the hosts’ own cell membranes. The viral surface is covered in glycoproteins whose glycan 
components account for ~25% of the protein mass.55 During replication EnV exploit the machinery of the 
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host cell to further glycosylate their envelope proteins with the host glycans, and these glycans act as 
camouflage so the viruses can evade the host immune system and inject their genetic materials into the 
host.56 This process results in an extensive assortment of different classes of viral glycans, including 
oligomannosides as well as hybrid and complex-type N-glycan structures.55 The viral O-linked 
glycosylation pathway is initiated by a family of transferases that covalently link an N-acetylgalactosamine 
(GalNAc) monosaccharide to serine (Ser), threonine (Thr), and tyrosine (Tyr) residues, structures which 
are referred to as the Tn antigen.10 Following this conjugation, a series of glycosyltransferases can act upon 
the primary GalNAc residue to generate the O-linked glucosaminoglycans (GAGs) at the Golgi apparatus.55 
The O-linked glycans include GAGs that are complex linear polysaccharides that are abundant in glucose, 
N-acetylglucosamine, galactose, and N-acetylgalactosamine residues.10 These cell-surface GAGs expressed 
are also subverted in the viral entry process, typically as co-receptors,57 or “possible accessible factors”58 
meaning they are work in combination with a main receptor to facilitate viral entry into the host cell. In 
addition, GAGs also serve as cofactors in major viral pathogens including Zika virus,59 herpes simplex 
virus,60 Merkel cell polyomavirus,61 and even other noteworthy dermal pathogens such as Leishmania 
(parasitic),62 Group A Streptococci, S. aureus (bacterial),63 and Candida (fungal).64 Other noteworthy 
examples of co-receptors that rely upon glycan-GBP interactions include the densely glycosylated viral 
surface spike glycoprotein (S) that binds to the human receptor angiotensin-converting enzyme 2 (ACE2) 
as the first step in viral entry of SARS-CoV,65 and SARS-CoV-2.66 
In eukaryotic cells, N-linked glycans are attached to asparagine (Asn) residues of glycoproteins 
through an N-linked trimannosylchitobiose fragment (GlcNAc2Man3).67 Thus, all of the N-glycans on the 
surfaces of EnV are linked to the membrane proteins through this conserved GlcNAc2Man3 fragment. Given 
the prevalence of glycans possessing the GlcNAc2Man3 fragment in viral development, this oligosaccharide 
fragment is a very compelling target for antivirals, who’s binding to this glycan substructure would 
competitively inhibit interactions between viruses and the host cells and thereby prevent infection by 
disrupting membrane fusion or viral endocytosis. Despite the central role of N-glycans in the viral life cycle 
they are still considered “undruggable targets”, meaning it is not believed that they can be targeted 
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pharmacologically with a reasonable amount of time, effort, and money.68 In the conventional rule-of-five 
drug-design paradigm,69 a drug fits into the binding site of a protein, thereby interfering with the enzymatic 
function. GBPs, however, do not readily interact with small molecule drugs,68 and “proteins lacking an 
enzymatically active site are generally not considered pharmacologically vulnerable under the current 
inhibitor paradigm and are therefore labeled undruggable”.22 Further, it has been stated that “carbohydrates 
make problematic drug targets; they are the most difficult biological molecules to analyze and synthesize, 
and are rapidly broken down in the bloodstream”.70 Another challenge when attempting to target cell-
surface glycans is that they may only differ from a non-target glycan by the orientation of a single 
stereocenter in structurally complex molecules. Following traditional drug-design paradigms, the subtle 
structural differences between glycans demands a possibly unachievable level of selectivity from any drug 
candidate if binding to only one target is required to minimize toxic off-target effects.   
Nevertheless, nascent attempts to 'drug' glycans are beginning to emerge from academic and 
industrial laboratories, where monoclonal antibodies (MAbs) are the most commonly pursued molecules 
for this purpose.71-74 MAbs that bind specific glycans, however, remain rare, and a recent report by the US 
National Academy of Sciences on the current state of glycoscience75  cited the lack of glycan-specific 
antibodies as a key barrier for advancing the field. Further the toxicity,76-77 immunological triggering,78-81 
and antinutritional properties77of MAbs and GBPs have limited their development as therapeutic or imaging 
agents.20-21 Although glycans are implicated in diseases ranging from cancer to bacterial and viral infections, 
there is only one clinically approved medication whose mode-of-action involves binding membrane 
glycans: the antibody 3F8, whose tradename is Unituxin, which is a treatment for pediatric neuroblastoma 
in patients with at least a partial response to prior first-line multiagent, multimodality therapy.82 The specific 
glycan targets of Unituxin are GD2 gangliosides, which are sialic acid-containing glycosphingolipids.83 
Given their widespread role in disease and that only a single glycan-binding drug exists, there remain 
substantial opportunities in exploring glycan-binding alternatives to MAbs and GBPs that could be used in 
diagnostics, as drug-delivery agents, or as therapeutics.84 One alternative that has recently gained substantial 
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interest for addressing these opportunities are small synthetic molecules that bind glycans, i.e. synthetic 
carbohydrate receptors (SCRs). 
1.2. Synthetic Carbohydrate Receptors  
SCRs are non-biologically derived, small molecules that bind carbohydrates through covalent85-86 
and/or noncovalent interactions.87-89 SCRs already have found several uses, including providing valuable 
model systems for studying fundamental carbohydrate recognition,53, 85, 90-131 as chemosensors,125, 132-143  and 
as potential therapeutics,144 including for combating viral threats.145-146 In the context of antivirals, it is 
envisioned (Figure 1.2.) that these small-molecule glycan receptors could disturb the glycan-GBP 
interactions between viruses and host cells, and thereby prevent membrane fusion. In doing so, they will 
disrupt the viral life cycle and mitigate active infections. As such, SCRs could fill unaddressed needs in 
antiviral therapies in the void left as a result of the inadequacies of GBPs and MAbs. Achieving this, 
however, will require substantial advances related to manipulating SCR selectivity, grasping the subtleties 
of glycan-SCR binding, and understanding the role of competitive inhibition of glycan-GBP interactions 
on biological activity.  
 
Figure 1.2. Enveloped viruses often dock to proteins on the membrane of host cells via glycan – mediated 
interactions prior to entering the cell. Here a method to mitigate the infectivity of viruses by using synthetic 
carbohydrate receptors to disrupt these interactions and, in turn, halt the viral life-cycle is proposed.  
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1.3. Covalent Synthetic Carbohydrate Receptors 
 SCRs can be categorized by the ways in which the receptor binds the glycan, and the classifications 
include SCRs that rely upon (i) dynamic covalent bonding,147 (ii) metal bonding, or (iii) noncovalent 
bonding to form supramolecular complexes with glycans (Figure 1.3.). Dynamic covalent SCRs harness 
the reversible bond formation between glycan syn-hydroxyl groups and boronic acids,142, 148 resulting in 
rapid formation of dynamic covalent cyclic boronate esters (Figure 1.3.A). Boronic acid-based SCRs have 
been extensively researched and the subject of numerous comprehensive reviews,115, 142, 148-149 and will only 
be discussed briefly here. These boronic-acid containing receptors bind monosaccharides that possess syn-
periplanar diols such as D-glucose (Glc), D-mannose (Man), D-galactose (Gal), D-arabinose (Ara), and D-
fructose (Fru). The first example of saccharide recognition using boronic acids was reported in 1991 by 
Shinkai et al. who used p-(hexadecyloxyphenyl) boronic acid as a phase transfer agent to pull solid samples 
or aqueous solutions of Fru into CDCl3 with 98% and 74% extraction efficiency, respectively.150 The 
equilibrium of the boronic bond with vicinal diols is pH dependent, thus, binding constants (Kas) for boronic 
esters are strongly dependent on solution conditions, with Kas in aqueous buffers ranging between 103‒104 
M−1. However, achieving specificity towards a particular glycan with these covalent SCRs is challenging 
as a result of the extensive number of glycans possessing syn-diols. Nevertheless, noteworthy examples of 
these covalent SCRs include the benzeneboronate receptors by Lorand and Edwards that have achieved 
remarkable binding affinity for Gal (2200 M−1), with modest affinity for Man (60 M−1), which is a milestone 
with respect to selectivity,151 and the chiral diboronic acid receptors by Shinkai that bind Fru and Glc with 
Kas of  ~104 M−1 in phosphate buffer of pH = 7.77 with 33% methanol.134 Further notable research by 
Shepartz and coworkers demonstrated that β-boronopeptidic receptors can selectively bind sorbitol over 
Glc,130 meaning that although the receptor binds multiple targets, “it may bind preferentially to one receptor 




Figure 1.3. A) Three most widely adopted approaches for the design of synthetic carbohydrate receptors, 
SCRs. SCRs are shown in grey, glycans in red, and metal ions (M) in green. Solid lines represent the 
dynamic covalent bonds. Sand-colored dashed lines represent noncovalent interactions, such as H-bonding 
and CH•••π interactions, and dashed blue lines represent metal-ligand interactions. B) Binding interactions 
that are common in SCR-glycan complexes.  
 
Boronic-acid based glycan binding has already been exploited in several promising applications. 
Anslyn and coworkers developed boronic acid receptors for pattern based recognition of saccharides in 
aqueous solution at physiological pH using principal component analysis.105, 140 Phenyl, naphthyl, and 
anthracene boronic acids have even been patented as part of dialysis technology to remove excess Glc from 
blood.153 Receptors bearing boronic acids in a pentapeptide have been prepared by solid phase synthesis 
and tested in a taste-chip platform – a device capable of doing simultaneous, real-time detection and 
quantification of multiple analytes in solution.154 It was found that monosaccharides and disaccharides were 
successfully classified, and compounds within each saccharide group were also differentiated. The array 
was able to discriminate structurally similar saccharide derivatives, such as sucrose, maltose, sucralose, and 
maltitol.140 Using the same covalent interaction of boronic acids to 1,2 or 1,3-diols, Lavigne and co-workers 
developed boronic acid-functionalized peptidic SCRs for the identification of cancer associated glycans 
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and glycoproteins.120, 155 It should be noted, however, that the preference of boronic-acid based SCRs for 
and strong binding to glucosides does limit their applications in terms of therapeutics, disease detection, 
and drug-delivery. Even though Glc is the monosaccharide found in the highest concentration in the body, 
it is almost entirely absent from the glycocalyx and viral envelopes.141, 156 As such SCRs boronic acid-based 
SCRs, have limited potential for applications that require binding to the non-glucosidic, disease-relevant 
glycans that dominate the glycocalyx.   
1.4. Metal-Assisted Synthetic Carbohydrate Receptors 
Metal-assisted SCRs bind glycans as a result of the chelation between vicinal diols on the glycan 
and metal ions on the receptor (Figure 1.3.). This binding is inspired by the interactions that occur in C-
type lectins, which are Ca2+-dependent GBPs that include collectins, selectins, endocytic receptors, and 
proteoglycans.10, 91, 157 C-lectins possess a C-type lectin fold (CTLF), which is a fold with amino acid 
residues with carbonyl side chains that coordinate Ca2+ ions, and theses ions, in turn, can bridge the amino 
acids and the hydroxyl groups of sugars.10 Even though C-lectins share some structural homology, they 
usually differ significantly in the glycans that they recognize. In C-lectins, the carbohydrate recognition 
domain (CRD) has two highly conserved disulfide bonds and up to four CTLF sites for binding Ca2+. These 
interactions favor the CRD residues that bind to sugars with Ca2+ as intermediary.10, 158 As a result, the 
glycan and the Ca2+ ion in the second site can form a ternary complex with the amino acids of the CRD. 
Sequence determinants in the CRD can provide clues to the monosaccharide specificity (e.g., Man vs. Gal) 
of C-type lectins and receptors, like DC-SIGN (Figure 1.1.A).159 Thus the structure and binding of C-
lectins provide a model for how metals can be used to bind glycans. 
Efforts to replicate and exploit metal-assisted carbohydrate recognition have resulted in several 
interesting SCR designs. Generally, these receptors involve ligands that affix the metal within a scaffold 
that leaves chelation sites open for additional binding to vicinal hydroxyl groups. For example, Striegler 
and coworkers reported a library of CuII complexes that bind sugars under alkaline conditions, achieving 
Kas of ~104 M−1 to Man, Fru, and Fru-containing disaccharides in aqueous buffer at pH of 12.4.160-161 Other 
examples include PdII square planar complexes that bind Glc at a biologically relevant pH of 7.4.162 
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Lanthanide ions that bind glucosides and sialylated oligosaccharides, including the neuronal plasticity-
related ganglioside GM1, with Kas up to 105 M−1, have also been reported to operate in Hepes buffer at pH 
of 7.0.163 Even though, antifungal natural products such as pradimycin and benanomycins have shown Kas 
of up to 104 M−1 with MeO-α-Man in the presence of Ca2+,164-165 SCRs have not yet incorporated 
successfully Ca2+ in their glycan binding complexes. If they can be developed, Ca2+-complexing SCRs 
could have biological activity comparable to their natural counterparts. As an alternative to being directly 
involved in binding the glycan itself, metal ions can provide structural preorganization to the SCRs without 
directly binding to the glycans. Examples of such designs include macrocycles with affinity for sucrose in 
water (Ka = 1170 M−1), where Pt organizes a polyaromatic cavity in the SCR,166 and metal organic 
frameworks (MOFs) that selectively adsorb cellobiose and lactose in water, where the Zr atoms serve as 
nodes for the MOF’s pyrene linkers.167 
1.5. Rigid Noncovalent Synthetic Carbohydrate Receptors 
As a consequence of the preference of covalent and metal-assisted SCRs for binding glucosides, 
SCRs that bind glycans noncovalently (Figure 1.3.A) have become the subject of increasing recent research 
because they are the most promising approach for developing receptors that bind non-glucosidic glycans 
and thus can potentially be used to disrupt interactions between viruses and host-cells. As a result of their 
inherently dynamic and weak noncovalent bonds, multivalent and cooperative binding equilibria that are 
otherwise unavailable to the more strongly bound SCRs arise. However, several challenges must be 
overcome to design SCRs where the glycans are bound solely by noncovalent interactions. These are (i) 
achieving strong binding by relying primarily on H-bonding, π•••π stacking, and van der Waals contacts in 
competitive solvents (Figure 1.3.B), (ii) understanding and anticipating the complex equilibria that may 
occur between SCR hosts and glycan guests, (iii) and achieving selectivity between complex molecules that 
may differ only by the orientation of a single stereocenter by appropriately orienting binding groups in 
three-dimensions. The structures of noncovalent SCRs include calixarenes and oligoaromatic receptors,137, 
168-173 cyclodextrins,90, 174-178 porphyrin conjugates,110 podand receptors,100, 106, 114, 118, 121, 123, 127, 129, 144-145, 179-
183 peptide-based receptors,130, 184 cholaphanes185 and the encapsulating temple receptors.88, 92, 101, 107, 113, 119, 
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125, 131, 143, 186-198 Although several reviews on noncovalent SCRs exist,87-89, 126, 191 the field continues to 
develop rapidly and a few key examples are highlighted below to discuss the design of noncovalent SCRs 
(Figure 1.4.) and their evolution as antivirals. 
Typically, artificial receptor design in supramolecular chemistry is guided by Cram’s principles of 
complementarity and preorganization. Complementarity dictates that “hosts must have binding sites which 
can simultaneously contact and attract the binding sites of the guests without generating internal strains or 
strong nonbonded repulsions”.199 Preorganization states that “the more highly hosts and guests are 
organized for binding and low solvation prior to their complexation, the more stable will be their 
complexes.”.199 The initial designs for noncovalent designs were both complementary – possessing groups 
to H-bond to the glycan hydroxyls and aromatic groups to form C−H∙∙∙π interaction with the glycan Hs – 
and highly preorganized. Beginning in 1990 with macrocycle 1 designed by Davis et al., the first entirely 
noncovalent SCR bound C1-octyloxy functionalized Glc (Oct-β-Glc) in CDCl3. This apolar, aprotic solvent 
was selected to maximize binding between host and guest because it does not compete with the receptor for 
H-bonding, like aqueous solvents would. In SCR 1 the complementary binding cavity is formed by two 
parallel, apolar steroidal surfaces held apart by linkers that contain both polar and apolar groups. They 
reported that Ka to Oct-β-Glc was ~103 M−1 in CDCl3. Using force field geometry optimization, they 
describe a glycan that is enclosed within the cavity of the receptor as a result of H-bonding between the 
equatorial hydroxyls of the glucoside and the hydroxyl and amide groups of the receptor.185 
A subsequent report from the Davis group describes SCR 2, whose major innovation involved the 
arrangement of planar biphenyl and polar side groups into a cage architecture so that peripheral amides 
bound the glycan hydroxyls and the biphenyl scaffold on the top and bottom bound the apolar faces of the 
glycan through C–H•••π interactions. This receptor bound preferentially Oct-β-Glc (Ka = 980 M−1) over 
Oct-β-Gal (Ka = 220 M−1) in CDCl3.187 Importantly, this was the first example of the class of receptors that 
follow this general design, now referred to as “temples”. In these temple receptors, the “roof” and “floor” 
of the temple consist of apolar aromatic groups, while the “pillars” are polar. Other temples prepared by 
the Davis group bind all manner of glucosides and other “all-equatorial” glycan derivatives, such as 
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chitobiose,198 cellobiose,107, 195-196 and  maltoside,192 where all of the hydroxyl groups are positioned 
equatorially around the pyranoside scaffold. Important achievements that have resulted from these efforts 
include new temple receptors which bound to octyloxy glucosides with Kas as high as 3.0 x 105 M−1 in 
CDCl3101, 119, 186-190, 194, 197 and 1.2 x 104 M−1 in aqueous solutions.198 Water solubility is achieved by 
appending dendritic groups to the temple,113 and different lengths and degrees of flexibility of the aromatic 
planar sections can be modulated to accommodate glucoside oligomers of different lengths.125, 131, 195-196 The 
polar aromatic pillars are sufficiently rigid to prevent the collapse of the apolar aromatic surfaces in water.113 
SCR 11, which possesses a pyrene roof binds negatively charged aminosugars multivalently forming 1:2 
host:guest complexes with mannosamine (K1 = 3000 M−1) and even α-sialyl units (K1 = 1300 M−1) in D2O. 
131, 198 Interestingly 11, which binds chitobiose with a Ka = 19 000 M−1 in D2O, threads polymeric chains of 
cellulose, providing the first example of a polysaccharide-based polypseudorotaxane.198 In a further attempt 
to bind glycans by organizing binding groups in three dimensions, other groups have also created 
macrocycle-based SCRs. Aoyama and coworkers, for example, provided the first examples of carbohydrate 
recognition with a resorcinol-aldehyde cyclooligomer capable of extracting D-ribose but not Glc from H2O 
into CCl4.168 This group then followed this research with one of the first attempts at glycan binding in H2O 
by complexing Fuc with a deprotonated calix[4]resorcarene to achieve a Ka of 26 M−1 in H2O.171  
In another milestone of noncovalent SCR research, the Mazik group introduced an acyclic, yet still 
preorganized, SCR 3 that binds glycans by arranging three heterocyclic binding groups around a benzene 
core, with the major advance being the synthetic ease by which these receptors are prepared. These receptors 
bind monosaccharides through H-bonding interactions between either the restricted secondary amide bonds 
or the heteroatoms in the pyrimidine group with hydroxyl groups on the monosaccharide, and C–H•••π 
interactions with the rigid aromatic surface. The rotational restriction of the amide bonds that link the 
pyrimidine arms to the center aromatic unit and the inflexible benzene ring, also provide partial 
prearrangement to result in a basket-like binding structure. Receptor 3 is particularly notable because it 
bound Oct-α/β-Glc with Kas ~104 in CDCl3.93 Building upon this accomplishment the Mazik group 
systemically varied the heterocyclic substituents, and found that pyrimidine-containing 4 bound glycans in 
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a 2:1 receptor:glycan complex, with K1 = 3640 and K2 = 82450, to achieve a cumulative binding affinity (β 
= K1 × K2) of ~108 M–2 in CDCl3.99 Importantly, intermolecular interactions between two SCRs contribute 
to the stabilization of the 2:1 SCR:sugar complex, thus illustrating that cooperative pathways can enhance 
the binding affinity towards a target glycan. This behavior is similar to that observed in natural GBPs, where 
the initial association of a target substrate induces conformational changes that enhance binding of a second 
site.200 
  
Figure 1.4. Milestones in the evolution of noncovalent SCRs. 
 
Subsequently the Mazik group explored the effect of varying heterocyclic binding groups of these 
acyclic tripodal SCRs on their Kas and selectivities towards different carbohydrates.99, 102, 108, 116-117, 124, 128, 
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201-203 They found that SCRs having three 2-amino-4,6-dimethyl-pyridine groups have β to Oct-β-Glc of 6.4 
x 107 M-2 in CDCl3. When one of the 2-amino-4,6-dimethyl-pyridine groups of this SCR was replaced by 
an amino-crown ether, the receptor was selective for Oct-β-Glc (K1 = 5.8 x 105 M-1, K2 = 1.4 x 104 M-1) over 
Oct-α-Glc (K2 = 1.4 x 103 M-1) in CDCl3. When two of the 2-amino-4,6-dimethyl-pyridine groups of this 
SCR were substituted with 5-imidazole,116 3-indole116 or isobutyl117 groups, the selectivity changed to Oct-
β-Gal with a β = 107 – 109 M-2 in CDCl3. Similarly, a tripodal SCR that possesses three 2-indolyl-amino 
groups bound Oct-β-Gal preferentially with selectivity as high as 2.4 x 103:1 Oct-β-Gal:Oct-α-Gal and 2.0 
x 103:1 Oct-β-Gal:Oct-β-Glc in CDCl3.128 However, the corresponding 3-indole derivative bound only Oct-
β-Glc with a relatively low Ka of 6.5 x 102 M-1 in CDCl3. Taken together, these studies showed the impact 
of the heterocyclic attachment on selectivity.128 Incorporation of ammonium-based ions such as 1,8-
naphthyridinium,109 guanidinium108 or quinolinium202 favored binding to negatively charged N-
acetylneuraminic acid (Neu5Ac) in H2O/DMSO with β of 107 – 109 M-2, forming neutral and charge-
reinforced H-bonds with Neu5Ac, similar to those observed in sialic acid-binding proteins.204-205 Finally, 
they reported cage-like receptor 10 that encloses the target glycan, and with this structure they confirmed 
that enhanced affinity occurs with increasing SCR rigidity, in-line with the predictions of Cram’s principle 
of preorganization, to achieve Kas with Oct-β-Glc of ~105 M-1 in CDCl3. Moreover, 2D NMR rotating-frame 
Overhauser effect spectroscopy (ROESY) confirmed the formation of an inclusion complex.203 
The Roelens group built another series of noncovalent SCRs from a similar phenyl core with 
binding arms at the 1,3,5-positions, and ethyl groups at 2,4,6, which force the heterocyclic binding groups 
into a basket-like conformation. In accordance with Cram’s principle of preorganization, the authors of 
these studies showed that the addition of the three aliphatic arms on the benzene ring add ~4.5 kcal mol−1 
of additional stabilization upon complexation by reducing the entropic penalty of binding.206 Additionally, 
they showed again that subtle changes to the heterocycle and its point of attachment have a profound impact 
on binding selectivity and affinity towards different monosaccharides. 100, 106, 114, 118, 123, 127, 144, 180-182, 207 The 
majority of these preorganized receptors generally target glucosides, but substantial efforts are underway 
to target non-glucosides.  Receptor 5, for example, possessing ureidic linkers between the phenyl core and 
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the heterocycles, showed affinities towards various C1-octyloxy-monosaccharides, with 1:1 and 2:1 
host:guest associations. In these complexes 1:1 K1s were ~102 M-1 and 2:1 K2s were ~105 M-2 in CDCl3, 
with a preference towards binding Oct-β-Gal and Oct-β-Glc.100 Further studying the role of heterocycles, 
they demonstrated that an SCR that has three primary amine groups with no heterocycles binds to Oct-β-
Glc with the intrinsic median binding concentration, BC050, of 3690 µM in CDCl3,181 whereas the 2-pyrrole 
amine-based SCR showed preference for Oct-β-GlcNAc (BC050 = 18 µM) in CDCl3, with selectivity as high 
as 44:1 Oct-β-GlcNAc:Oct-α-Gal and 2:1 Oct-β-GlcNAc:Oct-α/β-Man.181 Receptor 6 is particularly 
noteworthy because it shows a substantial preference for Oct-β-Man with a BC50<1 µM in CDCl3, which is 
achieved by attaching an acetal group to the aminopyrrolic binding groups.180 This was the highest 
selectivity of an SCR for Oct-β-Man at the time it was reported. Subsequently ditopic receptor 7 and others 
were developed127 that displayed affinity towards the dimannoside Oct-(α-Man)(1-2)-β-Man with a BC050 
= 15 µM in CDCl3/DMF 70:30. The design of ditopic receptor 7 was inspired by the success of the 
previously described aminopyrrolic receptors on carbohydrate recognition: 7 is the dimer of previously 
reported mannoside selective SCR123 , 6, that is linked by a dipyrrolic moiety.  
There are myriad applications for these rigid noncovalent SCRs, including the monitoring of blood 
glucose141 and the dissolution of polysaccharides.198 Activity against bacterial pathogens has been 
demonstrated with the mannose-binding aminopyrrolic-armed SCRs developed by Roelens,181 who 
reported activity of some SCRs against pathogenic yeast and yeast‐like microorganisms. While a direct 
correlation between antibacterial activity and affinities for mannosides was not found, compounds without 
measurable affinity for mannosides also failed to display any inhibitory activity.144  
1.6. Flexible Noncovalent Synthetic Carbohydrate Receptors 
Lectins, surface substrate-binding proteins, and other GBPs provide a model for SCRs that differ 
from the rigid receptors, whose structures are highly preorganized. In nature, GBPs obtain Kas up to 106 M-
1 by conforming to an “induced fit” model,91, 208 meaning that association of the substrate “may cause an 
appreciable change in the three-dimensional relationship of the amino acids at the active site”.208 An 
example of induced fit binding in GBPs includes the periplasmic Glc/Gal binding proteins, where the 
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complex is stabilized through an “adapted protein structure”, meaning the protein rearranges following the 
initial association of the glycan. The Glc/Gal binding protein undergoes a 31° change in torsional angle 
along a three‐segment hinge that closes a top hemisphere to form an inclusion complex around the bound 
guest that increases affinity and selectivity (Figure 1.5.A),200 illustrating how conformational flexibility 
and rearrangements are an important part of natural glycan recognition. The prevalence of multivalent and 
cooperative binding in glycan binding is called the “cluster glycoside effect”,209 which refers to the 
remarkable enhancement of affinities of polyvalent saccharide ligands for polyvalent lectins “over and 
beyond what would be expected from the concentration increase of the determinant sugar in a multivalent 
ligand”.209 These natural glycan binding proteins suggest a biomimetic approach towards SCR design, 
where flexibility is consciously incorporated into design to allow for multivalency and cooperativity, which 
may lead to non-glucoside binding with a high degree of specificity.  
To this end, the Braunschweig group has developed a series of flexible SCRs to examine how 
loosening structural preorganization can alter binding dynamics and selectivity (Figure 1.5.B), recognizing 
that Cram’s principle of preorganization does not proscribe flexible receptors but rather identifies that such 
flexibility comes at the cost of entropy. The design vision behind these receptors is that by densely 
incorporating groups for forming complementary H-bonding and C−H•••π interactions with glycans, while 
leaving conformational dynamics unrestricted, there was a chance that preferential non-glucosidic binding 
could be observed. Then, from this initial “hit”, systematic evaluation of structure-activity relationships 
could be carried out using a modular synthesis, and thereby lead design rules that could result in SCRs with 
increased selectivity and binding affinity towards biologically-relevant glycan targets. The initial design 
(Figure 1.5.B) of these flexible SCRs, SCR001, is comprised of a biaryl core, similar to that first used by 
Davis in 2187 and others92, 101, 189-191, however the biphenyl is a freely-rotating π-surface that can rearrange 
to form CH•••π interactions with various glycan targets and not exclusively glucosides. Attached to this 
biaryl core via secondary amine linkages are four heterocyclic pyrroles that can be easily varied. These 
heterocycles are similar to those found in the Mazik and Roelens receptors, albeit they exist in a far less 
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crowded environment, allowing for free conformational rearrangement of these H-bonding groups around 
glycan guests.  
 
Figure 1.5. A) Glucose/Galactose binding protein (GGBP) illustrating the flexible hinge (red arrows) that 
accounts for its binding selectivity. The open form of GGBP in light blue (left) (PDB: 2FW0),210 and a 
closed conformation in grey (right) binding to glucose. The box shows the bound glucose (blue) sitting on 
top of an indole ring (2GBP).200 B) Flexible SCR001 is inspired by the dynamics of flexible GBPs. The 
biaryl core provides the receptor a freely rotating axis to arrange C−H•••π interactions around the glycan. 
The aminopyrrolic arms can rotate freely to position H-bonding arms around the glycan.  
 
A key to pursuing this strategy for SCR discovery – where the intention is to achieve specificity 
through multiple cycles of synthesis and binding studies – requires a modular, high-yield, and high-
throughput synthesis. Such a modular route towards these tetrapodal receptors (Figure 1.6.) was 
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accomplished from the tetraazide synthetic precursor, 13, which is prepared in three steps from simple 
starting materials. Azides are a particularly versatile functional group because they can be used to link the 
biaryl core to various commercially available heterocycles and other functional molecules via secondary 
amine, imine, amide, or triazole linkages. So 13  is a platform for varying linkage and heterocycle, or 
incorporating diverse functional groups by leveraging the popular CuI-catalyzed azide-alkyne click 
reaction.211 Initially, 2-pyrroles were appended to the biaryl core via secondary amines, initially using 2-
pyrolle-carboxaldehyde, in a one-pot, three-step protocol involving a Staudinger amination of 13 to the 
corresponding iminophosphorane followed by an aza-Wittig reaction with four-fold excess of heterocyclic 
aldehyde. Finally, a reductive amination with NaBH4/MeOH provided SCR001 in 80 % yield. This same 
high-yield protocol produces the symmetrically substituted, tetrafunctionalized receptors in yields ranging 
from 34 % – quantitative, allowing for the preparation of these flexible SCRs on the gram-scale. 
 
Figure 1.6. Modular synthesis of flexible tetrapodal SCRs from common tetraazide intermediate 13. 18 
SCRs have been reported, highlighting the modularity of the synthetic scheme.  
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Binding studies between SCR001 and a series of eight octyloxy-C1-monosaccharides revealed a 
preference for mannosides in CDCl3 as a result of positively cooperative212-213 and multivalent binding 
pathways. In solution, SCR001 exists as a dimer that comes apart to form 1:1 complexes with all eight 
pyranosides with little selectivity. However, as a result of positive allosteric cooperativity – meaning the 
binding to a second glycan is stronger than the first –1:2 receptor:pyranoside complexes form with only 
Oct-α-Man (SCR001:Oct-α-Man2) and Oct-β-Man (SCR001:Oct-β-Man2). Thus SCR001 achieves 
selectivity between pyranosides that may differ only by the orientation of a single hydroxyl group, despite 
the entropic penalty that must be paid to organize the complexes, reaching selectivities as high as 16.8:1 
Oct-α-Man:Oct-α-Gal. More importantly, NMR and computational studies revealed additional 2:1 
SCR001:glycan binding pathways with Oct-β-Man and Oct-β-Glc, however, the SCR0012:Oct-β-Glc 
complex has low stability. These additional binding pathways contribute directly to the selectivity towards 
mannosides. Notably, the structure of SCR0012:Oct-β-Man indicates that only three of the four 
aminopyrrolitic arms are involved in binding, suggesting that the fourth arm could be replaced to append 
further functionality to future SCRs.  
A second generation (G2) of these flexible tetrapodal SCRs was prepared to examine the hypothesis 
that the atomic composition of the heteroatom (N, O, S), the bond between the heterocycle and the biaryl 
core (amide, imine, secondary amine), and the dimerization of the receptor would all affect the binding 
affinity and specificity between these flexible SCRs and the same five octyloxy monosaccharides. To this 
end, SCR002 – SCR009 and SCR012 were prepared from 13. SCR-glycan binding was studied by 1H 
NMR titrations. These studies showed that these changes to the SCRs had a significant impact on both the 
Kas and selectivities towards the glycans. The Ka values revealed that heterocycles containing N−H motifs 
were necessary to achieve strong binding to the glycans. Furan-containing SCR003, with N−H groups only 
in the linker, shows moderate binding, whereas SCR001, SCR005, and SCR012, which possess pyrrolic 
heterocycles, bind the strongest. In general terms, the trends from this study reveal that receptors with furan 
or thiophene heterocyclic groups bound the glycans weakly.214 In addition, the secondary amine linkers 
between the heterocycles and the biphenyl core increase binding strength compared to imines (SCR001 vs. 
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SCR005, SCR002 vs. SCR006, and SCR003 vs. SCR007). Amide linkers decreased the solubility of the 
SCRs to the point that Kas could not be measured accurately, and, as such, no relevant data could be 
obtained. In summary, SCR001 is selective for Oct-β‐Man, SCR002 – SCR004 and SCR006 are selective 
for Oct-α‐Man, SCR005 is selective for Oct-β‐Gal, and SCR012 is selective for Oct-α‐Glc, illustrating that 
with flexible receptors, subtle structural differences can lead to profound differences in selectivity when 
the receptor is allowed to rearrange and accommodate its guest.  
The dimer, SCR012, which brings together two subunits of SCR001, binds Oct-β‐Man with a 
higher entropic penalty than SCR001, which likely reflects the substantial reorganizational penalty of the 
larger, more flexible molecule. However, the increase in ΔHº for SCR012•Oct-β‐Man compared to 
SCR001•Oct-β‐Man indicates that SCR012 likely forms more noncovalent interactions with Oct-β‐Man 
compared to SCR001. Despite having more noncovalent contacts than SCR001, SCR012 bound Oct-β‐
Man less strongly, making this receptor a classic example of enthalpy-entropy compensation215 and 
illustrating the thermodynamic complexities inherent in attempts to rationally design SCRs. In addition, 
1H–1H nuclear Overhauser effect spectroscopy (NOESY) NMR studies and molecular modeling showed 
how the flexibility of the receptor enabled “induced‐fit” binding, illustrating again how natural glycan 




Figure 1.7. Binding of flexible tetrapodal SCRs to C1-octyloxy-O-glycans in CD2Cl2. Generation 1 (G1) 
is composed of Oct-β-Man-selective receptor SCR001. Generation 2 (G2) involves SCRs with altered 
heterocyclic binding arms and whether the binding arm is linked by an amine, imine or amide. Generation 
3 (G3) evaluates the effect of N−H containing heterocycles and their point of attachment to the secondary 
amines on glycan binding. The abbreviated heterocyclic binding arm corresponding to the specific 
tetrapodal SCR number sits above each labeled set of columns. Star over columns represent a cumulative 
association constant (β=K1×K2), alternatively Log(β)=LogK1. 
As the G2 results pointed towards the importance of secondary amine linkers and N–H containing 
heterocycles for achieving high Kas and non-glucosidic selectivity, a third generation (G3) of flexible, 
tetrapodal SCRs were prepared that focused upon varying the heterocycle and the regiochemistry of the 
linkage between the heterocycle and the biaryl core. To this end, SCR017‒SCR023 were synthesized from 
13 using the same modular synthetic approach described above. The new heterocycle substituents explored 
were 3-pyrrole (SCR017), 2- or 3-indole (SCR018 or SCR019), 2- or 3-pyridine (SCR020 or SCR021), 
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and 2- or 3-phenol (SCR022 or SCR023). Analysis of the binding data of all tetrapodal SCRs reveals that 
varying the heterocycles has substantial impact on their Kas and selectivities, where binding ranged from 
nonexistent, to promiscuous, to completely specific, the latter meaning they “only bind one particular target 
with negligible binding to other similar tagets”152. SCR017, SCR021, and SCR022 were completely 
specific and bind only Oct-β-Glc.216 SCR018 and SCR020, alternatively, bind preferentially to Oct-α-Man, 
an important biological target for which there is no other specific SCR, and SCR019 binds only Oct-β-
Man.216 Of these new SCRs, all bound their preferred substrate with either Log(K1) or Log(β) > 3.9. Thus, 
in three generations of iterative exploration of structure-activity motivated design, this class of receptors 
has advanced from promiscuous, moderate binders to strong and highly selective binders, and 18 flexible 
tetrapodal SCRs have been reported (Figure 1.8.).216 
 
Figure 1.8. Tetrapodal SCRs developed by the Braunschweig group. This image highlights the structural 
differences, including heterocycles in the binding arms, point of attachment of the heterocycles to the 
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secondary amines, valency, and whether the binding heterocyclic arm is linked to the biaryl core by amines, 
imines, or amides. 
1.7. Structure – activity relationships of flexible SCRs unveiled by computational modeling 
Computational methods that have been used to study SCR-glycan binding. For example, theoretical 
methods were used to determine the structure of the 1•Oct-β-Glc supramolecular complex. The rigid 
structure of the receptor allowed manual placement of the Glc molecule inside its cavity to promote 
favorable H-bonds and π-π contacts.185 Subsequent geometry optimization using a force field helped to 
confirm and visualize the interactions that led to the reported selectivity. Similar examples can be found in 
the work of Mazik,87, 93, 96, 99, 102, 104, 108-109, 111-112, 116-117, 124, 126, 128, 201-203, 217-224 Roelens,100, 114, 118, 127, 129, 180-182, 
207 and Davis.107, 119, 125, 131, 143, 186-187, 191-192, 195-198 These examples, however, strongly rely on chemical 
intuition to guess the placement of the guest inside the rigid cage, followed by a local conformational search 
and geometry optimization. Flexible SCRs constitute a further challenge for theoretical methods because a 
structural search must screen a much larger conformational space to localize and validate the structure of 
the complex. The noncovalent interactions that are the driving force in these complexes are also more 
challenging to describe within a force field framework. Instead, derivation of the lowest-energy structures 
should involve an electronic-structure theory, such as density-functional theory (DFT), to properly account 
for noncovalent interactions.225-227  
Molecular modeling was first used to investigate the conformation of the most flexible of the 
tetrapodal SCRs, dimeric SCR012, and its complex with Oct-β-Man.214 The conformational space was 
reduced by incorporating several constrains on H-H distances derived from a NOESY spectrum and 
sampled using low-mode sampling and AMBER* force field.228 The resulting menagerie of structures 
generated from different starting conformations were subsequently refined using dispersion-corrected DFT 
to identify those showing the most preferable binding. Notably, modeling showed the inclusion complex of 
SCR012•Oct-β-Man, where the glycan sits within a pocket formed by the receptor, which rearranges to 
accommodate the guest. Upon rearrangement, SCR012 forms multiple noncovalent interactions with Oct-
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β‐Man – three CH•••π and eight H-bonds that involve both halves of the dimeric SCR – indicating that, like 
many GBPs, the binding is best described as induced fit.  
Following this work, molecular modeling was used to investigate why changes to the heterocycle 
and linkage regiochemistry of the SCRs, explored in G3, cause dramatic change in substrate selectivity.216 
Here, the conformational space of 40 stoichiometric and 7 non-stoichiometric complexes was sampled 
using replica-exchange molecular dynamics, which showed more success in finding global minima than 
previously used algorithms. The representative structures of the most abundant conformational clusters 
were then submitted for DFT calculations. Following this protocol, binding energies that were consistent 
with experimental Kas and explain binding stoichiometry of selected SCR•glycan complexes were 
predicted. For instance, modeling explains why SCR001 shows a preference for Man over Glc (Figure 
1.9., top)214, 216, 229 and the absence of cooperativity in higher-stoichiometry complexes. More importantly, 
the calculations unraveled the driving force behind the binding cooperativity, which is a key factor in high 
Ka non-stoichiometric complexes. The enhancement of the second binding constant (K2) in cooperative 1:2 
SCR•glycan complexes arises from additional glycan-glycan interactions that are formed upon bringing the 
second monosaccharide into the complex, and the magnitude of this boost correlates with the number of H-
bonded interactions formed between the monosaccharides (Figure 1.9., bottom).216 A similar mechanism 
operates in 2:1 SCR•glycan complexes. The SCR0012•Oct-β-Man complex shows experimental K1/K2≈2 
which means that the second receptor binds weaker than the first. The simulations show that the first 
receptor saturates the H-bonded contacts with the glycan, which leaves only one unbound hydroxyl group 
for the second SCR. Effectively, both receptors ‘hug’ (hence, a hugging complex) tightly the 
monosaccharide. In the second case, SCR0222•Oct-β-Glc, it was observed that experimentally K2/K1≈6 
which means that the second receptor binds stronger with the glycan than the first. Here, the ortho position 
of the hydroxyl groups in the heterocycles promotes internal H-bonding with the receptors amine groups, 
which reduces the number of contacts formed with the glycan. Upon interaction with Oct-β-Glc the two 
SCRs approach from the same direction, creating a hydrophilic pocket for binding of the hexose in a 
spooning complex. The Oct-β-Glc forms only 3 H-bonds with both receptors, but is further stabilized by a 
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pronounced  C‒H1,3,5•••π  interactions between the  α-face  of  the  ring  and  an adjacent  phenolic  
heterocycle.   
The combination of sampling algorithms and DFT unraveled the binding structures of flexible 
SCR•glycan complexes. Systematic investigation of the binding activity of SCRs aides in understanding 
structure-activity relationships to establish design-rules for subsequent receptors. Furthermore, as a 
consequence of the increasing accessibility of electronic-structure theory calculations and their accuracy 
for reproducing noncovalent interactions, such methods could be employed routinely to predict binding of 
novel receptors to glycans, so time-consuming syntheses and binding studies can be circumvented.230 
 
Figure 1.9. Lowest-energy structures of six SCR•glycan complexes determined by Density-Functional 
Theory calculations and a continuous solvation model. The receptors are shown in gray, the glycans are 
shown in blue (Oct-α/β-Glc) or green (Oct-α/β-Man), and the H-bonds are shown as brown dashes. Top: 
An axial C2-hydroxyl group of Oct-β-Man positions the sugar between the two receptor arms, off-center 
of the biaryl core of the receptor, which allows formation of H-bonds. In contrast, all-equatorial orientation 
of hydroxyl groups in Oct-β-Glc, and additional three H-bonds, enable C−H•••π interactions between the 
α-face of the sugar and the biaryl ring. The α-configuration of the octyl chain in Oct-α-Glc disturbs the 
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stabilizing C−H•••π interactions, which results in weaker binding. Bottom: Cooperativity plays an 
important role in formation of the higher stoichiometry complexes. The off-center position of the saccharide 
in SCR001•Oct-β-Man complex opens a symmetric binding pocket on the opposite site of the receptor for 
binding of a second Oct-β-Man. The cooperative binding of the second sugar in SCR020•Oct-α-Man2 and 
SCR021•Oct-β-Glc2 arises from sugar-sugar interactions facilitated by the presence of the receptor. In 
weakly cooperative SCR020 complex, only 1 H-bond between sugars is formed, whereas in strongly 
cooperative SCR021 complex multiple interactions between the glycans are observed. 
1.8. Antiviral activity of Synthetic Carbohydrate Receptors 
The ability of SCRs to bind glycans and thereby disrupt interactions with their intended biological 
targets has been recently explored as a route towards developing new antiviral therapies. Targeting glycans 
with carbohydrate binding agents (CBAs), which includes SCRs and also biologically-derived molecules, 
has been highlighted as a promising strategy for antiviral therapeutics and vaccines,23, 231  but  this approach 
has not yet resulted in an approved drug. The abundance of the GlcNAc2Man3 core and mannosides on the 
terminal sugars of the glycan shield of several infectious diseases such as HIV, HCV, and others,38 has 
made these glycans an important target for CBAs. For example, pradimicin A and the benanomicin A 
antibiotics, which bind to the terminal mannosides on fungal membrane,164, 232-233 have antiviral activity 
against HIV‐1, with IC50 values in the micromolar range.234-235 However, because of their potential liver 
toxicity these compounds have not been approved through clinical trials.234, 236-237 Microvirin, a 
cyanobacterial monovalent lectin, exerts potent activity against HIV‐1 infection (IC50 = 2–12 nM) by 
targeting the Man-α-(1‐2)-Man fragment of the high‐mannose‐type oligosaccharides of the gp120 viral 
protein.238 However, the challenges of microvirin for clinical use include large scale production, and 
demonstrating low toxicity, mitogenicity, and immunogenicity. Despite the challenges presented in these 
CBAs, the strategy of targeting the glycans involved in viral docking has resulted in promising data and 
continues to merit further exploration. 
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SCRs, particularly those that are selective for mannosides could lead to the development of antiviral 
therapeutics. To this end, Roelens tested a library of structurally related aminopyrrolic SCRs,145  including 
SCR 9, that were previously shown to bind mannosides for their ability to bind the highly mannosylated 
gp120 and gp41 glycoproteins of the HIV envelope. Notably, SCR 9 demonstrated a significant inhibitory 
effect against the infection of T‐lymphocyte CEM cells by HIV (IC50 = 16 µM). The binding interaction 
with both glycoproteins was observed by SPR. More importantly, when comparing their binding properties 
to the glycoproteins with their binding affinities toward mannosides in solution, a direct correlation was 
reported, supporting the hypothesis that the antiviral activity arose from their ability to block glycan-
receptor interactions.145 
Aside from HIV many viral threats to global health persist, with new ones appearing suddenly, 
demanding new therapies and emphasizing the need for universal antiviral agents. Molecules that target 
EnV glycans, such as SCRs, could lead to broad-spectrum drugs against these emerging viral threats. An 
example of an emergent viral threat is the Zika virus (ZIKV), a member of the Flaviviridae (FLV), a class 
of EnV that also includes, West Nile, hepatitis C, dengue, yellow fever, chikungunya, and Japanese 
encephalitis.239 Since its arrival to Brazil in 2014 from Micronesia, ZIKV rapidly spread throughout the 
Americas causing a World Health Organization designated global health crisis.240-242 Although it is 
asymptomatic in most cases,243 ZIKV was associated with severe neurological disorders such as 
microcephaly244-246 and severe brain malformations in fetuses and newborn babies, and Guillan-Barré 
syndrome247-249 in adults.  
An important segment of the ZIKV lifecycle is the binding of proteins on the viral envelope to cell-
surface glycans.59 Following the viral attachment to the host cell surface, FLVs proceed to viral entry, most 
likely through clathrin-mediated endocytosis after glycan binding. This involves conformational adjustment 
of transmembrane proteins, following membrane fusion and ultimately, the release of the viral genetic 
material.54 In FLVs this attachment process requires receptors on the cell surface such as GAGs,31 Gas6-
AXL tyrosine kinase receptor complex,250-251 neolactotetraosylceramide,252 and DC-SIGN,41, 253 a Ca-
dependent GBP abundant in dendritic cells that binds to polymannosylated N-linked glycans on the FLV 
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envelope. Molecules that interrupt this viral mechanism have been studied as potential antivirals. For 
example, dendrimers decorated with high mannosides achieve anti-FLV activity through competition with 
the glycans of the viral envelope that bind DC-SIGN.39 Other approaches include using α-glucosidase 
inhibitors to modify the viral glycan structure have also been developed.254-257 SCRs could also interrupt 
this process by binding to the glycans of the host or of the virus to prevent docking.258 
To this end the flexible tetrapodal SCRs developed in the Braunschweig group were tested for their 
ability to inhibit ZIKV entry into Vero and HeLa cells, whose proposed mode of inhibition is preventing 
viral docking to the host cell by competitive inhibition of glycan binding.146 The anti-ZIKV activity the 
SCRs, was performed by pre-incubating the cells with the SCR for 30 min at room temperature before 
infection with ZIKV green fluorescent protein-labeled (GFP) reported virus particles. This experimental 
approach assured identical infection to native ZIKV, while providing the advantage of a rapid GFP readout 
and circumventing the need to work with dangerous live virus.259 Several of the SCRs demonstrated dose–
response curves with IC50 values as low as 160 nM (Figure 1.10.), making them amongst the most potent 
inhibitors yet reported against FLVs. In addition, these SCRs showed relatively low toxicities. The 
inhibition trends were reproducible against live virus as well. Inhibition in time-of-addition assays was 
highest when the SCRs were introduced prior to the virus, which is consistent with the proposed mechanism 
that stipulates that viral infection is inhibited by preventing docking to the host cell. A correlation between 
the previously reported Kas of the SCRs towards mannosides and glucosides and the anti-ZIKV activity 
was reported, further supporting the hypothesis that glycan binding has a central role in the anti-ZIKV 
activity of the SCRs. The ability of SCR012 to bind multivalently is magnified in the densely glycosylated 
environment compared to in solution, which may account for the potent activity of this SCR (IC50 = 0.16 
µM in Vero cells and IC50 = 0.24 µM in Hella cells). Ultimately, further pharmacokinetic investigation is 
needed to determine conclusively the mechanism by which these SCRs exercise their anti-FLV activity, 




Figure 1.10. A) Individual wells of a 96-well plate showing inhibition of ZIKV GFP-labeled RVPs 
infection in Vero Cells in the presence of SCR012 at different concentrations. ZIKV infection is represented 
by the number of GFP positive cells. Control represents ZIKV infection in the absence of any SCR. B) 
Dose-response inhibition curves of ZIKV infection in Vero Cells in the presence of flexible SCRs. 
 
This research on the antiviral activity of SCRs demonstrates their potential to become broad-
spectrum agents against EnVs (including coronaviruses, retroviruses, flaviviruses, bunyaviruses, 
alphaviruses, togaviruses, filoviruses, and others), where high mannoside glycans and the GlcNAc2Man3 
fragment are prevalent.54 These EnV threats are responsible for many recent health crises, including the 
HIV epidemic,260 the ZIKV outbreak in 2016,242 and the current severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) pandemic, which is also an EnV whose N-glycans share the GlcNAc2Man3 
core.261-262 Even months before the SARS-CoV-2 pandemic arose, the WHO published an annual report by 
the Global Preparedness Monitoring Board in September 2019, warning that “there is a very real threat of 
a rapidly moving, highly lethal pandemic of a respiratory pathogen” to which “the world is not prepared”.263 
Even with this explicit warning from the WHO, the ability to prepare for and defend against these threats 
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was limited. Thus, the potential ability of new compounds and strategies to combat EnV is a research area 
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Small Molecule Synthetic Carbohydrate Receptors 
Chapter 2:  
Contents from this chapter are adapted from the published paper: “Binding Studies on a 
Library of Induced‐Fit Synthetic Carbohydrate Receptors with Mannoside Selectivity”1  
K. Palanichamy, M. F. Bravo, M. A. Shlain, F. Schiro, Y. Naeem, M. Marianski, A. B. 




2.1. Introduction  
The surface of every eukaryotic cell is coated with a layer of glycolipids, glycoproteins, and 
glycopolymers – termed the glycocalyx – and binding events involving these oligosaccharides mediate 
a wide variety of biological events, including cell-cell communication, immunological response, cell-
pathogen interactions, and disease progression.2 Cell-surface glycosylation patterns are unique and 
accessible identifiers of cell-type. For example, α-mannose is overexpressed on the surface of human 
lung,3 and prostate4 cancer cells, whereas β-galactose is abundant on human testicular,5 brain,6 and white 
blood7 cancer cells.  So synthetic molecules that recognize with some preference specific mono- and 
oligosaccharides in the glycocalyx could be used for disease detection, drug delivery, therapeutics or 
even for understanding how information is transmitted in biological networks.8 Although mannose and 
galactose are abundant on cell-surface glycans, their epimer, glucose, is almost entirely absent from cell 
surfaces because it occurs in such high concentration in the blood and cytoplasm,9 and, as such, for 
sugar-binding molecules to migrate from the circulatory system, they must bind non-glucosides. Despite 
the medicinal and biological significance of targeting the glycocalyx, cell surface glycans are generally 
considered as “undruggable targets”10 because highly specific glycan receptors are confined to natural 
lectins and antibodies, which have potential toxicology and immunological limitations.11-15 In this 
context, small molecule receptors are of interest but their design is extremely challenging as selectivity 
is needed for complex molecules that differ sometimes by only the orientation of a single stereocenter. 
Despite these difficulties, a significant number of synthetic carbohydrate receptors – including some 
that bind in water – have been developed.16-31 These fall primarily into two classes: those that bind 
through the formation of boronate esters20-26 and rigid scaffolds that bind entirely through noncovalent 
contacts.16-19, 27-31 The latter include rationally-designed, small molecules as well as peptide- and 
aptamer-based hosts, and some discovered through dynamic libraries.32-33 The boronates bind 
monosaccharides possessing syn-diols with binding affinities (Kas) in water  ranging between 103‒104 
M−1, and particularly noteworthy examples are the chiral diboronic acid receptors by Shinkai that bind 
D-Fructose and D-Glucose with Kas of  ~104 M−1 34 and others developed by Anslyn for pattern-based 
saccharide sensing.35-37 The noncovalent, small molecule receptors, in contrast, organize polar and 
nonpolar domains around a rigid scaffold, and examples include calixarenes and oligoaromatic 
receptors,38-44 cyclodextrins,45-50 porphyrin conjugates,51 podand receptors,52-66 peptide-based 
receptors32-33 and the encapsulating receptors temple receptors11, 27-28, 30-31, 67-83 developed by Davis that 
bind primarily all-equatorial glycans in organic solvents67, 69-71 with Ka ~ 3.0 x 105 M−1 and in aqueous 
solvents with Kas as high as 1.2 x 104 M−1.81 The applications for these glucoside-binding receptors are 
manifold, including the monitoring of blood glucose,81, 84 the early detection of disease biomarkers such 
as sialyl Lewis X antigen and TF antigen,85 and the site-specific imaging of cancer cells,86 which is still 
dominated by glucose and sialic acid binders. However, for applications including cell-surface 
targeting, carbohydrate-based nanotechnology,8, 87-88 or characterizing the structure of complex 
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oligosaccharides, there remains a need to continue developing synthetic carbohydrate receptors that 
associate to non-glucosides or other all-equatorial glycans. 
Generally, the synthetic receptors that bind through noncovalent interactions are designed by 
following the principle of preorganization developed by Cram, who demonstrated that binding affinity 
increases in rigid receptors because the entropic penalty of reorganization is minimized.89-92 This design 
strategy is consistent with Fisher’s “lock-and-key” model of protein binding, which assumes that both 
enzyme and substrate have rigid conformations that lead to an ideal fit with relatively high Kas.93 Glycan 
binding proteins – like lectins or the periplasmic binding proteins – are examples of the more nuanced 
“induced-fit” model, where enzyme flexibility and substrate influence dictate the structure of the 
enzyme-substrate complex.94-95 Typically, glycan binding proteins are characterized by promiscuity2 – 
they will often bind several monosaccharides with weak 1:1 binding, but achieve affinity enhancement 
of up to 106 M−1 and increased selectivity by accessing cooperative and multivalent binding pathways, 
a phenomena termed the “cluster-glycoside effect”.96 Most synthetic carbohydrate receptor designs do 
not consider these aspects of natural systems. Thus, developing synthetic carbohydrate receptors that 
associate with non-glucosidic monosaccharides may require approaches towards receptor design that 
reconsider the role of preorganization and the meanings of selectivity and specificity in the unique 
context of carbohydrate recognition. 
To this end, we have reported previously a highly flexible synthetic tetrapodal carbohydrate 
receptor SCR001 (Figure 2.1.B) that possesses four aminopyrroles organized around biaryl core that 
binds α-mannosides preferentially in chloroform through H-bonding and C−H•••π interactions in 
concert with multivalent and cooperative equilibria.97 This receptor is one of only very few synthetic 
receptors so far reported that are selective for mannose.54-55, 57-59, 61, 63-64 Like natural glycan binding 
proteins, this receptor is promiscuous and forms 1:1 complexes in CHCl3 with all monosaccharides 
assayed, and selectivity as high as 16.8:1 α-Man: α-Gal and 1.5:1 α-Man:β-Glc is achieved as a result 
of 2:1 and 1:2 receptor:substrate complexes. This receptor demonstrates the potential of flexible 
scaffolds for addressing the unmet challenge of creating synthetic carbohydrate receptors that possess 
non-glucosidic selectivities. Davis et al., using an anthracene-based receptor, have subsequently 
confirmed the value of incorporating conformational flexibility in receptor design as a route to 
increasing binding affinity.83 Building upon this result, they subsequently reported a pyrene-based 
synthetic carbohydrate receptor that binds some axially substituted pyranosides in water, whose 
negatively charged variant forms 1:2 host:guest complexes with aminosugars, with K1 of ~3.0 x 103 M−1 
for D-mannosamine. In turn, a positively charged variant binds α-sialyl units with K1 of ~1.3 x 103 
M−1.11 These studies show the promise of flexible molecules as selective carbohydrate receptors, and 
that there remains a need to continue exploring how changes in synthetic carbohydrate receptor structure 
can access the binding modes common in nature – particularly cooperativity and multivalency.29, 96, 98-
101 Here we do so by exploring how receptor structure affects Ka and selectivity in a library of flexible 
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synthetic carbohydrate receptors based upon the structure of previously-studied receptor SCR001, and 
these data will guide the rational design of future carbohydrate receptors. 
2.2. Results and Discussion 
Here, we seek to understand how variations in the structures of flexible carbohydrate receptors 
affect their Kas and selectivities towards a series of carbohydrate guests. To this end, we have prepared 
a library of receptors based upon the biaryl core of our previously reported tetrapodal synthetic receptor 
SCR001, and these synthetic carbohydrate receptors differ from SCR001 in the nature of the 
heterocycle, the bond between the heterocycle and the biaryl core, and whether the receptor is dimeric 
(Figure 2.1.).  
 
Figure 2.1. A) The equilibrium between flexible receptors (blue) and pyranosides (red) is governed by 
the equilibrium constant, Ka. B) Synthetic receptors. C) C1-Octyloxy pyranosides, whose binding with 
the receptors have been studied. 
Subsequently, their binding to a small library of glycans functionalized with solubilizing 
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octyloxy groups at the anomeric (C1) carbon was studied in CH2Cl2 by mass spectrometry and in 
CD2Cl2 by NMR spectroscopy, where the latter was used to quantify Kas. Finally, variable temperature 
(VT) NMR titrations, Nuclear Overhauser Effect (NOE) 2D NMR spectroscopy, and molecular 
modeling were used to interrogate the thermodynamic and structural details of the association between 
SCR012 and β-Man. The data from the host:guest system composed of SCR012 and β-Man is used as 
an illustrative example to describe how each of the different analyses were performed, and the data from 
the other 39 host:guest pairs are provided in the Experimental Section, with results summarized below. 
Because SCR008 and SCR009 were not soluble in CH2Cl2, their binding with the monosaccharides 
was not studied.  
2.3. Synthesis of the receptors.  
Inspired by the initial results with SCR001, we sought to vary the receptor structures, while 
maintaining the overall flexibility of the scaffold by building upon the freely rotating biphenyl core. 
Based on prior work by the groups of Roelens52-66 and Mazik,16-19, 102-129 we reasoned that receptors with 
different H-bond donors and acceptors may differ in their specificities to the carbohydrate guests as a 
result of differences in noncovalent bonding with the sugars. The structural variations explored here 
consist of changing the heterocycles to include furan, thiophene, and N-methyl imidazole groups with 
amine, provide the respective imine intermediate, which when treated with NaBH4 provided tetrapodal 
receptor SCR001 in 80% yield. In the same manner, receptors SCR002 – SCR004 were synthesized 
from intermediate 1 by using the respective heterocyclic aldehyde in yields ranging from 40 – 95%. 
From 1, the imine-based receptors SCR005 – SCR007 were synthesized but isolated in poor yields (17 
– 32%), presumably because of hydrolysis during purification by column chromatography on silica gel. 
The amide-based receptors SCR008 and SCR009 were synthesized via HBTU-mediated coupling of 
the corresponding heterocyclic carboxylic acid with the tetraamine 2, which was obtained from 1 
through a Staudinger amination in quantitative yield. For the synthesis of dimeric receptor SCR012, 
two units of 1 were linked with the alkyne-terminated triethylene glycol chain via a CuI-catalyzed azide-
alkyne Huisgen reaction (azide:alkyne 5:1) in the presence of CuSO4, sodium ascorbateimine and amide 
linkages of the heterocycle to the and increasing receptor valency by linking two biaryl cores with an 
oligoethylene glycol chain, the latter inspired from previous studies showing SCR001 binds β-Glc and 
β-Man in a 2:1 host:guest stoichiometry.97  All receptors were synthesized from the common tetraazide 
intermediate 197 (Scheme 2.1.). The amine-based receptors SCR001 – SCR004 were prepared from 
intermediate 1 in a one-pot procedure involving three reactions occurring on each of the four azide sites. 
To form SCR001, a Staudinger amination of tetraazide 1 to the corresponding iminophosphorane was 
followed by an aza-Wittig reaction with four-fold excess of 1H-pyrrole-2-carbaldehyde to provide the 
respective imine intermediate, which when treated with NaBH4 provided tetrapodal receptor SCR001 
in 80% yield. In the same manner, receptors SCR002 – SCR004 were synthesized from intermediate 1 
by using the respective heterocyclic aldehyde in yields ranging from 40 – 95%. From 1, the imine-based 
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receptors SCR005 – SCR007 were synthesized but isolated in poor yields (17 – 32%), presumably 
because of hydrolysis during purification by column chromatography on silica gel. The amide-based 
receptors SCR008 and SCR009 were synthesized via HBTU-mediated coupling of the corresponding 
heterocyclic carboxylic acid with the tetraamine 2, which was obtained from 1 through a Staudinger 
amination in quantitative yield. For the synthesis of dimeric receptor SCR012, two units of 1 were 
linked with the alkyne-terminated triethylene glycol chain via a CuI-catalyzed azide-alkyne Huisgen 
reaction (azide:alkyne 5:1) in the presence of CuSO4, sodium ascorbate and bathocuproinedisulfonic 
acid disodium salt (Batho) to provide the hexaazide 3 in 39% yield. Hexaazide 3 was converted into 
dimeric receptor SCR012 by following the three-step amine-forming protocol, where 18 bond-forming 
steps proceed in one-pot and in 50% overall yield. Importantly, by using diferent diynes and 
heterocyclic precursors, this synthetic strategy can be easily diversified to create expanded libraries of 
carbohydrate receptors beyond those described herein. 
 
Scheme 2.1. Synthesis of receptors SCR001- SCR009 and SCR012 from 1. 
2.4. Mass spectrometry binding studies.  
We first investigated binding between glycans and the synthetic receptors by electrospray 
ionization (ESI) mass spectrometry. Initially, solutions containing the receptors alone were subjected 
to mass spectrometry because understanding the fragmentation patterns of the receptors is necessary to 
interpret the mass spectra of the host-guest complexes. To this end, 1 mM solutions of receptors were 
prepared in CH2Cl2, diluted to 1 µM with 40% CH2Cl2 in CH3CN, and then injected via direct infusion 
into the spectrometer with a syringe pump. The receptors had a distinct fragmentation pattern, where 
ions corresponding to the cleavage of each heterocyclic arm were prevalent because of the stability of 
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the benzylic anions that are generated upon breaking of the N‒C bond. For example, the positive mode 
ESI-MS spectrum of SCR012 possesses [M+H]1+ peaks corresponding to the molecular ion as well as 
1+ ions corresponding to the loss of one 2-methyl pyrrole group in addition to 2+ peaks corresponding 
to the molecular ion and loss of one 2-methyl pyrrole group (Figure 2.2., bottom). In addition, 
ionization conditions could be found so that peaks corresponding to the loss of all six pyrrole groups 
were observed (see Experimental Section). In the case of other receptors SCR001 – SCR007, the 
positive ESI-MS spectrum possess [M+H]1+ and 1+ ions or 2+ ions corresponding to the loss of one or 
more heterocyclic groups (see Experimental Section).  
 
Figure 2.2. Top: ESI mass spectrum of a 1:1 mixture (0.5 µM, 40%:60% v/v CH2Cl2:CH3CN) of 
SCR012 and β-Man. Bottom: ESI mass spectrum of SCR012 alone (1.0 µM, 40%:60% v/v 
CH2Cl2:CH3CN). Peaks were assigned using Compass Data Analysis Software (Bruker).  
To study the binding of the glycans with the receptors, 1 mM solution of octyloxy glycans were 
prepared in CH2Cl2 and diluted to 1 µM with 40% CH2Cl2 in CH3CN. These diluted glycan solutions 
were mixed in one-to-one fashion with 1 µM of receptor solution prepared as mentioned above, to create 
a mixture that was introduced into the spectrometer via direct infusion with a syringe pump. These same 
solutions were prepared for all 40 receptor:glycan combinations. Compass Data Analysis software 
(Bruker) was used to simulate the expected masses and isotopic distributions of the complexes and 
individual components to assign the ions observed in the spectra. For the SCR012•β-Man mixture, 
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various ions corresponding to the host-guest complex were observed (Figure 2.2., top). The most 
prominent receptor-glycan ions corresponded to the [SCR012•β-Man+2H]2+ complex, and the isotopic 
distributions of the peaks further confirm the formation of the SCR012•β-Man complex. In addition, 
ions corresponding to [SCR012•β-Man+H+Na]2+, [SCR012•β-Man+2Na]2+ and [SCR012•β-
Man2+2H]2+ were also seen in addition to [SCR012+2H]2+and [SCR012‒Pyr+2H]2+. Various other ions 
were common in the ESI spectra of SCR012•glycan when other carbohydrates were added to the 
solutions of SCR012, with the relative intensities of the ions dependent on the particular host:guest 
combination. While these same [SCR012•glycan+2H]2+ ions were observed in the case of SCR012•α-
Man and SCR012•β-Glc complexes, [SCR012•glycan+3H]3+ ions were found to be prominent in the 
ESI-MS spectrum of SCR012•α-Glc and SCR012•β-Gal solutions (see Experimental Section). These 
ESI experiments were repeated for all receptors that had solubility in CH2Cl2 with all five glycans. The 
positive mode ESI-MS spectra revealed the presence of a 1:1 receptor-glycan complex in all 40 
receptor:glycan mixtures. These mass spectrometry experiments confirm the stability of the host:guest 
complexes in the gas phase, and demonstrate that – like natural glycan-binding proteins – the synthetic 
receptors studied here are promiscuous, and that all receptors bind to all glycans to some degree. 
2.5. NMR titrations and determination of Kas.  
To confirm host:guest association and determine quantitatively how the receptor structures 
affect Kas and selectivities, binding was studied by performing NMR titrations at 298 K in CD2Cl2. 
NMR is widely used to study host-guest binding, and in particular for complexes whose Kas range from 
1 – 105 M‒1,130 which is a typical range for synthetic carbohydrate receptors. Also, synthetic 
carbohydrate receptor binding is commonly studied in non-aqueous solvents16-19, 52-67, 69-71, 102-129 because 
Kas are generally higher than they would be in aqueous solvents, so changes in Kas as a result of 
structural variations are amplified and more easily understood. Here CD2Cl2 was chosen as the solvent 
because it does not compete for H-bonds between the glycans and the receptors. Previously, we showed 
that 1 undergoes dimerization with a Kd = 13.0 M‒1 in CDCl3 at 298 K. So prior to performing the 
receptor:glycan titrations, dilutions were performed at a concentration range of 12.5 mM ‒ 65.6 µM 
with receptors SCR001 ‒ SCR007 and SCR012, and, when peak shifts occurred, they were fit to a 
dimerization model to determine Kd (see Experimental Section). Dimerization was only observed in 
receptor SCR001 and SCR005 in the receptor concentration range at which the host-guest association 
was studied (0.2 – 8.8 mM).  
To quantify Kas, 1H NMR titrations were subsequently performed by adding aliquots of receptor 
solutions (12.5 mM) to 1 mM glycan solutions in CD2Cl2. The receptor:glycan concentrations were 
varied from 1:5 to 30:1, with the glycan concentration kept at ~1 mM. All spectra obtained from these 
titrations are presented in the Experimental Section, and, as an example, the spectra of SCR012, β-Man, 
and a 2:1 mixture of SCR012:β-Man are shown in Figure 2.3.A. The peaks in the 1H NMR spectra of 
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SCR012 and the octyloxy glycans were assigned with the assistance of 1H‒1H DQF COSY and 1H‒1H 
NOESY NMR spectra (see Experimental Section). Upon association, distinct shifts occurred in the 
peaks corresponding to all the identifiable protons of both receptor and glycan, which indicates 
complexation-induced changes in chemical environments. In combination with mass spectrometry data 
as well as our previous studies on the binding of SCR001,97 we attribute these changes in δ to the 
supramolecular association between the receptors and the various octyloxy glycans. In the spectra in 
Figure 2.3.A, the largest shift of the β-Man proton peaks correspond to the H5 peak, which shifts 0.13 
ppm upfield. Similarly, the signals assigned to H1 and H2 of β-Man shifted upfield by 0.09 and 0.08 
ppm, respectively. The Mazik group16-19, 102-129 and the Roelens group52-66 have observed upfield 
chemical shifts of 0.15–1.72 ppm and 0.01–1.76 ppm, respectively, for the C‒H protons of sugars upon 
complexation in organic media, while the Davis group27-28, 30-31 have reported upfield shifts of 0.2–0.3 
ppm for the same. So the glycan and receptor peak shifts that occur with our receptors are consistent 
with these reports. These upfield shifts upon complexation suggest that shielding of these protons is 
likely the result of C‒H•••π interactions. Shifts are also seen for the peaks corresponding to the host 
protons, with the largest downfield shifts of 0.11 ppm observed for the pyrrole N‒H protons, suggesting 
that H-bonding has a role in the complexation. The Roelens group have reported a change in chemical 
shift of 0.70–0.96 ppm for the pyrrole N‒H peak of the receptors upon complexation.52-66 The relatively 
low shift for the peaks corresponding to the pyrrole N‒H protons in SCR012 upon complexation 
compared to those of others’ more preorganized receptors can be accounted for by considering that the 
N‒H protons in SCR012 are already involved in H-bonding prior to complexation that is allowed by 
the flexibility of the structure, so changes in the chemical environment of this proton are less dramatic. 
This supposition is supported by the molecular modelling of SCR012, which shows internal H-bonding 
involving the pyrroles (see Experimental Section). Chemical shift changes of 0.01–0.04 ppm were 
observed for the aromatic protons of SCR012, while a Δδ of 0.01–0.80 ppm for aromatic and 
heteroaromatic protons is typical.16-19, 52-67, 69-71, 102-129 Complexation of SCR012 and β-Man also caused 
a downfield shift of about 0.25–0.30 ppm for the peaks corresponding to the secondary amines N‒Hk 
and N‒Ht of SCR012, however, these signals were found to overlap with peaks of the octyloxy side 
chain of β-Man at lower equivalents of SCR012, and were therefore difficult to track and determine 
their Δδ. These same titrations were repeated on all other receptor-glycan combinations. In the 
complexes of receptors SCR001, SCR004, SCR005, SCR006 and SCR012 with all octyloxy glycans, 
and in titrations of SCR002•β-Glc, SCR002•α-Man, SCR002•β-Man, SCR003•β-Glc and SCR003•α-
Man, significant peak-shifting (Δδ>0.02 ppm) was observed, whereas in the other receptor-sugar 
titrations, the changes in chemical shift were <0.02 ppm. The maximum complexation-induced Δδ was 
0.65 ppm for the peak corresponding to H3 proton of SCR005•β-Gal complex.  
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Figure 2.3. A) 1H NMR (700 MHz, CD2Cl2, 298 K) of β-Man (1 mM, top), a 2:1 ratio of SCR012 and 
β-Man (middle) and SCR012 (0.5 mM, bottom). Dashed lines track the shifts of peaks upon mixing of 
SCR012 and β-Man. B) The shifts of the NMR peak of the Hm,v, Hn,w, and Ho,x protons of SCR012 upon 
addition to β-Man in CD2Cl2 at 298 K, with bullets and lines representing the experimental data and the 
fit from a 1:1 binding model, respectively. C) The shift of the NMR peaks for protons H5, H2 and H1 of 
β-Man at 298 K, with bullets and lines representing the experimental data and the fit from a 1:1 binding 
model, respectively.  
Determining Ka from NMR peak shift data requires choosing an appropriate model that accounts 
for all the equilibria present and fitting the peak shifts to these models to extract Kas.97 We have 
previously shown that for the association between SCR001 and β-Man in CDCl3, multiple equilibria, 
including 1:1, 1:2, and 2:1 β-Man: SCR001, occur. With the exception of the binding between SCR001 
and β-Man, we found no evidence of these higher order complexes from the peak fitting (see 
Experimental Section), which is consistent with the results from ESI-MS spectra. So a 1:1 binding 
model was considered to fit the titration data with the exception of the SCR001•β-Man system, where 
a SCR0012•β-Man equilibrium was also considered. In the case of SCR001•β-Man system, the titration 
data did not fit well when only a 1:1 binding model was considered. Thus, the data were best fit with a 
2:1 receptor-sugar binding model, and the requirement of considering a 2:1 binding was further 
supported by the Van’t Hoff plot (vide infra), which did not fit the data well when only 1:1 binding was 
considered. To quantify Kas, the shifts (Δδ) in the positions of glycan and receptor peaks that could be 
clearly resolved were plotted, and they were fit to the appropriate binding model, and Kas were 
determined by minimizing the sum of squared residuals between the experimental data and the modelled 
fit. Based on the literature reports62, 109 we have set a threshold that at least two peaks in each titration 
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must have Δδ>0.02 ppm to fit the data and to avoid overestimation of Kas. Although binding between 
SCR007 and the sugars was observed in the mass spectrometry data, as the change in the chemical shift 
for receptor SCR007 with all sugars was <0.02 ppm, the attempted fits of the titration data were not 
satisfactory, and, as such, we did not report a Ka. All host and guest peaks that shifted above the 
threshold of Δδ>0.02 ppm were fit simultaneously to maximize the accuracy of the fit, although it 
should be noted that many peaks with Δδ>0.02 ppm could not be used to calculate Kas because they 
overlapped with other peaks in the spectra and could not be tracked accurately. The data and fits of the 
guest and host protons for the titration of SCR012 into a solution of β-Man are provided in Figure 
2.3.B and 2.3.C, respectively. The NMR and fits to the other 39 host:guest combinations are provided 
in the Experimental Section. The Kd for all receptors, and Ka and ΔGo values for all glycan-receptor 
combinations from the fits are presented in Table 2.1. To quantify the error in the NMR measurements, 
the titrationsbetween SCR012 and β-Man were performed in triplicate, and the error in Ka was 15%. 
These data show that both binding strength and the receptor selectivity for different glycans – defined 
here as the ratio of Kas – are dependent sensitively on the receptor structures. Binding results reveal that 
receptors SCR001, SCR004, SCR005, SCR006 and SCR012 are promiscuous and form 1:1 complexes 
with all monosaccharides examined, while SCR002 had measurable binding with only β-Glc, β-Man 
and α-Man, and SCR003 only had measurable binding with β-Glc, and α-Man. Receptor SCR007 did 
not have quantifiable  binding  (Δδ<0.02 ppm) with any of the glycans. 
 
Table 2.1. Association (Ka) and dimerization (Kd) constants and free energy of binding (ΔGo) of the 
receptors (SCR001 – SCR007, SCR012) with the five octyloxy pyranosides as determined from NMR 
titrations in CD2Cl2 at 298 K.[a,b] 
 
[a] Titrations were done in triplicate for 10•β-Man, and the standard deviations of Ka and ΔGo were 3.2 
x 102 M‒1 (15% error)  and 0.1 kcal mol‒1, respectively. [b] Kas are based on 1:1 binding models that also 
consider Kd when appropriate. [c] Cumulative association constant[34] (β = K1K2 (M‒2)) involving a 2:1 
receptor-sugar binding model where K1 (1.2 x 103 M‒1) and K2 (3.0 x 101 M‒1) correspond to 1:1 and 
2:1 receptor-sugar association constants, respectively. [d] Sum of free energy of binding associated with 
K1 and K2. [e] No detectable binding/dimerization above the threshold of Ka=3.0 x 101 M‒1. [f] No NMR 




Analysis of the data revealed that receptors with pyrrole and imidazole heterocycles bind to all 
five glycans tested (Figure 2.4.). Furan and thiophene-based receptors showed either weak, negligible, 
or no binding. The promiscuous and strong binding of pyrrole-based receptors underscore the 
importance of H-bond donors for supramolecular association with the glycan guests. This hypothesis is 
supported by the downfield shifts of the NMR peaks corresponding to the receptor N‒H groups. 
Generally, receptors with furan or thiophene heterocyclic groups that lack heterocyclic H-bond donors 
bound the glycans weakly, which may account for their weak binding.  
For many applications, selectivity may be more important than Ka, and the changes in receptor 
structure explored here have significant consequences on receptor selectivity (Figure 2.4. top). Among 
all the receptors tested, SCR001 has selectivity for β-Man with K1 of 1.2 x 103 M‒1 and K2 of 3.0 x 101 
M‒1, and a cumulative ΔGo of –6.1 kcal mol‒1. While SCR001 shows selectivity for β-Man as high as 
103:1 β-Man:β-Gal, SCR002 ‒ SCR006 show selectivity for α-Man. Receptors SCR004 and SCR005 
show selectivity as high as α-Man:β-Gal 8:1 and  α-Man:β-Glc 4:1, respectively. Receptor SCR002 
prefers α-Man:β-Man at a ratio of 2:1, SCR003 binds α-Man:β-Glc at a ratio of 2.8:1, and SCR006 
shows selectivity  as high as 4.8:1 α-Man:β-Gal. Dimeric receptor SCR012 prefers α-Glc with 
selectivity as high as α-Glc:β-Man 4.9:1. We have set a threshold of 3.0 x 101 M‒1, below which we did 
not report Kas, as shown in the cases of SCR002•α-Glc, SCR002•β-Gal, SCR003•α-Glc, SCR003•β-
Man and SCR003•β-Gal. Alternatively, selectivity can also be analyzed from the perspective of the 
glycans (Figure 2.4., bottom). β-Man has a selectivity for SCR001 over SCR006 at a ratio of 973:1. β-
Glc binds preferentially SCR0012:SCR003 at a ratio of 55:1, and α-Glc prefers SCR012:SCR006 at a 
ratio of 74:1. α-Man and β-Gal are selective towards SCR005. α-Man prefers SCR005:SCR002 at a 
ratio of 63:1, and for β-Gal the preference is SCR005:SCR006 at 140:1. The Kas provided in Table 
2.1. reveal the importance of H-bonding motifs, like N‒H groups, in the receptor for strong glycan 
binding. This could account for the observation that receptor SCR003 with N‒H groups in the linker 
shows moderate binding, whereas SCR001, SCR005, and SCR012, which possess H-bonding donors 
in the heterocycles, bind the strongest.  Further, although receptor SCR012 has more N‒H groups 
compared to SCR001, entropy plays a major role in attenuating binding.  Moreover, further experiments 
are necessary to understand why furan-functionalized receptors bind the glycans more strongly than the 
thiophene-functionalized receptors. To summarize, SCR001 is selective for β-Man, receptors SCR002‒ 
SCR004 and SCR006 are selective for α-Man, SCR005 is selective for β-Gal (receptor SCR005 shows 
a nominal preference for β-Gal over α-Man, but the difference in these two Kas is close to the reported 
error of our measurements), and SCR012 is selective for α-Glc. Although there are several factors like 
electronegativity, polarizability and atomic radius that may affect both Ka and selectivity, we do not yet 
understand what causes the differences in selectivity. While these empirical data will guide the design 
of future synthetic carbohydrate receptors, further experimental and theoretical investigations are 




Figure 2.4. Left: Relative affinities of the receptors towards different glycans. Right: Relative affinities 
of the glycans towards different receptors. In both graphs, the baseline is set to log Ka of 1.5 (Ka=3.0 x 
101 M‒1) as a threshold below which binding is not reported. 
2.6. Thermodynamic study on the binding of SCR001 and SCR012 with β-Man.  
To determine how the dimeric structure affected ΔHo and ΔSo, variable temperature titrations 
between SCR012 and β-Man and SCR001 and β-Man were performed. The titrations and 
determinations of Kd and Ka were repeated at 273, 278, 283, and 288 K following the same procedures 
described above (see Experimental Section). These titration data were fit to the same binding model 
involving Kd and 1:1 equilibria to determine the Kas at each temperature between SCR012 and β-Man. 
The Kas increase with decreasing temperature, suggesting that the binding is entropically disfavored, 
which is consistent with previous studies of the binding of SCR001 with β-Man.97 The obtained Kas 
were subjected to a van’t Hoff analysis to determine ΔHo and ΔSo for the binding of SCR012 to β-Man, 
and values of ‒28.5 kcal mol‒1 and ‒81.3 e.u. were determined, respectively (see Experimental Section). 
Similarly, the variable temperature titration data of the SCR001 and β-Man system were fit using a 
model involving Kd, 1:1 and 2:1 receptor-sugar equilibria, and the determined Kas also increased with 
decreasing temperature. A van’t Hoff plot was generated from the K1s, and ΔHo and ΔSo were 
determined to be ‒21.6 kcal mol‒1 and ‒58.5 e.u., respectively (see Experimental Section). Similarly, a 
van’t Hoff plot generated from the K2s revealed ΔHo and ΔSo of ‒4.8 kcal mol‒1 and ‒9.4 e.u., 
respectively (see Experimental Section). To understand how dimerizing the receptor structure affects 
the thermodynamics of binding, the enthalpy and entropy of the binding of SCR012•β-Man should be 
compared to the sum of the enthalpy and entropy from both binding events of SCR001•β-Man. In doing 
so, the decrease in unfavorable ΔSo for SCR001•β-Man compared to SCR012•β-Man reveals that 
SCR001 binds β-Man with less entropic penalty compared to SCR012, which likely reflects the 
substantial reorganizational penalty of the larger, flexible molecule. The increase in ΔHo for SCR012•β-
Man compared to SCR001•β-Man indicates that SCR012 likely forms more noncovalent interactions 
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with β-Man compared to SCR001, which may occur between the glycan and the ethylene glycol chain. 
These thermodynamic studies suggest that dimerizing the receptor imbues SCR012 with multivalency 
that manifests as an overall increase in binding enthalpy compared to SCR001. 
2.7. Structure of the SCR012•β-Man complex.  
We sought to investigate the structure of the SCR012•β-Man complex to determine how the 
flexibility of the receptor enabled “induced-fit” binding, in other words, how the host reorganizes from 
its lowest energy conformation to form a more stable complex with the glycan. The host:guest structure 
was determined by 1H‒1H NOESY measurements in CD2Cl2 and by computational modelling. 1H‒1H 
NOESY spectra provide through-space contacts between the host and guest, and were taken at 700 MHz 
on a 1:1 mixture of SCR012 and β-Man so that the peaks of host and guest could both be resolved 
(Figure 2.5.). Because binding is entropically disfavored, the measurements were performed at 268 K 
to drive the mixture towards complexation. In addition, the 1H‒1H NOESY and DQF COSY spectra 
were also recorded at 268 K and 298 K to assign the peaks of the individual components and to 
determine if SCR012 rearranges upon complexation (see Experimental Section).  
 
Figure 2.5. 1H‒1H 2D NOESY spectrum (700 MHz, CD2Cl2, 268 K) of a 1:1 mixture of SCR012 (5.6 
mM) and β-Man (5.6 mM) showing the intermolecular correlations between host and guest protons. 
In the NOESY experiment, the ratio of complexed over uncomplexed host in equilibrium was estimated 
to be 1:1.2 based on the Ka at 268 K. Several cross-peaks corresponding to host-guest contacts were 
observed in the NOESY spectrum. As shown in Figure 2.5., the intermolecular NOE contours between 
H4, H6 and H6’ of β-Man with He of SCR012 show the interaction of receptor with the β-face of β-Man. 
The NOE contacts between H1, H2 and H5 of β-Man with Hi, Hq and Hr of SCR012 show evidence for 
the interaction of SCR012 with the α-face of sugar. Observing cross-peaks with SCR012 on both faces 
of β-Man suggest an inclusion complex where the glycan rests within a pocket formed by the receptor 
(Figure 2.6.).  
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Theoretical techniques have been employed to elucidate the structural details of the SCR012•β-Man 
complex. First, an initial screening of the guest:host conformational space at the force-field level was 
performed using mixed torsional/low-mode sampling algorithm available in Maestro software131 (for 
details, see Experimental Section). The screening consisted of several constrained, using through-space 
contacts derived from the NOESY spectrum, and unconstrained runs which were initiated from different 
starting structures. The search yielded more than 1500 conformations featuring different host:guest 
arrangements. Subsequent clustering of these structures, using loose geometric criterion (RMSD ≤ 0.2 
Å), yielded a set of 117 representative structures. The set was further augmented by 40 conformations, 
generated from two additional conformational search runs, which featured H‒H contacts closest to those 
provided by the NOESY experiment.  The resulting 157 structures were next optimized using PBE132 
exchange-correlation density functional augmented with long-range dispersion correction (PBE+vdWTS 
133) using the FHI-aims code134. Accurate energetics of different complex binding modes derived from 
density-functional calculations can add extra dimension to the structural analysis to pinpoint and 
validate the structure of the complex.135 The geometry-optimizations rendered one exceptionally stable 
conformation that surpassed the next low-energy structural candidate by 8.6 kcal mol‒1. Although no 
restraints derived from NOE data were applied to generate this model, all H‒H contacts observed in the 
NOE spectrum are within 10 Å (see table in Experimental Section). This structure (Figure 2.6.A) 
features the receptor wrapping around the guest molecule in an inclusion-type complex.  An aryl ring 
of one of the two biaryl subunits participates in C‒H•••π interaction with the α-face of the sugar whereas 
four H-bonds in an equatorial arrangement around the sugar ring are formed by two 
aminomethylpyrroles and a triazole groups of the same biaryl subunit. Furthermore, the glycol linker 
wraps the second subunit around the cavity to from four axial H-bonds with the guest. These H-bonding 
motifs are also consistent with the 2D NOE data. This conformation is further boosted by several 
additional intramolecular H-bonds, which provides some additional structural stability. While the 
proposed structure is in satisfactory agreement with the experimental data, we recognize that this single-
molecule model does not fully explain all H-H contacts and for such conformationally flexible receptors 
other low-energy structures could coexist. Nevertheless, the predicted structure of the complex validates 
the premise of the design: first, it provides multiple bonding groups that adapt to the guest molecule, 
which render binding to different monosaccharides promiscuous. Second, the guest binding engages 
both subunits of the dimeric host molecule, the structural design that was postulated based on study on 
monomeric receptors.97 
The conformational search was repeated for the receptor itself, following the same procedure as for the 
host:guest complex. The density-functional optimization yielded the most stable structure in which 
importantly, the receptor alone does not bear any cavity suitable for binding the guest (Figure 2.6.B). 
Instead, the binding must proceed by inducing a major conformational change within the receptor to 
accommodate the guest molecule (Figure 2.6.B). As such, the receptor itself maintains a large degree 
of flexibility which enables desired promiscuous binding of sugars with different hydroxyl group 
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orientations, displaying a behaviour similar to many natural glycan binding proteins.2 Importantly, the 
pyrroles in this structure are involved in internal H‒bonding in the absence of the receptor, which 
explains why relatively small shifts are observed in the peaks corresponding to the pyrrole N‒H protons 




Figure 2.6. A) Two different views of global energy-minimum structure of the 1:1 SCR012•β-Man 
inclusion complex.  The grey dashed lines denote intermolecular H‒bonds, and the green dashed lines 
show the C‒H•••π interactions. The C1 carbon of β-Man is represented as a sphere and non-polar 
hydrogens are omitted for clarity. The carbons of the segment of SCR012 binding the α-face of β-Man 
are colored blue, and the carbons of the segment of SCR012 bound to the β-face are colored red. B) An 
induced-fit model shows that the structure of SCR012 changes substantially to accommodate the 
monosaccharide guest.  
2.8. Conclusions 
Inspired by our earlier work on tetrapodal receptor SCR001, which showed selectivity towards 
mannosides, we designed an additional 9 flexible receptors to understand relationships between receptor 
structure and Ka. These receptors were all synthesized from common intermediate 1 in moderate to 
excellent yields, demonstrating a modular synthesis that is appropriate for making a broad range of 
glycan-binding molecules. The binding of these receptors was studied against five octyloxy pyranosides 
by ESI mass spectrometry in CH2Cl2 and 1H NMR titrations in CD2Cl2 at 298 K to quantify Kas. Binding 
studies were not carried out on SCR008 and SCR009 because the amides rendered these molecules 
insoluble in CH2Cl2. ESI-MS spectra of all receptor-sugar complexes showed the presence of the 1:1 
receptor-sugar complex in all cases, revealing that, similar to many natural glycan binding proteins, the 
receptors are promiscuous and bind all glycans in a 1:1 stoichiometry. NMR titrations further confirmed 
binding was driven by H-bonding and C‒H•••π interactions between the glycan protons and the 
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aromatic groups of the receptors. Curve fitting of the titration data was carried out to quantify 
association for all 40 sugar-receptor combinations, and showed that, with the exception of SCR005 and 
SCR012, all receptors were selective for mannosides, a compelling biological target. The binding 
studies also reveal that amine- and imine-based receptors with pyrrole and N-methyl imidazole 
heterocycles are particularly important. Receptor SCR001 shows the greatest binding with β-Man with 
K1 = 1.2 x 103 M‒1 and K2 = 3.0 x 101 M‒1, and selectivity of β-Man:β-Gal of 103:1. Moreover, the 
change of solvent from CDCl3 to CD2Cl2 does not modify significantly the affinity and specificity of 
SCR001 other than the increased selectivity towards β-Man. While SCR001, SCR004, SCR005, 
SCR006 and SCR012 bind all five glycans, SCR002 binds only β-Glc, β-Man, and α-Man, and 
SCR003 binds only β-Glc and α-Man.  
The table of Kas revealed the importance of H-bonding motifs for the strong binding of glycans. 
By changing the number of H-bonding donors, acceptors, and receptor valency, the selectivity towards 
the carbohydrates we assayed could be altered. Although we cannot yet fully rationalize the affinities 
the different receptors display towards the different monosaccharides, which is probably rooted in the 
subtle interplay of van der Waals and H-bonding interactions, the data provides empirical guidance for 
designing this class of synthetic carbohydrate receptors. The structure and binding thermodynamics of 
the SCR001•β-Man complex was explored to determine how the dimerization affected binding, which 
indicate that SCR001 binds β-Man with larger entropic penalty but forms more intermolecular H−bonds 
compared to SCR001 with β-Man. The intermolecular NOE contacts of the receptor with both faces of 
the sugar suggest an inclusion complex where the glycan rests within a pocket formed by the receptor. 
Formation of the 1:1 receptor-sugar complex and the intermolecular interactions were further supported 
by molecular-modelling studies. Importantly, the host rearranges to accommodate the guest, confirming 
that the “induced-fit” model accurately describes this complex. Upon rearrangement, SCR012 forms 
multiple noncovalent interactions with β-Man, but none of the specific supramolecular contacts were 
designed, rather, our approach involved adding sufficient flexibility into the host and retroactively 
determining the structure.  
The majority of synthetic receptors for carbohydrates are specific for all-equatorial 
monosaccharides, while other monosaccharides are desirable targets for drug delivery or therapeutics 
because they are over-expressed on the surfaces of many diseased cells. Glycan binding proteins are 
generally flexible and promiscuous, and achieve selectivity through cooperative and multivalent 
binding modes. Here, with a series of conformationally-flexible hosts we demonstrate the value of 
considering and incorporating biomimetic binding modes into the design of synthetic carbohydrate 
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Small Molecule Synthetic Carbohydrate Receptors 
Chapter 3:  
Contents from this chapter are adapted from the published paper: “Anti-Zika Activity 
of a Library of Synthetic Carbohydrate Receptors”1  
K. Palanichamy, A. Joshi, T. Mehmetoglu-Gurbuz, M. F. Bravo, M. A. Shlain, F. Schiro, 






The Flaviviridae (FLVs), which is a family of viruses that includes Zika (ZIKV), West Nile, 
hepatitis C, dengue, yellow fever, and Japanese encephalitis, are an emerging global health threat.2 
ZIKV3-4 was first isolated5-6 in the Zika forest of Uganda in 1947 from a febrile sentinel rhesus monkey. 
Although it is mainly transmitted to humans by mosquitoes of Aedes genus,7 sexual,8-10 maternal-to-
fetal,11 blood transfusion, and other modes of transmission have also been reported.7 ZIKV was detected 
in Asia in the 1980s and then outbreaks were reported in Micronesia and French Polynesia in 2007 and 
2013, respectively.4 Since its arrival to Brazil in 2014, infecting millions of people, it has rapidly spread 
throughout the Americas causing an expanding pandemic.12-13 ZIKV infection can cause symptoms such 
as fever, rash, muscle pain, headache, retro-orbital pain, joint pain, and conjunctivitis, but it is 
asymptomatic in most cases.14 Recent studies, however, have shown that ZIKV is also linked to severe 
neurological disorders such as microcephaly15-17 or other severe brain malformations in fetuses and 
newborn babies, and Guillan-Barré syndrome18-20 in adults. Further studies revealed that ZIKV also 
causes severe eye diseases and blindness in newborns, and conjunctivitis and uveitis in adults.21-23 
Because of the severity of these symptoms, the World Health Organization declared ZIKV a global 
health emergency of international concern in February 2016.24 Although great strides have been made 
since 2016 in the search for drugs for the treatment of ZIKV, there is to date no vaccine or antiviral 
therapy approved specifically to treat ZIKV.25-26 Rather, treatment is focused currently on relieving 
symptoms with analgesics and antipyretics.27 Thus, there is an urgent need to develop novel agents with 
anti-ZIKV activity that can prevent or mitigate infection.  
To this end, significant recent efforts have been devoted to testing libraries of compounds and 
repurposing of drugs already approved towards viral targets or cellular targets.28-33 Drugs such as 
BCX4430,34 brequinar,35 gemcitabine,36 sofosbuvir,37-38 and finasteride35 inhibit ZIKV replication by 
targeting RNA-dependent RNA polymerase. Other classes of agents such as viral protease inhibitors,39-
40 virucidal agents,41 antimalarials,28, 42-43 antibiotics,28, 44 immunomodulators,45 immunosuppressants,28 
fusion inhibitors,35-36, 42, 46 antiparasitic,28 proteasome inhibitors,28 antidepressant,28 cyclin-dependent 
kinase inhibitor,46 apoptosis-related drugs36, 46-47 and hypolipidemic drugs44 also possess anti-ZIKV 
activity. Although several compounds have advanced to phase I clinical trials,48-49 without an approved 
compound to treat the infection, there still remains a pressing need to explore molecules that inhibit 
ZIKV using alternate, less conventional strategies. 
An important part of the ZIKV lifecycle – and one that is not widely targeted by antiviral 
therapies – is the binding of proteins on the viral envelope to cell-surface glycans.50 After making 
contact with host cell surface, FLVs enter the host cell through clathrin-mediated endocytosis involving 
conformational changes of envelope proteins, resulting in membrane fusion and release of the viral 
genome. A promising therapeutic strategy involves disrupting this process with compounds that can 
mimic or, alternatively, bind the glycans of the host or of the virus.51 In FLVs this docking process 
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involves cellular receptors like glycosaminoglycans (GAGs),52 neolactotetraosylceramide,53 Gas6-AXL 
tyrosine kinase receptor complex54-55 and the dendritic cell-specific intercellular adhesion molecule-
grabbing non-integrin (DC-SIGN),56-57 a carbohydrate-binding lectin abundant in immature dendritic 
cells that interacts with the highly mannosylated N-linked glycan on the FLV envelope protein. Natural 
and synthetic compounds that inhibit this process by mimicking or targeting glycans of host cells or of 
viruses have been investigated therapeutically. For example, the highly mannosylated N-glycans of the 
human immunodeficiency virus (HIV) have a crucial role in transmission of the pathogen into the target 
cells, and also act as a shield to protect the virus from the host immune response.58-60 To this end, lectins 
such as microvirin and cyanovirin interact with the densely mannosylated gp120 of HIV envelope and 
inhibit viral transmission.61-62 However, because of their high molecular weight and peptidic nature, 
further development of these lectin-based therapeutic agents was unsuccessful. Alternatively, small 
molecule-based carbohydrate-binding agents can also disrupt the viral docking process.  For example, 
the antibiotics pradimicin A, benanomicin A and their analogues that bind terminal D-
mannopyranosides exhibit antiviral activity in cell culture with 50% effective concentration against 
HIV-1 in the micromolar concentration range.63-64 Similarly, 1,3,5-triazines bind gp120 of the HIV 
envelope and inhibit HIV-1.65 Aminopyrrolic synthetic carbohydrate receptors (SCRs) – synthetic 
molecules that are designed to form supramolecular complexes with carbohydrates – bind gp120 and 
inhibit HIV-1 infection at micromolar concentrations.66 With respect to FLVs, bovine lactoferrin, an 
antimicrobial protein, and basic peptides derived from antimicrobial chemokines, CXCL9 and 
CXCL12γ, show anti-FLV activity by binding GAGs.67-68 In addition, high mannose-based dendrimers 
achieve anti-FLV activity by competing with the high mannose glycans of the viral envelope protein 
that interact with DC-SIGN.69 Similarly, iminosugar-based α-glucosidase inhibitors that permanently 
modify the viral glycan structure in cytoplasm have also been developed.70-73 There are still no reports, 
however, on SCRs whose anti-FLV activity derives from binding of glycans on the viral envelope 
protein or disrupting interactions between host-cell glycans and glycan binding proteins on the viral 
envelope, and pursuing this strategy could lead to new lead compounds with potent anti-FLV activity.  
In an effort to explore molecules with just such a mode of action, our group has developed 
recently a series of small molecule SCRs that preferentially bind mannosides and glucosides. The 
binding of 10 of these SCRs with a series of monosaccharides was studied by 1H NMR in chloroform74 
and dichloromethane,75 and their association constants (Kas) towards a series of biologically-relevant 
monosaccharides were reported, with selectivities as high as 103:1 β‐Man:β‐Gal. This preference for 
binding mannosides is driven by cooperative binding modes that arise from the flexible and multivalent 
structures of the SCRs. As association between glycan binding proteins on the envelope of ZIKV and 
glycans on the cell surface is an important part of viral entry into the host cell, we envisioned that the 
SCRs could disrupt this process, so we assessed the anti-ZIKV activity of these SCRs, and the results 
74 
 
of those studies are described herein. While our study clearly demonstrates the potential of SCRs to 
inhibit ZIKV, further studies are needed to define the precise mechanism of action.  
3.2. Results and discussion 
Here, we report the ability of  the components of a library containing 16 novel, small molecule 
SCRs to mitigate ZIKV infection in Vero and HeLa cells using a ZIKV reporter virus-based infection 
assay. The C-prM-E (Capsid-preMembrane-Envelope) gene construct of ZIKV is used to generate 
Reporter Virus Particles (RVPs) that package a GFP reporter expressing WNV replicon. These RVPs 
infect cells in a manner identical to native ZIKV, with the advantage of providing a rapid GFP readout 
in a 96 well format.76 Results of cell viability/cell toxicity, inhibition of ZIKV infection, the IC50 values 
of these compounds, and some mechanistic insights based on time of compound addition are presented 
herein. Structure-activity relationships and correlations between mannose-binding of the SCRs and anti-
ZIKV activity are discussed. 
 
Figure 3.1. Synthetic Carbohydrate Receptors (SCRs) screened for activity against ZIKV.   
Synthesis of carbohydrate receptors 
The 16 SCRs studied here (Figure 3.1.) were based upon the structure of SCR001 – a mannose-
selective SCR41b – with systematic structural alterations designed to explore relationships between 
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molecular design and anti-ZIKV activity. Compounds SCR002‒SCR009 maintain the biphenyl core 
and vary the heterocycle. Dimeric SCRs SCR012 and SCR015 were designed to investigate the role of 
multivalency on binding carbohydrate guests. Compounds 1‒5 are intermediates in the syntheses of the 
receptors and were assayed to investigate the importance of the heterocyclic ring and the linker on anti-
ZIKV activity. All of these compounds were synthesized from common intermediate 1.74 We have 
reported the synthesis of compounds 2, 3, SCR002 ‒ SCR009, and SCR012 previously,75 and the 
preparation of compounds 4, 5, and SCR015 is described in the Supporting Information. The strategy 
used to prepare these compounds is modular, scalable, and amenable to formulating large libraries of 
similar molecules that can be readily synthesized to maximize antiviral activity or to understand 
relationships between molecular structure and viral inhibition.  
Anti-ZIKV activity of SCRs  
To determine the anti-ZIKV activity of the 16 SCRs, Vero cells were pre-incubated with the 
compounds for 30 min at room temperature followed by infection with ZIKV GFP RVPs (Figure 3.2. 
and Supplementary Figure S202). Vero cells were chosen because they are highly permissive to 
infection by FLVs. The number of GFP-positive cells, which is a measure of virus infection, was 
determined 72 h post-infection. Compounds were screened for anti ZIKV activity at 100µM 
concentration and those compounds that showed activity were further assayed in dose response curves. 
Figure 3.2.A shows a representative image of ZIKV RVP infection in the presence of different 
concentrations of SCR012. As depicted in the fluorescent microscopy image of a single well of a 96 
well plate, the number of GFP-positive cells increases with increasing dilution of SCR012, with the 
control (complete absence of SCR012) showing maximum infection. This same assay was then used to 
measure ZIKV infection in the presence of all 16 SCRs. Six of the 16 SCR receptors showed some level 
of activity against ZIKV infection in Vero cells, with SCR012 being the most potent (Table 3.1.). 
Suramin, an FDA-approved drug for the treatment of trypanosomiasis, has recently been shown to have 
activity against several viruses including ZIKV by inhibiting different aspects of the virus life cycle 
including, attachment, fusion, and reverse transcription.77-82 As Suramin has been reported to interfere 
with ZIKV attachment, we conducted the same assay using Suramin for comparison. As demonstrated 
in Figure 3.2.C, Suramin showed a dose dependent inhibition of ZIKV infection, although with 
significantly lower potency than the screened SCRs. These findings establish the anti-ZIKV activity of 
this class of molecules. Data for selected compounds are shown in Figure 3.2. (data for all compounds 
are provided in Supplementary Figure S202), and these data indicate that receptor SCR012 shows the 





Figure 3.2. Anti-ZIKV activity of SCRs in Vero cells and comparison with Suramin. (A) Representative 
images of individual wells of a 96 well plate showing inhibition of ZIKV infection in the presence of 
SCR012. ZIKV infection is represented by the number of GFP positive cells. Control represents ZIKV 
infection in the absence of any SCR. (B) Inhibition curves of ZIKV infection in the presence of indicated 
SCRs. (C) Inhibition curves of ZIKV infection in the presence of Suramin.  
 
As Vero cells are derived from African green monkeys, we also tested the anti-ZIKV activity 
of SCRs in cells of human origin. HeLa cells were recently used by Barrows et al.28 to screen for ZIKV 
inhibitors and by Chan et al.83  to study ZIKV pathogenesis and transmission. To this end, we determined 
IC50 values for the six SCRs that were the strongest inhibitors of ZIKV infection in Vero cells using the 
same RVP assay (Supplementary Figure S203). In HeLa, SCR012 remains the most potent, with a 
similar IC50 value (Table 3.2.). This result confirms that the anti-ZIKV activity of the SCRs is 




Table 3.1. Inhibitory activity of SCRs against ZIKV infection in Vero cells 





1 >100 b b b 
2 >100 b b b 
SCR001 0.36 ± 0.15 34.15 1.4 x 103 3.6 x 104 
SCR002 1.13 ± 0.23 5.43 1.1 x 102 5.4 x 101 
SCR003 1.31 ± 0.13 4.12 1.4 x 102 c 
SCR004 >100 b 4.4 x 103 5.9 x 102 
SCR005 1.36 ± 0.27 46.11 3.0 x 103 2.4 x 103 
SCR006 >100 b 2.0 x 102 3.7 x 101 
SCR007 >100 b c c 
SCR008 Not soluble b b b 
SCR009 >100 b b b 
4 >100 b b b 
3 >100 b b b 
5 >100 b b b 
SCR012 0.16 ± 0.05 36.2 2.6 x 103 1.7 x 103 
SCR015 12.37 ± 2.99 51.52 b b 
Suramin 44.02 ± 4.19 >200 b b 
a) Association constant (Ka) between octyloxy pyranosides and SCRs from NMR titrations in CD2Cl2 





Table 3.2. Inhibitory activity against ZIKV infection and toxicity of select SCRs in HeLa cells. 
SCR IC50 (µM) 
TC50 
(µM) 
SCR001 0.45 ±0.06 2.43 
SCR002 0.35 ± 0.09 2.51 
SCR003 0.56 ± 0.08 2.47 
SCR005 3.06 ± 0.59 17.59 
SCR012 0.24 ± 0.02 2.48 
SCR015 1.37 ± 0.18 2.22 
IC50: 50% inhibitory concentration; TC50: 50% toxic concentration. 
 
Cytotoxicity and cell viability study 
For a compound to have therapeutic potential it should have a high efficacy with minimum 
toxicity. To this end, the cytotoxic activity of the screened compounds was assessed in Vero cells. For 
this, Vero cells were incubated with different concentrations of the SCRs for 72 h (Table 3.1. and 
Supplementary Figure S202). Cell viability was determined by measuring intracellular ATP levels using 
Cell Titer Glo assay. Cell viability curves were fit using Sigma plot and 50% toxic concentration (TC50) 
of each compound was determined. Changes in cell morphology were also assessed via microscopy. As 
demonstrated in Table 3.1., the TC50 values for all compounds that showed anti-ZIKV activity were 
several fold higher than their anti-ZIKV IC50, suggesting the potential for therapeutic exploration. For 
the most potent ZIKV inhibitor, SCR012, the TC50 of 36.2 μM was >220-fold higher than the IC50 of 
0.16 μM. For comparison, Suramin, which also demonstrated anti-ZIKV activity, had an IC50 that was 
much higher than the SCRs. Cytotoxicity was also assessed in a cell line of human origin-HeLa cells 
for the most active subset of SCRs. As demonstrated in Table 3.2. and Supplementary Figure S203, the 
TC50 values of the SCRs tested were several fold higher than the IC50 value.   
Time of addition study 
To gain insight into the mechanism via which the synthetic carbohydrate receptors inhibit ZIKV 
infection in the Vero cells, time-of-addition experiments were carried out. The compounds were added 
to the Vero cells either 30 min prior to infection or at 4 h or 24 h post-infection. Plates were incubated 
for 72 h and degree of infection was determined by the number of GFP+ cells. Suramin was also studied 
for comparison. As seen in Figure 3.3., the SCRs were most effective when added ‒30 min (prior to 
infection), and were less effective at 4 h and least effective at 24 h post-infection. These results were 
similar to those obtained with Suramin, a known inhibitor of virus attachment and infection,77 
suggesting that – similar to Suramin – the SCRs act upon the virus by inhibiting early stages in the virus 
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life cycle, most likely by preventing virus attachment and/or viral entry. These data are consistent, 
although not conclusive, with a proposed mechanism of activity, where the SCRs operate on the virus 
by binding glycans involved with viral docking. While these studies provide mechanistic insights 
regarding SCR mediated inhibition of ZIKV infection, inhibition of replicating ZIKV by the SCR 
supports the idea that the compounds are active in targeting multiple round virus replication as well.  
Further experiments will be needed before a mechanism of inhibition is conclusively determined. 
 
Figure 3.3. Time of compound addition studies and inhibition of ZIKV infection with the five most 
potent SCRs. (A) Schematic of time of addition experiments. Cells were treated with SCRs either 30 
min prior to infection or 4 h and 24 h post ZIKV RVP infection. Plates were read 72 h post infection. 
(B) Vero cells were treated with the indicated compounds or DMSO control as indicated in part (A) 
above. The number of GFP positive cells was determined 72 h post infection.  
 
Inhibition of infectious virus with SCRs 
As RVPs are only capable of initiating a single round of infection, we next tested the anti-ZIKV 
activity of the most potent SCR, SCR012, using infectious Zika virus isolate PRVABC-5984 as well as 
Suramin and DMSO as controls. Vero cells were pre-incubated with the compounds or DMSO followed 
by infection with a predetermined amount of ZIKV based on titration data (Supplementary Figure 
S204). Cells were then fixed and stained for ZIKV protein expression using the anti-FLV group antigen 
antibody 4G2. As shown in Figure 3.4., there is excellent inhibition of infectious ZIKV with SCR012 
and to a lesser extent with Suramin (Figure 3.4.B). As expected, there was no inhibition seen with 
DMSO control (Figure 3.4.A). Moreover, fluorescent microscopy analysis showed characteristic peri-
nuclear staining pattern for ZIKV Envelope in DMSO treated but not SCR012 (8 µM) or Suramin (200 
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µM) treated cells.  This suggests that the SCRs are not only capable of inhibiting RVPs but also 
infectious virus in multiple round infection assays. 
 
Figure 3.4. Anti-ZIKV activity of SCR012 and Suramin against infectious ZIKV.  Vero cells were 
treated with (A) SCR012, DMSO control, or (B) Suramin for 30 min at room temperature followed by 
infection with ZIKV. Cells were fixed and stained for ZIKV protein expression using the 4G2 antibody. 
Images of wells were acquired and number of GFP positive cells quantified. Data are mean ±SD of 
triplicate observations. Data from one representative experiment are shown. (C) Representative 
fluorescent microscopy images of cells treated with SCR012 (8 µM) or Suramin (200 µM) or DMSO 
followed by ZIKV infection and staining. Blue=DAPI; Green=ZIKV Env. 
 
SCRs do not affect the N154 glycosylation site of ZIKV Env. 
Based on our preliminary data we anticipate that the SCRs could likely be binding to N-
mannosylated regions of Zika E protein. One such glycosylation site, N154, has been shown to be 
important for ZIKV cell surface binding and infection.85 To understand whether this site was involved 
in the antiviral activity of SCRs we generated the N154Q mutant and analyzed inhibition mediated by 
SCR012. Interestingly, the N154Q mutant was inhibited with both SCR012 and Suramin, similar to 
WT RVPs (Figure 5A and B). This suggests that glycosylation sites other than N154Q may be important 
for ZIKV attachment in Vero cells, or that SCR012 may disrupt other virus carbohydrate interactions. 
These results are strikingly similar to Suramin, our control compound, suggesting that the mechanism 
of inhibition by SCRs may be similar to other entry inhibitors like Suramin. In support of this, it was 
shown for a related flavivirus, WNV that the presence of a single N-linked glycosylation sites on the 




Figure 3.5. Abolishing the ZIKV Env glycosylation site N154 does not affect the inhibition mediated 
by SCRs. Vero cells were treated with (A) SCR012, DMSO control, or (B) Suramin for 30 min at room 
temperature followed by infection with WT or ZIKV-N154Q mutant RVPs. Images of wells were 
acquired 72h post infection and number of GFP positive cells quantified. Data are mean ±SD of 
triplicate observations. Data from one representative experiment is shown.  
 
Structure-activity analysis 
In Vero cells, the best inhibitory activity corresponded to SCR012 and its monomer SCR001, 
respectively, indicating that the pyrrolic heterocycles and secondary amine groups are important for 
anti-ZIKV activity. Further, the improved activity of SCR012 compared to SCR001 (approximately 
double) shows the importance of multivalency for antiviral activity: SCR012 has approximately double 
the number of aminopyrrolic groups compared to SCR001. The synthetic intermediates did not show 
activity against ZIKV as anticipated, confirming the necessity of both the biaryl core and the pendant 
π-electron rich heterocycles. Receptors SCR002, SCR003 and SCR005 which lack either a secondary 
amine group or a pyrrole ring, are less potent in Vero cells, although SCR002 is more potent than 
SCR001 in HeLa cells.  However, furan-based multivalent receptor SCR015 shows activity far lower 
that of its monomer SCR002, the reasons for which are not well understood.  Imine- and amide-based 
receptors SCR006‒SCR009 were not effective against ZIKV. These data indicate that both the 
aminopyrrolic groups and secondary amine linkers contribute to high ZIKV inhibition. 
There appears to be a correlation between anti-ZIKV binding and the previously determined 
binding affinities of the SCRs for mannosides and glucosides (Table 3.1.).75 While SCRs SCR001, 
SCR004, and SCR012 are the strongest carbohydrate binders, SCR012 exhibits the best inhibitory 
activity. This result suggests that carbohydrate binding may play a role in the anti-ZIKV activity of the 
SCRs, but stronger inhibition of SCR012 may suggest that the effects of multivalency are magnified in 
the dense cellular environment compared to in solution. SCR004, which also binds α-mannosides 
strongly in solution,75 but does not show any anti-Zika activity, further suggests the importance of 
pyrroles in cellular environments and that other glycans, besides mannosides, may be involved in viral 
82 
 
entry.  Other cell-surface glycans, such as GAGs, which are densely decorated with N-acetyl 
glucosamines have a role in ZIKV infection and may also be involved in the anti-ZIKV activity of these 
compounds, so these studies are inconclusive with respect to the mechanism of inhibition, and clearly 
indicate that further research is needed to confirm the origin of anti-ZIKV activity. 
In conclusion, we have synthesized and evaluated the anti-ZIKV activity of 16 SCRs, a class 
of compounds whose anti-ZIKV activity has not been previously reported. Both SCR001 and SCR012 
are active at sub-micromolar concentrations, which is comparable to the best anti-ZIKV agents known, 
and significantly more potent than Suramin. The TC50 values are significantly greater than the IC50 
values, suggesting that these compounds merit further therapeutic exploration. Based on the importance 
of pyrrolic heterocycles, secondary amine groups, and multivalency on the potency of SCRs, we 
propose that the anti-ZIKV activity can be enhanced by increasing multivalency by incorporating more 
pyrrolic heterocycles and secondary amine groups in future inhibitors. Time of addition studies imply 
a mode of action whereby the SCRs inhibit attachment of the virus to the host cell. Structure-activity 
analysis suggests that anti-Zika activity may correlate to glycan binding ability, and further studies are 
needed to confirm the mode of inhibition. These results confirm that SCRs have the potential to become 
powerful therapeutic agents in the battle against ZIKV, and they may act by a mechanism that has not 
yet been explored widely despite its therapeutic potential. Given the proposed mode of action of these 
SCRs, involving disrupting glycan-protein binding on the cell surface, it is worth evaluating SCRs as 
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Small Molecule Synthetic Carbohydrate Receptors 
Chapter 4:  
Contents from this chapter are adapted from the published paper: “Synthesis  and  Binding  of  
Mannose-Specific  Synthetic Carbohydrate Receptors”1  
M. F. Bravo, K. Palanichamy, M. A. Shlain, F. Schiro, Y. Naeem, M. Marianski, A. B. 





Interactions between glycan-binding proteins and carbohydrates in the glycocalyx have a critical 
role in immune response, cell-cell communication, cell-pathogen interactions, disease progression, and 
many other complex biological processes,2-10 with each cell and virus type presenting unique glycosylation 
pattern. For example, α-mannose is overexpressed on the surface of colorectal11 and ovarian12-16 cancer cells 
and several infectious viruses, including the Flaviviridae,17-19 HIV,20 and ebola,21 whereas β-galactose and 
N-acetylglucosamine are overexpressed on the surface of malignant melanoma cells.22-23 Although natural 
lectins and antibodies recognize specific glycans,24-26 their toxicity27-28 and immunological triggering have 
limited their development as therapeutic or imaging agents.29-30 So despite having a role in multiple high-
priority diseases, there are currently only two glycan-binding antibodies in clinical trials and only one that 
has received FDA approval, which is approved for treating high-risk childhood neuroblastoma.31-33 As a 
result, cell- and viral-surface glycans are still considered “undruggable targets”,34-36 meaning they have a 
known role in disease progression, but no widely adopted therapeutic strategies exploit this information.37  
Small molecules that bind the glycans common to the surfaces of pathogens or diseased cells could 
have a transformational impact on understanding and treating disease. Synthetic carbohydrate receptors38-
42 (SCRs) – synthetic molecules that form supramolecular complexes with glycans – could be used as 
substitute for lectins and antibodies in the context of drug delivery agents, disease or biofilm detection 
platforms, or as therapeutics. A major advantage of SCRs compared to antibodies or lectins is that SCR 
structures can be easily manipulated through the versatility of organic synthesis to tune substrate selectivity 
or mitigate toxicity. A challenge that has prevented the wider adoption of SCRs by the medical and research 
communities is that the majority of SCRs preferentially bind glucosides – all equatorial glycans that are 
prevalent in the blood and cytoplasm but are not major components of glycocalyx oligosaccharides – and, 
as a result, have limited uses.22 Thus there is a pressing need for developing SCRs that preferentially, or 
even selectively, bind non-glucosidic glycans, which is a major challenge for supramolecular chemists 
because it requires designing receptors that can distinguish between structurally complex guests that 
sometimes differ by only the orientation of only a single stereocenter.  
Nevertheless, substantial research efforts have been devoted to the development of SCRs, and these 
molecules can generally be subdivided into two classes: in the first,43-47 binding occurs through the 
formation of a covalent boronate ester on the SCRs with syn diols on the glycans, and in the second,38-42, 48-
99 binding is noncovalent and is the result of H-bonding, C−H···π interactions, and van der Waals forces. 
Of the latter class, SCRs with some non-glucosidic selectivity have been successfully developed by Davis, 
48, 59, 76, 86, 97   Roelens,58, 66-68, 80-82, 85, 88, 92, 100 and Mazik.56, 60, 64, 71, 78, 90-91, 93, 96, 101 However, only a fraction of 
those SCRs are known to bind mannosides.66-67, 80-82, 85, 88, 92 
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   Like natural lectins, however, these noncovalent SCRs are promiscuous and bind many glycans, 
sometimes showing a preference for one glycan, and specific SCRS – those that only bind one non-
glucosidic glycan – are still needed. Towards this goal,  our group has developed a series of noncovalent 
SCRs based upon the biaryl-tetrapodal receptor SCR001 that is selective towards mannosides102-103 – the 
C2 epimers of glucosides – as a result of multivalent and cooperative binding modes.  Subsequently, we 
explored the role of the bonding and valency of a small library of tetrapodal SCRs on glycan association, 
and found that subtle changes in both have profound effects on their affinity and selectivity.103 Further 
studies revealed that these tetrapodal SCRs inhibit Zika virus entry into Vero and HeLa cells,104 most likely 
by interrupting the clathrin-mediated endocytosis that follows glycan binding. Some of these tetrapodal 
receptors possessed nanomolar inhibition, making them amongst the most potent inhibitors yet reported 
against Flaviviridae in vitro, and, thus, supports continuing to explore how altering the structures of these 
SCRs affects glycan binding and antiviral activity.  
The challenge of selectivity must be addressed before SCRs are widely adopted as sensors, 
therapeutics, or delivery agents. SCRs that bind non-glucosides, however, continue to resist rational design. 
To achieve selectivity the binding motifs found in their biological archetypes, lectins, where binding is 
characterized by shallow wells, promiscuity, multivalency, and cooperativity, must be reduced to a 
molecular design. Moreover, the binding pockets of SCR-glycan supramolecular structures exceed 
substantially the complexity of most host-guest complexes, and, as such, molecular modeling approaches 
are needed that can predict SCR selectivity and guide their design. Here we sought to address these 
challenges and create SCRs with increased selectivities towards non-glucosidic monosaccharides. An 
approach that has been adopted widely in modulating SCR affinity is to vary the heterocyclic units that 
form C−H···π and H-bonding interactions with the glycan guests and their linkage regiochemistry.66, 68, 78, 
93, 101 Inspired by this previous work, here we adopt this approach of varying the heterocycle and the 
regiochemistry of attachment of the heterocycle to the biaryl core to study how this changes the binding of 
the resulting tetrapodal SCRs towards a series of biologically-relevant glycans. Of the seven new tetrapodal 
receptors we prepared, the result is two receptors that bind primarily α-mannosides, a receptor that is 
selective towards β-mannosides, and three receptors that are specific towards β-glucosides, all of which are 
biologically relevant targets, and these selectivities are explained by examining the molecular models. 
Importantly, the work described in these studies lays out a viable pathway towards the development of 
selective SCRs, and, as a result, realizing their full potential in a variety of medical, research, and industrial 
applications. 
4.2. Results and Discussion 
The synthesis and binding of SCR001 – SCR009 and SCR012 were reported previously.102-103 
SCR017‒SCR023 (Scheme 4.1.A) are new and were synthesized from common intermediate 1 in yields 
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ranging from 34% to quantitative using our standard three-step one-pot protocol,102 which involves a 
Staudinger amination of tetraazide 1 to give the corresponding iminophosphorane intermediate. A 
subsequent aza-Wittig reaction with the appropriate aryl/heteroaryl aldehyde is followed by reduction of 
the resulting imine with sodium borohydride. These new SCRs vary from SCR001 in either the heterocycle 
structure or regiochemistry of heterocycle attachment, while maintaining the secondary amine groups and 
the C2h symmetry of our previous tetrapodal SCRs. The heterocycle substituents explored here include 2- 
or 3-pyrrole, 2- or 3-indole, 2- or 3-pyridine, and 2- or 3-phenol. The SCR structures were characterized by 
1H NMR, 13C NMR, and high-resolution mass spectrometry, and all spectroscopic data were consistent with 
the proposed structures (see Supporting Information for details).  
 
 
Scheme 4.1. A) Synthesis of SCR017 ‒ SCR023 from 1 and the corresponding heterocyclic aldehyde. B) 
Octyloxy pyranosides whose binding to the SCRs was studied. 
 
4.3. Binding studies by mass spectrometry 
Binding of the 7 new SCRs to the 5 glycans (Scheme 4.1.B) was first studied by positive ion ESI 
mass spectrometry because the presence of ions corresponding to the SCR•glycan complex confirms 
supramolecular association.63, 66, 80, 84, 103 As fragmentation peaks of the SCRs taken in the absence of glycan 
are necessary to interpret the mass spectra of the SCR•glycan complexes, we first subjected solutions 
containing only the SCRs to mass spectrometry analysis. 1 µM solutions of SCRs, were prepared by diluting 
1 mM of the SCRs stock solutions in CH2Cl2 with 40% CH2Cl2 in CH3CN. These solutions were then 
injected via direct infusion into the spectrometer with a syringe pump. Previously, in studying SCRs with 
pyrrole and furan substituents, the fragmentation patterns showed ions corresponding to the loss of 
heteroaryl arms via cleavage of the C–N bond,103 which is a favored cleavage point for electron-rich 
heterocycles because of the stability of the resulting benzylic anions. Consistent with this, for example, the 
ESI mass spectrum of SCR019 shows the [M+H]1+ molecular ion in addition to [M+H]n+ ions 
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corresponding to loss of either one or more 3-indolebenzylic groups. Conversely, in the case of SCR020, 
which has electron poor pyridine heterocycles for instance, [M+H]1+ and [M+2H]2+ ions were observed, but 
ions corresponding to the cleavage of the C–N bond were not prominent, likely because the benzylic radical 
would not be stabilized in electron poor heterocycles. Similar trends were observed in all other SCR 
ionizations, showing that SCRs with electron rich heterocycles (SCR001, SCR017 – SCR019) eject 
benzylic fragments, while SCRs with electron poor heterocyclic arms (SCR020 – SCR023) do not (see 
Supporting Information).  
With this understanding of how the SCRs fragment, the spectra of the SCR•glycan complexes were 
studied. 1 µM solutions of glycans in 40% CH2Cl2 in CH3CN were prepared, and they were mixed one-to-
one with the 1 µM solution of SCRs in 40% CH2Cl2 in CH3CN. The mixture was then injected into the 
spectrometer via direct infusion with a syringe pump. Simulations of the expected masses and the isotopic 
distributions of the complexes, the individual components, and their fragmentation patterns were performed 
with Compass Data Analysis software (Bruker) to identify peaks corresponding to supramolecular 
association between the SCRs and the glycans. In the case of SCR019•β-Man, the ions corresponding to 
[SCR019•β-Man+H]1+, [SCR019•β-Man+2H]2+ and the ion [SCR019‒Ind•β-Man+H]1+, resulting from 
loss of one indole-benzyl group, were observed (Figure S4.22). In the case of SCR020•α-Man, 
[SCR020•α-Man+H]1+ and [SCR020•α-Man+2H]2+ were observed (Figure S4.22). These studies were 
repeated for all SCR•glycan mixtures, and revealed that all SCRs bind all glycans assayed to some extent, 
forming 1:1 SCR•glycan complexes (Figures S4.23-S4.29). It should be noted, however, that these mass 
spectrometry experiments reveal little about strength and selectivity of association given the challenges 
related to the quantification of mass spectrometry binding data, and so other analytical techniques are 
required to determine association constants (Kas) and selectivities of the SCRs towards the different glycans. 
 
4.4. Determination of Kas by NMR titrations 
The Kas between the glycans and the SCRs were determined by NMR titrations at 298 K in CD2Cl2, 
since 1H NMR titrations are widely used for quantifying host-guest binding processes with Kas ranging 
from 1 to 105 M−1.105 Also, synthetic carbohydrate receptor binding is commonly studied in non-aqueous 
solvents39, 42, 48, 50-51, 53, 56-58, 60-68, 71-72, 74-75, 78-85, 87-88, 90-96, 98, 100-101, 106-111 because Kas are generally higher than 
they would be in aqueous solvents, so changes in Kas as a result of structural variations are amplified and 
more easily understood. Here CD2Cl2 was chosen as the solvent because it does not compete for H-bonds 
between the glycans and the receptors. For SCR017, SCR019 and SCR023, 0.5% CD3OD, 1% CH3OH, 
and 4% CD3OD, respectively, were added to the titration to increase the solubility of the SCRs. Prior to the 
SCR•glycan titration, dilution experiments were performed for all SCRs at a concentration range of 1 mM 
‒ 25 µM to determine if they undergo dimerization, and if the observed change in chemical shift (Δδ) was 
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>0.02 ppm,103 the data were fit to a dimerization model102-104 to determine the dimerization constant, Kd (see 
Supporting Information). Dimerization was observed only for SCR001, which has been reported 
previously,102 and SCR023. Following the dilution experiments, the 1H NMR titrations were performed by 
adding 6.25 µL aliquots of 16 mM solutions of glycans to 500 µL (1 mM) solutions of the SCRs, and the 
additions were continued to a 30:1 glycan:SCR ratio. As an illustrative example, the 1H NMR spectra of 
SCR019•β-Man is presented and discussed in detail here (Figure 4.1.). For β-Man, the largest shift upon 
association was for the peak corresponding to the H4 proton, with Δδ = 0.13 ppm downfield, and the second 
largest shift was for the peak corresponding to H6, with Δδ = 0.11 ppm downfield. The peak shifts are 
attributed to the change in chemical environment as a result of reversible supramolecular association 
between the glycan and the SCR that is occurring in the fast exchange regime. When involved in C‒H···π 
interactions with aryl rings of SCRs, protons shift upfield,50-51, 53, 56-58, 60-68, 71-72, 75, 78-85, 87-88, 90-96, 98, 101, 106-110, 
112-115 so these results suggest that these Hs do not form C‒H···π interactions with SCR019. In contrast, the 
peaks corresponding to H1 and H5 of β-Man both shift upfield 0.04 ppm, upon association, suggesting the 
formation of C−H···π interactions with the aromatic rings of SCR019, which is corroborated by molecular 
modeling (Figure S4.80). Significant shifts were also observed for the SCR protons upon complexation. 
The largest shift was 0.20 ppm downfield for the peak corresponding to the indole N‒H proton, indicating 
their participation in H‒bonding with the glycans. The peak representing aromatic proton Hk shifted 
downfield 0.06 ppm, and the peak corresponding to Hf shifted 0.02 ppm upfield.  
Titrations were repeated for all SCR•glycan combinations, and they are presented in the Supporting 
Information. Among all SCR•glycan complexes, the largest shift for a glycan C‒H proton was Δδ = 0.15 
ppm downfield for the peak corresponding to H6 in the SCR017•α-Man complex, and the largest shift for 
the aromatic proton was Δδ = 0.17 ppm downfield for Hf of the 3-pyrrole ring of the SCR017•α-Man 
complex. Similarly, the largest shift for the N‒H proton of pyrrole or indole heterocycle was Δδ = 0.74 ppm 
downfield for N‒H proton of 2-indole in the SCR018•β-Gal complex. 1H NMR of most of the titrations 
presented significant shifts for SCR and glycan peaks upon mixing, indicating supramolecular association. 
It should be noted also that the spectra of several of the SCR•glycan combinations (e.g. SCR018•β-Glc, 
SCR019•α-Glc, SCR021•α-Glc, SCR022•α-Glc, SCR021•β-Gal, SCR022•β-Gal, SCR023•α-Glc, 
SCR023•β-Man, SCR023•α-Man, SCR023•β-Gal) did not show peak shifting upon mixing, indicating 
that no substantial binding was occurring under these experimental conditions. This result is significant 
because these data suggest that these SCRs do not bind all sugars – which is an important departure from 
previously studied tetrapodal SCRs, which were generally promiscuous binders, and associate with all 






Figure 4.1. A) 1H NMR (800 MHz, 1% CH3OH in CD2Cl2, 298 K) of β-Man (16 mM, top), a 2:1 ratio of 
β-Man : SCR019 (middle), and SCR019 (1 mM, bottom). Dashed lines track the shifts of peaks upon 
mixing of SCR019 and β-Man. B) The shift of the NMR peaks for protons H1, H4, H5 and H6 of β-Man at 
298 K, with bullets and lines representing the experimental data and the fit from a 1:2 SCR•glycan binding 
model, respectively. C) The shifts of the NMR peak of the Ha, Hb, Hf, and Hk protons of SCR019 upon 
addition of β-Man in CD2Cl2 at 298 K, with bullets and lines representing the experimental data and the fit 
from a 1:2 SCR•glycan binding model, respectively.  
 
These NMR titrations were used to quantify the Kas for the supramolecular binding between the 
glycans and the SCRs. To determine the Kas, 1H NMR Δδ were fit to binding models that considered the 
different possible equilibria that can occur. For example, we have shown previously that the SCRs can 
dimerize, and that SCR001 can form 1:1, 2:1, and 1:2 complexes with certain β-Man in CDCl3102 and 
CD2Cl2103, and all these equilibria were considered when fitting the binding data.  The Kas and ΔGo for all 
SCR•glycan complexes and Kd for all SCRs were determined by minimizing the sum of squared residuals 
(SSRs) between the experimental data and the modelled fit (Table 4.1). To maximize the accuracy of the 
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Ka values, NMR peak shift data of only clearly resolved peaks of glycans and SCRs that shifted a Δδ > 0.02 
ppm were fit simultaneously to an appropriate binding model, and the model that had the lowest error with 
the titration data was selected as the correct equilibrium. In an effort to avoid overestimation of Kas, no 
binding values are reported for Kas < 3.0 x 101 M-1, NMR peaks shift < Δδ = 0.02 ppm, and unless 2 peaks 
in the 1H NMR spectra have Δδ > 0.02 ppm. To demonstrate the data analysis, the NMR peak shift data for 
the association of SCR019 with β-Man are shown (Figure 4.1.B & C). The peak shifts were best fit with 
a 1:2 SCR•glycan binding model with K1, K2 and β of 2.3 M-1, 3.2 x 104 M-1 and 7.4 x 104 M-2 where K1, 
K2 and β correspond to 1:1 and 1:2 SCR:glycan Kas and cumulative Ka (K1 x K2 M‒2), respectively. The 
higher stability of the 1:2 SCR•mannoside complex, SCR019•(β-Man)2,  compared to the 1:1 
SCR•mannoside complex, SCR019•(β-Man) occurs as a result of positive allosteric cooperativity, as K2 
> K1, 102, 116-117 and the source of this cooperativity is explained with the molecular modeling results. Fitting 
of NMR peak shift data revealed that similar multiple equilibria also occur in the association of SCR017 
(3-pyrrole) with β-Glc, SCR020 (2-pyridine) with α-Man and SCR021 (3-pyridine) with β-Glc. On the 
other hand, the association of SCR022 (2-phenol) with β-Glc showed formation of 1:1 and 2:1 SCR•glycan 
complexes in CD2Cl2. In all these cases, the K2/K1 ratio was >1, indicating that the formation of higher 
stoichiometry complexes proceeds with positive cooperativity. For all other SCR•glycan systems, the best 
fit of the NMR peak shift data was obtained with a 1:1 SCR•glycan binding model indicating that higher 
stoichiometry complexes did not form.  
 
 
Table 4.1. Complexation (Ka), dimerization (Kd), and cumulative (β) association constants of SCR001 and 
SCR017 ‒ SCR023 with the five octyloxy pyranosides as determined from 1H NMR titrations in CD2Cl2 
at 298 K.[a,b] 
 
[a] Titrations were performed in triplicate for SCR019•β-Man to determine experimental error, and the 
standard deviations of Ka were 3.2 x 102 M‒1 (15% error). [b] Kas are based on 1:1 binding models that also 
consider Kd when appropriate. [c] Cumulative association constant (β = K1K2 (M‒2)) involving a 2:1 
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SCR•glycan binding model where K1 and K2 correspond to 1:1 and 2:1 SCR•glycan association constants, 
respectively. [d] Cumulative association constant (β = K1K2 (M‒2)) involving a 1:2 SCR•glycan binding 
model where K1 and K2 correspond to 1:1 and 1:2 SCR•glycan association constants, respectively. [e] No 
detectable binding/dimerization above the threshold of Ka = 3.0 x 101 M‒1. [f] No NMR peak shifts above 
the threshold of Δδ > 0.02 ppm. [g] Titration data fit unsatisfactory, although evidence of binding exists. 
 
 Analysis of the binding data of all tetrapodal SCRs reveals that varying the heterocycles has 
substantial impact on their Kas and selectivities, and that, just by varying the heterocycle, binding can be 
varied from no binding, to promiscuous binding, to completely selective binding (Figure 4.2.). The first 
tetrapodal SCR, SCR001, was promiscuous with a slight preference for β-Man.102 Previous manipulations 
of the bonding between the biaryl core or the heterocycle103 to include furan, thiophene, or imidazoles 
(SCR002 – SCR009) either lead to promiscuous binders (SCR002, SCR004 – SCR006), a slightly 
selective binder with weak overall binding (SCR003), or a lack of binding altogether (SCR007 – SCR009). 
In contrast, the heterocycles explored here resulted in receptors that were highly specific. SCR017, 
SCR021, and SCR022 were completely specific and bind only β-Glc. SCR018 and SCR020, alternatively, 
bind preferentially to α-Man, an important biological target for which there is no other specific SCR, and 
SCR019 binds only β-Man. Of these new SCRs, all bound their preferred substrate with either Log(K1) or 
Log(β) > 3.9.  
 
Figure 4.2. Log (β) values of the receptors towards different glycans. The baseline is set to Log (β) of 1.5 
(Ka=3.0 x 101 M‒1) as the threshold below which binding cannot be reported accurately from 1H NMR 
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titrations. Star over bars indicate a cumulative association constant (β=K1*K2), alternatively Log (β) = 
LogK1. 
 
4.5. Computational modelling 
Calculations were performed on all 40 SCR•glycan combinations to determine the structures of 
the supramolecular complexes and estimate their binding energies, ΔEs. In addition to clarifying why the 
changes to the heterocycles and linkage regiochemistry cause dramatic changes in the affinities and the 
selectivities of the SCRs towards different glycans, such computational guidance is invaluable in the design 
of future of SCRs because the laborious syntheses and binding studies on SCRs that have insignificant Kas 
could be avoided. Estimating Kas and host•guest structures must involve a long timescale molecular 
dynamics (MD) simulations married to the accuracy of ab initio potentials. While long-time MD 
simulations of the SCR•glycan complexes using an empirical potential function (force field) could 
reproduce the experimental Kas, such modeling remains largely underexplored because of the lack of 
appropriate parameters for carbohydrate-receptor interactions in non-aqueous solutions, and, as such, is too 
preliminary to apply here. The alternative, ab initio MD, which utilizes density-functional theory (DFT) for 
propelling the equation of motions, is prohibitively expensive for systematically deriving the structures of 
molecular complexes.118 Another computation hurdle is the complexity of the SCR•glycan conformational 
space. The inherent flexibility of the glycosides and the SCRs, encoded in ring puckering and rotatable 
bonds, respectively, results in a substantially greater computational challenge than, for instance, docking a 
conventional ligand into the active site of a rigid protein. A systematic search on the potential-energy 
landscape will underexplore the host•guest complex conformational space, so metadynamics techniques 
must be employed to accelerate the sampling process. To tackle these challenges, we applied a cascade-like 
protocol119-121 that starts by sampling using replica-exchange MD at the force field level and refines the 
promising candidates, immersed in the continuous solvation model, at the DFT level of theory.  
With this approach, all 40 1:1 SCR•glycan complexes combinations and the 7 complexes with 
higher (2:1 or 1:2) binding stoichiometries were screened to determine ΔE (Table 4.2.) and supramolecular 
structures. The computational ΔEs lack vibrational and entropic contributions and cannot therefore be 
compared directly to experimentally derived ΔG values. The ΔH values for association of SCR001 with α-
Glc, β-Gal, β-Glc, and β-Man in CDCl3, have, however, been reported,102 and these can be compared more 
directly to the ΔE values derived from the computational approach. Experimentally, the magnitude of ΔH 
of 1:1 binding of the glycans to SCR001 follow the trend β-Man > β-Glc > β-Gal > α-Glc, and DFT-based 
computational methods reproduce this trend. In addition to this qualitative accord, quantitative agreement 
between the experimentally- and computationally-derived binding values is observed. For example, the 
difference in ΔH between SCR001•β-Man and SCR001•α-Glc is 7.4 kcal mol—1, and in ΔE, by 
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comparison, was 7.1 kcal mol—1. Furthermore, experimentally β-Glc, β-Man and α-Man bind 4-5 times 
stronger to SCR001 compared to β-Gal and α-Glc, which at room temperature translates to approximately 
1 kcal mol-1 difference in binding free energy, and theory predicts a 4 kcal mol-1 energy gap between these 
two groups. Similar matches exist when comparing all 1:1 complexes, which have measurable Ka. Besides 
SCR001, only SCR018•α-Man, SCR018•β-Gal and SCR020•β-Man have substantial K1. Theory confirms 
that SCR018 binding energy with α-Man and β-Gal is at least 3.5 kcal mol-1 greater than with the next 
glycan. Similarly, theory predicts than SCR020 forms the strongest interaction with β-Man. These matches 
confirm the ability of our computational approach to predict accurately which host-guest pairs have ΔH of 
association.  
 
Table 4.2. Computationally-derived, solvent-corrected binding energies (kcal mol–1) of the SCR•glycan 
complexes. The underlined complexes have been determined experimentally to form supramolecular 
complexes, and the bold numbers are experimentally determined.102-103  
 
a 1:2 SCR•glycan binding model, b 2:1 SCR•glycan binding model. 
 
1:1 Binding Structures 
 Structural analysis was carried out on the 11 SCR•glycan complexes that were confirmed 
experimentally to bind. These analyses revealed three types of 1:1 supramolecular structures occurred, 
which are referred to as “center-parallel”, “center-perpendicular”, and “off-center”. The structures of 
SCR001•β-Glc, SCR001•α-Glc, and SCR001• β-Man are used to illustrate the differences in the three 
binding geometries, respectively (Figure 4.3). Structures of other complexes are shown in Figures S4.80-
S4.82 in the Experimental Section, including xyz Cartesian coordinates for all analyzed structures. The 
SCR001•β-Glc is a center-parallel binder in that the glycan rests above the center of the biaryl ring, where 
the diagonal axis of the hexose ring (a line connecting the C1 and C4 carbons) and the biaryl group are 
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parallel (Figure 4.3.A). In this complex, several noncovalent interactions operate in concert to stabilize the 
supramolecular association. The β-glucoside accepts two H-bonds from the pyrrole rings – Npyr‒H•••O2 and 
Npyr‒H•••O4 – and donates an O6‒H•••Namine‒H bond. The structure is further stabilized by C‒H1,3,5•••π 
interactions between the hexose α-face and the benzene rings. The involvement of three of four receptor 
arms is consistent with previously reported spectroscopic and computational data,102 providing further 
validation that our computational approach provides accurate structural data. The equatorial orientation of 
the octyloxy group appears to be structural prerequisite for the formation of a center-parallel complexes, 
although having an equatorial octyloxy group does not necessarily dictate the formation of a center-parallel 
structure. It should be noted that the interaction involving the α-face hydrogens of the hexose observed in 
the models agreed well with the NMR titration data reported previously,102-103 where C‒H1,3,5•••π 
interactions caused an average upfield shift of 0.3 ppm of the hexose. Furthermore, the Npyr‒H proton shifts 
downfield by 0.16 ppm validates the H-bonds observed in the model. Other complexes that adopt the center-
parallel geometry include SCR019•β-Man and SCR021•β-Glc (see Experimental Section for details), both 
of which form strongly cooperative higher stoichiometry complexes.  
 
Figure 4.3. Three different types of 1:1 SCR001•glycan complexes. The top two rows show a model of 
the complex in two different perspectives (front and side), along with a simplified view in the top left corner. 
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The gold dashed lines indicate H-bonding contacts. The bottom row shows a space-filling model of the 
host•guest complexes in the side-view perspective.  
 
In the center-perpendicular geometry adopted by SCR001•α-Glc, the diagonal axis of the hexose 
is perpendicular to the biaryl axis (Figure 4.3.B). In this complex, the α-Glc accepts three H-bonds from 
the pyrrole rings – Npyr‒H•••O6, Npyr‒H•••O3 and Npyr‒H•••O2. While the hexose is still centered over the 
biaryl core, the axial octyloxy group at the anomeric carbon forces the perpendicular orientation and 
prevents the formation of stabilizing C‒H•••π interactions. As a consequence, the α-Glc binds weaker than 
β-Glc to the SCR001 by 4.2 kcal mol-1. Again these structures agreed well with the NMR titration data, 
where a pyrrolic H-bond caused a 0.11 ppm downfield shift in Npyr‒H.102-103 The titration data also indicates 
that both H3 and H4 experience an upfield shift of 0.18 ppm and 0.29 ppm respectively. Because these Hs 
are on the opposite faces of the hexose ring, the α-Glc must adopt perpendicular orientation to the biaryl 
core so both protons can form C‒H•••π interactions, which, again, is entirely consistent with the lowest 
energy structure. Other complexes that adopt the center-perpendicular geometry include SCR001•β-Gal, 
SCR020•β-Man and SCR020•α-Man. In all cases, the K1 is reported to be 100‒350 M-1, and, of these, 
only SCR020•α-Man forms a higher stoichiometry complex that is only weakly cooperative.  
In the off-center geometry adopted by SCR001•β-Man, the hexose does not bind directly above 
the biaryl core, but instead it rests between the two arms on the same side of the long axis of the biaryl 
group of the receptor (Figure 4.3.C). Although this geometry lacks stabilizing C‒H•••π interactions, the 
two amine groups and two 2-pyrrole heterocycles form a pocket that binds the axially oriented O2‒H of β-
Man. The Namine‒H•••O2‒H•••Namine‒H bonding motif, is further stabilized by adjacent Npyr‒H•••O6‒H and 
O6‒H•••Namine‒H bonds. As a result of these multiple interactions, the SCR001•β-Man has the strongest 
predicted ΔE amongst all the computed SCR001•glycan complexes. As with the above geometries, this 
structure was in good agreement with the NMR data where an upfield 0.15 ppm shift is observed in Npyr‒
H.102-103 The binding also causes upfield shifts of H1 and H3,4,5 protons. These protons are readily accessible 
for heterocycles to form C‒H•••π interactions, whereas access to the H2 proton is blocked by the alkyl chain. 
Furthermore, the off-center structures can form symmetric higher-stoichiometry complexes by stabilizing 
another glycan in an identical binding pocket, as observed experimentally for SCR001•(β-Man)2 and 
SCR001•(α-Man)2 in CDCl3.102 Other complexes that adopt the off-center geometry include SCR017•β-
Glc, SCR018•α-Man, SCR018•β-Gal, and SCR022•β-Glc. Among these complexes, only SCR018•α-
Man does not form higher stoichiometry complexes because the bulky heterocyclic groups block the second 






 In the titrations, it was found that several SCR•glycan combinations formed higher-order (1:2 and 
2:1) complexes that, in some cases, assemble with substantial positive cooperativity (K2 >> K1). The origin 
of the cooperativity can be understood by examining the computed structures. SCR001•(β-Man)2, 
SCR017•(β-Glc)2, SCR019•(β-Man)2, SCR020•(α-Man)2, SCR021•(β-Glc)2 all form 1:2 SCR•glycan 
supramolecular complexes. Of those, only the SCR001•β-Man complex has K2 < K1. The 1:2 binding of 
SCR001•β-Man in CDCl3 has been explained previously.102 We had shown using computational and 
experimental data that the β-Man occupied identical binding pockets on opposite faces of the biaryl ring, 
and the more sophisticated computational approach presented here reproduces this result ‒ the symmetric 
complex (Figure 4.4.A) is more stable than any other complex of SCR001•(β-Man)2 found during the 
structural search. Most importantly, this molecular modeling reveals why the SCR001•(β-Man)2 has 
minimal cooperativity – there are no stabilizing interactions that form between the two glycan guests. 
 
Figure 4.4. Three different 1:2 SCR•glycan complexes with varying degrees of cooperativity, along with 
a simplified view in the top left corner. The top row shows the stick models and the bottom row shows 




Unlike the higher-order complex with weak cooperativity, computations revealed that all the 1:2 
SCR•glycan complexes where K2 >> K1 (SCR020•(α-Man)2, SCR021•(β-Glc)2, SCR017•(β-Glc)2, 
SCR019•(β-Man)2) are stabilized by sugar-sugar contacts  (Figure 4.4.B and C and Figure S4.83), and 
the ratio K2/K1 increases with increasing number of sugar - sugar contacts. In the case of SCR020•(α-
Man)2, the K2/K1 is approximately 4, and interactions between the two α-Man species are limited to one 
O3‒H•••O6‒H contact that contributes 5 kcal mol-1 of stabilization. The remaining 1:2 SCR•glycan 
complexes, SCR017•(β-Glc)2, SCR019•(β-Man)2 and SCR021•(β-Glc)2, however, feature K2s that are 3-
4 orders of magnitude larger than K1, which means that the binding of the second hexose is strongly 
cooperative. Computational methods confirm that in each of these complexes the binding of the first hexose 
is relatively weak. The binding of the second hexose, however, is at least as strong as the binding of the 
first sugar. Furthermore, the interaction energy between two hexoses in these strongly cooperative 
complexes is predicted to be >10 kcal mol-1 in magnitude because at least two H-bonds are formed between 
each pair of hexoses.  
Titrations also showed that SCR001•β-Man and SCR022•β-Glc, form 2:1 complexes in which 
multiple receptors bind to one sugar. Previously, we reported that SCR0012•β-Man exists in complex 
equilibrium with SCR001•β-Man and SCR001•β-Man2 species.102 Here, the two SCR001 receptors were 
wrapped around the glycan in a “hugging” complex (Figure 4.5.A), where the axially oriented O2–H and 
O6–H that occur in a gauche conformation of β-Man stabilizes the complex by forming four H-bonds with 
both receptors. However, the second receptor adds only one more H-bond than those already present in the 
1:1 SCR001•β-Man complex, and there is little interaction between the receptors. In effect, the binding 
energy of the second receptor is weaker by 3.4 kcal mol-1 than the binding of the first, the experimentally 
determined K2 is 2 orders of magnitude smaller than K1 indicating a non-cooperative complex. In the case 
of SCR0222•β-Glc, however, we observe that K2/K1 is ~6, indicating a weakly cooperative complex 
(Figure 4.5.B). Here, the theory predicts that the phenolic O‒H groups, which serve as H-bond donors and 
acceptors, interact strongly with the glycans. In an unbound receptor, these O‒H groups are locked by a 
strong H-bond with adjacent amine group, Oph‒H•••Namine‒H. Upon interaction with β-Glc, however, two 
receptors interact with each other in a “spooning” complex, which creates a hydrophilic pocket for binding 
of the hexose. The β-Glc accepts a- Namine‒H•••O6–H H-bond from and donates a O6‒H •••Ophe–H H-bond 
to the same receptor. The other receptor supports this binding with an additional Namine‒H•••O1 H-bond and 
a pronounced C‒H1,3,5•••π interaction between α-face of the hexose and a neighboring phenyl ring. Finally, 
theory predicts that the binding of the second receptor is stronger by more than 10 kcal mol-1 than the first, 
although our computational approach may be overestimating the strength of the van der Waals interactions 




   
 
Figure 4.5. Two different 2:1 SCR•glycan complexes shown using stick and space-filling model, along 
with simplified view in the top left corner. The columns show whole complex, each pair of SCR•glycan 
components. The top row shows SCR0012•β-Man complex adopting a “hugging” geometry. The bottom 




 Here, we have reported the synthesis of seven new C2h tetrapodal SCRs, and their binding against 
five biologically relevant octyloxy O-glycans was studied in CH2Cl2 by mass spectrometry, 1H NMR 
titrations, and molecular modeling. These receptors varied only by the composition and attachment 
regiochemistry of the heterocyclic binding arms. Of these, three were selective binders of β-Glc, one was 
selective for β-Man, and two bound preferentially α-Man. By comparison with previously synthesized 
tetrapodal SCRs, we see that in only three generations, this class of receptors has been advanced from 
promiscuous, moderate binders to strong and highly selective binders. All 40 1:1 SCR•glycan 
supramolecular complexes and 7 addition higher stoichiometry (1:2 and 2:1) complexes were analyzed by 
molecular modeling, whose binding energies and structural models agreed well with experimental data. 
Binding was dictated by C–H‧‧‧π contacts and H-bonding, and the 1:1 structures formed three general 
binding motifs that are classified as “center-parallel”, “center-perpendicular”, or “off-center”. Modeling 
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also revealed that when the 1:2 SCR•glycan complexes formed with substantial positive cooperativity, it 
was the result of new glycan-glycan contacts.  
 This work promises to advance the field of SCRs in several important ways. First, we echo the 
findings of others in the field who show the importance of the heterocyclic binding groups for manipulating 
selectivity and binding affinity. Secondly, the advent of accurate molecular modeling approaches provides 
the ability to predict accurately how a particular SCR will bind to a receptor, so arduous and time-
consuming syntheses and binding studies can be avoided. The antiviral performance of these new receptors 
is currently being assessed, and how the increased selectivity and binding affinity affect antiviral activity 
and toxicity is a topic of substantial current interest. Moreover, having a library of SCRs with different 
selectivities could form the basis of powerful new sensor platforms for the in situ detection of glycans, a 
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1. Experimental Section 
1.1. Organic Synthesis 
General methods. All solvents, reagents and starting materials were purchased from commercial sources 
and used without further purification unless otherwise noted. All solvents were dried using a JC Meyer 
solvent purification system. Aqueous solutions were prepared from nanopure water from a Milli-Q plus 
system, with a resistivity over 18 MΩ cm-1. Chromatography purifications were performed using silica gel 
(60 Å, 70-230 mesh). Thin-layer chromatography (TLC) was carried out using aluminum sheets precoated 
with silica gel 60 (EMD 40-60 mm, 230-400 mesh with 254 nm dye). TLC plates were visualized by UV-
light and using charring solution (prepared by dropwise addition of conc.H2SO4 (5 mL) to a solution of 
H3PMo12O40 (1 g) and Ce(SO4)2 (2 g) in water (95 mL)), alkaline KMnO4 solution (prepared by dissolving 
KMnO4 (2 g) and NaHCO3 (4 g) in water (100 mL)), and heat as developing agents. All reactions were 
carried out under an inert atmosphere of Ar using standard Schlenk techniques unless otherwise noted. 
Reaction flasks were dried in an oven at 100 °C for 12 h. Compounds 1, SCR0011 and 1,2-bis(prop-2-yn-
1-yloxy)ethane,2 and 3,6,9,12,15,18-hexaoxaicosa-1,19-diyne2 were synthesized according to published 
literature procedures. Deuterated solvents were purchased from Cambridge Isotope Laboratories Inc. and 
used as received. NMR spectra were obtained on a Bruker AVANCE 300 MHz spectrometer. All chemical 
shifts are reported in δ units (ppm) using the solvent residual signal as an internal standard. The following 
abbreviations are used for signal multiplicities: s, singlet; br s, broad singlet, d, doublet; t, triplet; q, quartet; 
m, multiplet; dd, doublet of doublets. High-resolution electrospray ionization mass spectra were obtained 
on Agilent Q-TOF system. 
SCRs were synthesized following the procedure described below unless otherwise noted. PPh3 (5 mmol, 5 
eq) was added to a stirring solution of 1 (1 mmol, 1 eq) in THF (5 mL) at room temperature. The reaction 
was refluxed under Ar atmosphere for 1 h before the addition of the heteroarylaldehyde (5 mmol, 5 eq) at 
room temperature. The reaction mixture was refluxed for additional 48 h, cooled to room temperature, and 
concentrated under reduced pressure. The residue was dissolved in MeOH (5 mL), and NaBH4 (10 mmol, 
10 eq), was added in portions at room temperature under Ar atmosphere followed by stirring for 16 h. The 
reaction mixture was concentrated under reduced pressure, treated with CHCl3 (30 mL) and H2O (30 mL), 
and the organic layer was separated. The aqueous layer was extracted with CHCl3 (3 x 30 mL), and the 
combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced 
pressure to give the crude product, which was purified by column chromatography (SiO2, 9:1:0.5 CHCl3: 
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Scheme S2. Synthesis of receptors SCR017-SCR023 from 1. 
 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-(furan-2-ylmethyl)methanamine) 
SCR002. PPh3 (1.76 g, 6.7 mmol) was added to a stirring solution of 1 (500 mg, 1.34 mmol) in THF (30 
mL) at room temperature. The reaction was refluxed under Ar atmosphere for 1 h before the addition of 
furan-2-carbaldehyde (640 mg, 6.7 mmol) at room temperature. The reaction mixture was refluxed for 
additional 48 h, cooled to room temperature, and concentrated under reduced pressure. The residue was 
dissolved in MeOH (30 mL), and NaBH4 (507 mg, 13.4 mmol), was added in portions at room temperature 
under Ar atmosphere followed by stirring for 16 h. The reaction mixture was concentrated under reduced 
pressure, treated with CHCl3 (50 mL) and H2O (50 mL), and the organic layer was separated. The aqueous 
layer was extracted with CHCl3 (3 x 50 mL), and the combined organic layers were dried over anhydrous 
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Na2SO4, filtered and concentrated under reduced pressure. The crude product was treated with H2O (10 
mL), acidified with 3M HCl and washed with CHCl3 (3 x 40 mL). The pH of the aqueous layer was raised 
with 3M NaOH and extracted with CHCl3 (3 x 40 mL). The combined organic layers were dried over 
anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide SCR002 (750 mg, 95%) as 
a brown gum. 1H NMR (300 MHz, CDCl3) δ = 7.46 (d, J = 1.4 Hz, 4H), 7.37 (dd, J = 1.9, 0.8 Hz, 4H), 7.28 
(s, 2H), 6.32 (dd, J = 3.1, 1.9 Hz, 4H), 6.20 (dd, J = 3.1, 0.5 Hz, 4H), 3.84 (s, 8H), 3.83 (s, 8H), 1.88 (br s, 
4H); 13C NMR (75 MHz, CDCl3) δ = 153.90, 141.98, 141.47, 140.70, 127.26, 126.03, 110.25, 107.23, 
53.00, 45.66; HRMS (ESI): m/z calcd for C36H39N4O4 [M+H]+: 591.2966, found 591.2958. 
 
 1H NMR of SCR002 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR002 (75 MHz, 25° C) in CDCl3. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-(thiophen-2-
ylmethyl)methanamine) SCR003. PPh3 (1.76 g, 6.7 mmol) was added to a stirring solution of 1 (500 mg, 
1.34 mmol) in THF (30 mL) at room temperature. The reaction was refluxed under Ar atmosphere for 1 h 
before the addition of thiophene-2-carbaldehyde (751 mg, 6.7 mmol) at room temperature. The reaction 
mixture was refluxed for an additional 48 h, cooled to room temperature, and concentrated under reduced 
pressure. The residue was dissolved MeOH (30 mL), and NaBH4 (507 mg, 13.4 mmol) was added in 
portions at room temperature under Ar atmosphere followed by stirring for 16 h. The reaction mixture was 
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concentrated under reduced pressure, treated with CHCl3 (50 mL) and water (50 mL), and the organic layer 
was separated. The aqueous layer was extracted with CHCl3 (3 x 50 mL), and the combined organic layers 
were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure. The crude product 
was treated with H2O (10 mL), acidified with 3M HCl and washed with CHCl3 (3 x 40 mL). The pH of the 
aqueous layer was raised with 3M NaOH and extracted with CHCl3 (3 x 40 mL). The combined organic 
layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to provide 
SCR003 (350 mg, 40%) as a colorless gum. 1H NMR (300 MHz, CDCl3) δ = 7.48 (d, J = 1.2 Hz, 4H), 7.31 
(s, 2H), 7.22 (dd, J = 4.6, 1.7 Hz, 4H), 7.00-6.87 (m, 8H), 4.04 (s, 8H), 3.91 (s, 8H), 1.82 (br s, 4H); 13C 
NMR (75 MHz, CDCl3) δ = 144.25, 141.51, 140.84, 127.17, 126.77, 125.97, 125.09, 124.54, 52.94, 47.80; 
HRMS (ESI): m/z calcd for C36H39N4S4 [M+H]+: 655.2052, found 655.2048. 
 
   1H NMR of SCR003 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR003 (75 MHz, 25° C) in CDCl3. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-((1-methyl-1H-imidazol-2-
yl)methyl)methanamine) SCR004. PPh3 (1.76 g, 6.7 mmol) was added to a stirring solution of 1 (500 mg, 
1.34 mmol) in THF (30 mL) at room temperature. The reaction was refluxed under Ar atmosphere for 1 h 
before the addition of 1-methyl-1H-imidazole-2-carbaldehyde (740 mg, 6.7 mmol) at room temperature. 
The reaction mixture was refluxed for an additional 48 h, cooled to room temperature, and concentrated 
under reduced pressure. The residue was dissolved MeOH (30 mL), and NaBH4 (507 mg, 13.4 mmol) was 
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added portion wise at room temperature under Ar atmosphere followed by stirring at the same temperature 
for 16 h. The reaction mixture was concentrated under reduced pressure, treated with CHCl3 (50 mL) and 
H2O (50 mL), and the organic layer was separated. The aqueous layer was extracted with CHCl3 (3 x 50 
mL), and the combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was treated with water (10 mL), acidified with 3M HCl and washed 
with CHCl3 (3 x 40 mL). The aqueous layer was basified with 3M NaOH and extracted with CHCl3 (3 x 40 
mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under 
reduced pressure. The resulting residue was purified by column chromatography (SiO2, 9:1:0.5 CHCl3 : 
MeOH : NH3) to provide SCR004 (400 mg, 46%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ = 
7.44 (s, 4H), 7.29 (s, 2H), 6.92 (br s, 4H), 6.80 (br s, 4H), 3.87 (s, 8H), 3.86 (s, 8H), 3.62 (s, 12H), 2.28 (br 
s, 4H); 13C NMR (75 MHz, CDCl3) δ = 146.40, 141.23, 140.55, 127.10, 127.01, 125.75, 121.19, 53.50, 
45.17, 32.70; HRMS (ESI): m/z calcd for C36H47N12 [M+H]+: 647.4041, found 647.4036.  
 
 1H NMR of SCR004 (300 MHz, 25° C) in CDCl3. 
 
 
 13C NMR of SCR004 (75 MHz, 25° C) in CDCl3. 
Synthesis of (1E,1'E,1''E,1'''E)-N,N',N'',N'''-([1,1'-biphenyl]-3,3',5,5'-
tetrayltetrakis(methylene))tetrakis(1-(1H-pyrrol-2-yl)methanimine) SCR005. PPh3 (1.76 g, 6.7 mmol) 
was added to a stirring solution of 1 (500 mg, 1.34 mmol) in THF (30 mL) at room temperature. The reaction 
was heated to 90 °C under Ar atmosphere and stirred for 1 h before the addition of 1H-pyrrole-2-
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carbaldehyde (637 mg, 6.7 mmol) at room temperature. The reaction mixture was stirred for an additional 
30 h at 90 °C, cooled to room temperature, and concentrated under reduced pressure. The crude product 
was purified by column chromatography (SiO2, 9:1:0.5 CHCl3 : MeOH : NH3) to provide SCR005 (250 mg, 
32%) as a yellow solid. 1H NMR (300 MHz, DMSO) δ = 11.43 (br s, 4H), 8.25 (s, 4H), 7.50 (s, 4H), 7.26 
(s, 2H), 6.88 (s, 4H), 6.49 (dd, J = 3.3, 1.0 Hz, 4H), 6.12 (t, J = 3.0 Hz, 4H), 4.73 (s, 8H); 13C NMR (75 
MHz, DMSO) δ = 152.60,140.90, 140.42, 129.95, 126.94, 124.95, 122.29, 113.92, 108.97, 63.90; HRMS 
(ESI): m/z calcd for C36H35N8 [M+H]+: 579.2979, found 579.2973. 
 
 1H NMR of SCR005 (300 MHz, 25° C) in DMSO.  
 
 13C NMR of SCR005 (75 MHz, 25° C) in DMSO. 
Synthesis of (1E,1'E,1''E,1'''E)-N,N',N'',N'''-([1,1'-biphenyl]-3,3',5,5'-
tetrayltetrakis(methylene))tetrakis(1-(furan-2-yl)methanimine) SCR006. PPh3 (1.76 g, 6.7 mmol) was 
added to a stirring solution of 1 (500 mg, 1.34 mmol) in THF (30 mL) at room temperature. The reaction 
was refluxed under Ar atmosphere for 1 h before the addition of furan-2-carbaldehyde (643.8 mg, 6.7 mmol) 
at room temperature. The reaction mixture was refluxed for an additional 48 h, cooled to room temperature, 
and concentrated under reduced pressure. The crude product was purified by column chromatography 
(SiO2, 9:1:0.5 CHCl3 : MeOH : NH3) to provide SCR006 (150 mg, 19%) as a light brown solid. 1H NMR 
(300 MHz, CDCl3) δ = 8.17 (s, 4H), 7.50 (s, 4H), 7.45 (s, 4H), 7.26 (s, 4H), 6.76 (d, J = 3.3 Hz, 4H), 6.46 
(dd, J = 3.3, 1.7 Hz, 4H), 4.82 (s, 8H); 13C NMR (75 MHz, CDCl3) δ = 151.55, 150.52, 144.79, 141.69, 
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139.51, 127.36, 126.25, 114.34, 111.64, 65.13; HRMS (ESI): m/z calcd for C36H31N4O4 [M+H]+: 583.2340, 
found 583.2335. 
 
 1H NMR of SCR006 (300 MHz, 25° C) in CDCl3. 
 
  13C NMR of SCR006 (75 MHz, 25° C) in CDCl3. 
Synthesis of (1E,1'E,1''E,1'''E)-N,N',N'',N'''-([1,1'-biphenyl]-3,3',5,5'-
tetrayltetrakis(methylene))tetrakis(1-(thiophen-2-yl)methanimine) SCR007. PPh3 (1.76 g, 6.7 mmol) 
was added to a stirring solution of 1 (500 mg, 1.34 mmol) in THF (30 mL) at room temperature. The reaction 
was refluxed under Ar atmosphere for 1 h before the addition of thiophene-2-carbaldehyde (751 mg, 6.7 
mmol) at room temperature. The reaction mixture was refluxed for an additional 48 h, cooled to room 
temperature, and concentrated under reduced pressure. The crude product was purified by column 
chromatography (SiO2, 9:1:0.5 CHCl3 : MeOH : NH3) to provide SCR007 (150 mg, 17%) as a light brown 
solid. 1H NMR (300 MHz, CDCl3) δ = 8.49 (s, 4H), 7.47 (s, 4H), 7.40 (br s, 4H), 7.34 (br s, 4H), 7.28 (d, 
2H), 7.08 (br s, 4H), 4.85 (s, 8H); 13C NMR (75 MHz, CDCl3) δ = 155.36, 142.53, 141.74, 139.78, 130.78, 





 1H NMR of SCR007 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR007 (75 MHz, 25° C) in CDCl3. 
Synthesis of [1,1'-biphenyl]-3,3',5,5'-tetrayltetramethanamine tetrahydrochloride 2. PPh3 (5.25 g, 
20.0 mmol) was added to a stirring solution of 1 (1.00 g, 2.67 mmol) in THF (80 mL) at room temperature. 
The reaction was heated at 65 °C under Ar atmosphere for 1 h before the addition of H2O (20 mL) at room 
temperature. The reaction mixture was heated at 65 °C for an additional 18 h, cooled to room temperature, 
and HCl (37% in H2O, 20 mL) was added dropwise. After stirring the solution for 2 h, the reaction mixture 
was washed with CH2Cl2 (3 x 100 mL), and the aqueous layer was filtered and concentrated under reduced 
pressure to give 2 (1.1 g, 99%) as pale white solid.  1H NMR (300 MHz, D2O) δ = 7.75 (d, J = 1.4 Hz, 4H), 
7.49 (s, 2H), 4.25 (s, 8H); 13C NMR (75 MHz, D2O) δ = 141.03, 134.40, 128.69, 128.38, 42.75; HRMS 




 1H NMR of 2 (300 MHz, 25° C) in D2O. 
 
 13C NMR of 2 (75 MHz, 25° C) in D2O. 
Synthesis of N,N',N'',N'''-([1,1'-biphenyl]-3,3',5,5'-tetrayltetrakis(methylene))tetrakis(furan-2-
carboxamide) SCR008. N,N-diisopropylethylamine (4.2 mL, 24 mmol) was added dropwise to a 
suspension of [1,1'-biphenyl]-3,3',5,5'-tetrayltetramethanamine tetrahydrochloride (0.50 g, 1.2 mmol) and 
furan-2-carboxylic acid (0.65 g, 5.76 mmol) in dry DMF (10 mL) at room temperature under Argon 
atmosphere followed by stirring for 10 min. HBTU (2.19 g, 5.76 mmol) was added at room temperature 
and then stirred for 36 h. The reaction mixture was concentrated under reduced pressure to remove DMF, 
and the resulting residue was dissolved in 10% MeOH/EtOAc (40 mL), washed successively with saturated 
NaHCO3 (aq) solution (3 x 20 mL) and water (3 x 20 mL). The organic layer was dried over anhydrous 
Na2SO4, filtered and concentrated under reduced pressure to give the crude product which was triturated 
with diethyl ether and dried in vacuo to afford SCR008 (0.65 g, 84%) as a light brown solid. 1H NMR (300 
MHz, DMSO) δ = 8.96 (t, J = 6.0 Hz, 4H), 7.83 (d, J = 1.1 Hz, 4H), 7.42 (s, 4H), 7.26 (s, 2H), 7.10 (d, J = 
3.4 Hz, 4H), 6.62 (dd, J = 3.4, 1.8 Hz, 4H), 4.46 (d, J = 6.0 Hz, 8H); 13C NMR (75 MHz, CDCl3) δ = 158.21, 
148.26, 145.50, 140.83, 140.79, 126.15, 125.13, 113.94, 112.29, 42.48; HRMS (ESI): m/z calcd for 




 1H NMR of SCR008 (300 MHz, 25° C) in DMSO. 
 
 13C NMR of SCR008 (75 MHz, 25° C) in DMSO. 
Synthesis of N,N',N'',N'''-([1,1'-biphenyl]-3,3',5,5'-tetrayltetrakis(methylene))tetrakis(thiophene-2-
carboxamide) SCR009. N,N-diisopropylethylamine (0.42 mL, 2.4 mmol) was added dropwise to a 
suspension of [1,1'-biphenyl]-3,3',5,5'-tetrayltetramethanamine tetrahydrochloride (0.05 g, 0.12 mmol) and 
thiophene-2-carboxylic acid (0.074 g, 0.576 mmol) in dry DMF (3 mL) at room temperature under Argon 
atmosphere followed by stirring for 10 min. HBTU (0.219 g, 0.576 mmol) was added in one portion at 
room temperature and then stirred for 36 h. The reaction mixture was concentrated under reduced pressure 
to remove DMF, and the resulting residue was dissolved in 10% MeOH/EtOAc (10 mL), washed 
successively with saturated NaHCO3 (aq) solution (3 x 10 mL) and H2O (3 x 10 mL). The organic layer 
was dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to give the crude 
product which was triturated with diethyl ether and dried in vacuo to afford SCR009 (0.035 g, 41%) as a 
light brown solid. 1H NMR (500 MHz, CDCl3) δ = 9.08 (t, J = 5.9 Hz, 4H), 7.81-7.70 (m, 8H), 7.45 (s, 4H), 
7.29 (s, 2H), 7.13 (dd, J = 5.0, 3.7 Hz, 4H), 4.49 (d, J = 5.9 Hz, 8H); 13C NMR (75 MHz, CDCl3) δ = 
161.12, 140.43, 140.38, 139.80, 130.81, 128.14, 127.91, 125.69, 124.68, 42.59; HRMS (ESI): m/z calcd 




 1H NMR of SCR009 (300 MHz, 25° C) in DMSO. 
 
 13C NMR of SCR009 (75 MHz, 25° C) in DMSO. 
Synthesis of 1,12-bis(1-((3',5,5'-tris(azidomethyl)-[1,1'-biphenyl]-3-yl)methyl)-1H-1,2,3-triazol-4-yl)-
2,5,8,11-tetraoxadodecane 3. 4,7,10,13-tetraoxahexadeca-1,15-diyne (240 mg, 1.06 mmol) and 1 (2.0 g, 
5.34 mmol) were dissolved in 90 mL anhydrous DMF. 10 mL H2O was added, followed by sodium 
ascorbate (828 mg, 4.17 mmol), CuSO4 (35.4 mg, 0.21 mmol) and bathocuproinedisulfonic acid disodium 
salt (145 mg, 0.26 mmol). The mixture was stirred at room temperature under Ar for 24 h. The reaction 
mixture was concentrated under reduced pressure and purified by column chromatography (SiO2, 100:1.4 
CHCl3 : MeOH) to provide 3 (400 mg, 39%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ = 7.58 (s, 
2H), 7.51 (s, 2H), 7.47 (s, 2H), 7.46 (s, 4H), 7.29 (s, 2H), 7.23 (s, 2H), 5.58 (s, 4H), 4.65 (s, 4H),  4.44 (s, 
8H), 4.42 (s, 4H), 3.70-3.64 (m, 4H), 3.64-3.58 (m, 4H), 3.57 (s, 4H); 13C NMR (125 MHz, CDCl3) δ = 
145.83, 141.83, 141.17, 137.44, 137.12, 136.23, 127.28, 127.23, 127.05, 126.89, 126.82, 122.80, 70.62, 





 1H NMR of 3 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of 3 (75 MHz, 25° C) in CDCl3. 
Synthesis of 1,2-bis((1-((3',5,5'-tris(azidomethyl)-[1,1'-biphenyl]-3-yl)methyl)-1H-1,2,3-triazol-4-
yl)methoxy)ethane, 4. 1,2-bis(prop-2-yn-1-yloxy)ethane (200 mg, 1.5 mmol) and 1 (2.7 g, 7.2 mmol) were 
dissolved in 135 mL anhydrous DMF. 15 mL H2O was added, followed by sodium ascorbate (1.2 g, 6.0 
mmol), CuSO4 (49 mg, 0.30 mmol), and bathocuproinedisulfonic acid disodium salt (200 mg, 0.38 mmol). 
The mixture was stirred at room temperature under Ar for 24 h. The reaction mixture was concentrated 
under reduced pressure, triturated with CHCl3, passed through a silica column, and eluted with CHCl3 to 
remove 4N3. Then the column was flushed with 10% MeOH/CHCl3, and the fractions were concentrated to 
give the crude which was further purified by column chromatography (SiO2, 1 to 1.5% MeOH in CHCl3) 
to provide 4 (310 mg, 24%) as a pale yellow oil. 1H NMR (300 MHz, CDCl3) δ = 7.59 (s, 2H), 7.51 (s, 2H), 
7.48 (s, 2H), 7.45 (s, 4H), 7.29 (s, 2H), 7.23 (s, 2H), 5.58 (s, 4H), 4.65 (s, 4H),  4.44 (s, 8H), 4.42 (s, 4H), 
3.68 (s, 4H); 13C NMR (75 MHz, CDCl3) δ = 145.08, 141.76, 141.09, 137.38, 137.06, 136.16, 127.22, 
127.18, 127.01, 126.84, 126.76, 122.74, 69.75, 64.65, 54.41, 54.28, 53.80; HRMS (ESI): m/z calcd for 





 1H NMR of 4 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of 4 (75 MHz, 25° C) in CDCl3. 
 
 ESI high resolution mass spectrum of 4. 
Synthesis of 1,18-bis(1-((3',5,5'-tris(azidomethyl)-[1,1'-biphenyl]-3-yl)methyl)-1H-1,2,3-triazol-4-yl)-
2,5,8,11,14,17-hexaoxaoctadecane, 5. 3,6,9,12,15,18-hexaoxaicosa-1,19-diyne (310 mg, 1.0 mmol) and 1 
(1.87 g, 5.0 mmol) were dissolved in 90 mL anhydrous DMF. 10 mL H2O was added, followed by sodium 
ascorbate (825 mg, 4.17 mmol), CuSO4 (34 mg, 0.21 mmol) and bathocuproinedisulfonic acid disodium 
salt (140 mg, 0.26 mmol). The mixture was stirred at room temperature under Ar for 24 h. The reaction 
mixture was concentrated under reduced pressure, triturated with CHCl3, passed through a silica column, 
and eluted with CHCl3 to remove 4N3. Then the column was flushed with 10% MeOH/CHCl3, and the 
fractions were concentrated to give the crude which was further and purified by column chromatography 
(SiO2, 1 to 3% MeOH in CHCl3) to provide 5 (425 mg, 40%) as a pale yellow oil. 1H NMR (300 MHz, 
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CDCl3) δ = 7.62 (s, 2H), 7.51 (s, 2H), 7.48 (s, 2H), 7.46 (s, 4H), 7.29 (s, 2H), 7.23 (s, 2H), 5.60 (s, 4H), 
4.66 (s, 4H),  4.44 (s, 8H), 4.42 (s, 4H), 3.71-3.54 (m, 20H); 13C NMR (75 MHz, CDCl3) δ = 141.76, 141.12, 
137.37, 137.06, 136.22, 127.20, 127.17, 126.98, 126.82, 126.76, 122.81, 70.51, 70.47, 70.29, 69.82, 64.70, 
54.42, 54.30, 53.81; HRMS (ESI): m/z calcd for C48H54N24O6 [M+H]+: 1063.4731, found 1063.4737. 
 
 1H NMR of 5 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of 5 (75 MHz, 25° C) in CDCl3. 
 
 ESI high resolution mass spectrum of 5. 
Synthesis of SCR012. PPh3 (1.535 g, 5.85 mmol) was added to a stirring solution of 3 (830 mg, 0.851 
mmol) in PhMe (90 mL) at room temperature and heated at 90 °C under Ar atmosphere for 1 h before the 
addition of 1H-pyrrole-2-carbaldehyde (556 mg, 5.84 mmol) at room temperature. The reaction mixture 
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was stirred for an additional 48 h at 110 °C, cooled to room temperature, and concentrated under reduced 
pressure. The resulting residue was dissolved in MeOH (90 mL), and NaBH4 (319 mg, 8.44 mmol) was 
added to the solution over 20 min at room temperature. After stirring for 1 h, the reaction mixture was 
poured into H2O /brine (70 mL 1:1) and extracted with CH2Cl2 (4 x 70 mL). The organic fractions were 
combined, dried over anhydrous Na2SO4, concentrated under reduced pressure, and purified by column 
chromatography (SiO2, 7:1:1 CHCl3 : MeOH : NH3) to provide SCR012 (550 mg, 50%) as a brown solid. 
1H NMR (700 MHz, CD2Cl2) δ = 9.65 (s, 6H), 7.67 (s, 2H), 7.50 (s, 2H), 7.40 (s, 4H), 7.37 (s, 2H), 7.20 (s, 
4H), 6.80 (s, 6H), 6.19-6.13 (m, 12H), 5.45 (s, 4H),  4.66 (s, 4H), 3.88 (s, 8H), 3.85 (s, 4H), 3.79 (s, 12H), 
3.68 (s, 4H), 3.60 (s, 4H), 3.54 (s, 4H), 3.10-2.23 (br s, 6H); 13C NMR (175 MHz, CD2Cl2) δ = 145.85, 
141.06, 140.59, 135.98, 129.46, 129.02, 128.07, 127.61, 127.07, 126.01, 125.85, 123.49, 121.00, 117.86, 
117.58, 108.19, 107.07, 106.98, 70.69, 70.14, 64.81, 53.19, 52.97, 46.26; HRMS (ESI): m/z calcd for 
C74H89N18O4 [M+H]+: 1293.7314, found 1293.7417. 
 
 1H NMR of SCR012 (700 MHz, 25° C) in CD2Cl2. 
 




 ESI HRMS of SCR012 (40 µM) in MeCN, direct infusion 0.3 ‒ 0.5min, biased>300 m/z  
Synthesis of SCR015. PPh3 (1.0 g, 3.9 mmol) was added to a stirring solution of 3 (500 mg, 0.51 mmol) 
in THF (30 mL) at room temperature and refluxed under Ar atmosphere for 1 h before the addition of furan-
2-carbaldehyde (370 mg, 3.85 mmol) at room temperature. The reaction mixture was refluxed for an 
additional 48 h, cooled to room temperature, and concentrated under reduced pressure. The resulting residue 
was dissolved in MeOH (30 mL), and NaBH4 (291 mg, 7.69 mmol) was added portion wise at room 
temperature. After stirring for 16 h, the reaction mixture was poured into ice, and the MeOH was 
evaporated. The residue was acidified with 3N HCl at room temperature and extracted with CH2Cl2 (3 x 40 
mL). The aqueous layer was basified with 3N NaOH and extracted with CH2Cl2 (3 x 40 mL). The combined 
organic layers were dried over to anhydrous Na2SO4, filtered, and concentrated under reduced pressure to 
provide SCR015 (610 mg, 92%) as a brown gum. 1H NMR (700 MHz, CD2Cl2) δ = 7.54 (s, 2H), 7.51 (s, 
2H), 7.45-7.38 (m, 6H), 7.36 (s, 6H), 7.28 (s, 2H), 7.22 (s, 2H), 6.36-6.26 (m, 6H), 6.23-6.11 (m, 6H), 5.52 
(s, 4H),  4.63 (s, 4H), 3.90-3.72 (m, 24H), 3.68-3.45 (m, 12H); 13C NMR (75 MHz, CD2Cl2) δ = 153.75, 
153.61, 145.59, 142.18, 141.92, 141.87, 141.61, 140.80, 140.54, 135.20, 127.53, 127.49, 126.94, 125.84, 
122.56, 110.16, 107.22, 107.14, 70.50, 70.47, 69.74, 64.70, 54.14, 52.81, 52.52, 45.58, 45.52; HRMS (ESI): 




 1H NMR of SCR015 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR015 (75 MHz, 25° C) in CDCl3. 
 
 
 ESI high resolution mass spectrum of SCR015. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-((1H-pyrrol-3-
yl)methyl)methanamine) (SCR017). Following the General Procedure, SCR017 was synthesized from 1 
and 1H-pyrrole-3-carbaldehyde and purified by column chromatography (SiO2, 9:1:0.5 CHCl3: MeOH : 
NH3 (aq)) to provide a pale yellow solid (393 mg, 67%). 1H NMR (300 MHz, CD2Cl2) δ 7.48 (s, 4H), 7.31 
(s, 2H), 6.76 (d, J = 2.3 Hz, 8H), 6.21 (t, J = 2.2 Hz, 4H), 3.88 (s, 8H), 3.74 (s, 8H); 13C NMR (75 MHz, 
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CD2Cl2) δ = 140.93, 127.23, 125.58, 122.09, 117.68, 116.03, 108.25, 108.21, 52.93, 45.65; HRMS (ESI): 
m/z calcd for C36H42N8 [M+H]+: 587.3605, found 587.3606. 
 
 H NMR of SCR017 (300 MHz, 25° C) in CDCl3. 
 
 3C NMR of SCR017 (75 MHz, 25° C) in CDCl3. 
 
 HR-MS of SCR017. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-((1H-indol-2-
yl)methyl)methanamine) (SCR018). Following the General Procedure, SCR018 was synthesized from 1 
and 1H-indole-2-carbaldehyde and purified by column chromatography (SiO2, 9:1:0.5 CHCl3 : MeOH : 
NH3 (aq)) to provide a pale yellow solid (661 mg. 84%).  1H NMR (300 MHz, CDCl3) δ 8.75 (s, 4H), 7.57 
(d, J = 7.4 Hz, 4H), 7.40 (s, 4H), 7.30 (s, 4H), 7.27 (s, 2H), 7.12 (m, 8H), 6.38 (s, 4H), 3.97 (s, 8H), 3.81 
(s, 8H), 2.10 (s, 4H); 13C NMR (75 MHz, CD2Cl2) δ 141.47, 141.03, 137.95, 136.57, 128.85, 127.63, 126.14, 
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121.74, 120.38, 119.88, 111.16, 100.76, 77.96, 46.61.; HRMS (ESI): m/z calcd for C52H50N8[M+H]+: 
787.4231, found 787.4230. 
 
 
 1H NMR of SCR018 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR018 (75 MHz, 25° C) in CD2Cl2. 
 




yl)methyl)methanamine) (SCR019). Following the General Procedure, SCR019 was synthesized from 1 
and 1H-indole-3-carbaldehyde and purified by column chromatography (SiO2, 9:1:0.5 CHCl3: MeOH : NH3 
(aq)) to provide a pale yellow solid (763 mg, 97%). 1H NMR (300 MHz, DMSO) δ 10.83 (s, 4H), 7.61 (d, 
J = 7.7 Hz, 4H), 7.52 (d, J = 8.0 Hz, 4H), 7.37 - 7.27 (m, 6H), 7.24 (s, 4H), 7.04 (t, J = 7.0, 4H), 6.92 (t, J 
= 6.9, 4H), 3.88 (s, 8H), 3.81 (s, 4H); 13C NMR (75 MHz, CD2Cl2) δ 141.52, 141.01, 136.79, 127.84, 
127.41, 126.24, 123.68, 122.08, 119.49, 118.83, 113.84, 111.68, 78.05, 43.98; HRMS (ESI): m/z calcd for 
C52H50N8 [M+H]+: 787.4231, found 787.4227. 
 
 
 1H NMR of SCR019 (300 MHz, 25° C) in DMSO-d6. 
 





 HR-MS of SCR019. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-(pyridin-2-
ylmethyl)methanamine) (SCR020). Following the General Procedure, SCR020 was synthesized from 1 
and picolinaldehyde and purified by column chromatography (SiO2, 9:1:0.5 CHCl3:MeOH : NH3 (aq)) to 
provide a pale yellow gum (628 mg, quant.). 1H NMR (300 MHz, CDCl3) δ 8.50 (s, 4H), 7.56 (t, J = 7.6 
Hz, 4H), 7.47 (s, 4H), 7.33-7.23 (m, 6H), 7.08 (t, J = 7.1 Hz, 4H), 3.91 (s, 8H), 3.85 (s, 4H), 2.53 (br s, 
4H); 13C NMR (75 MHz, CDCl3) δ 159.67, 149.24, 141.33, 140.71, 136.41, 127.14, 125.89, 122.37, 121.91, 
54.56, 53.52; HRMS (ESI): m/z calcd for C40H42N8 [M+H]+: 635.3605, found 635.3607. 
 





 13C NMR of SCR020 (75 MHz, 25° C) in CDCl3. 
 
 HR-MS of SCR020. 
Synthesis of 1,1',1'',1'''-([1,1'-biphenyl]-3,3',5,5'-tetrayl)tetrakis(N-(pyridin-3-
ylmethyl)methanamine) (SCR021). Following the General Procedure, SCR021 was synthesized from 1 
and nicotinaldehyde and purified by column chromatography (SiO2, 9:1:0.5 CHCl3:MeOH : NH3 (aq)) to 
provide a pale yellow gum (630 mg, quant.). 1H NMR (300 MHz, CDCl3) δ 8.61 (s, 4H), 8.52 (d, J = 3.2 
Hz, 4H), 7.73 (d, J = 7.8 Hz, 4H), 7.48 (s, 4H), 7.36-7.22 (m, 6H), 4.07-3.61 (m, 16H), 1.88 (br s, 4H); 13C 
NMR (75 MHz, CDCl3) δ 149.80, 148.57, 141.46, 140.74, 135.86, 135.53, 127.00, 125.88, 123.42, 53.24, 






 1H NMR of SCR021 (300 MHz, 25° C) in CDCl3. 
 
 
 13C NMR of SCR021 (75 MHz, 25° C) in CDCl3. 
 
 HR-MS of SCR021. 
Synthesis of 2,2',2'',2'''-((([1,1'-biphenyl]-3,3',5,5'-
tetrayltetrakis(methylene))tetrakis(azanediyl))tetrakis(methylene))tetraphenol (SCR022). Following 
the General Procedure, SCR022 was synthesized from 1 and 2-hydroxybenzaldehyde and purified by 
column chromatography (SiO2, 9:1:0.5 CHCl3: MeOH : NH3 (aq)) to provide a yellow solid (660 mg, 95%). 
1H NMR (300 MHz, CDCl3) δ 7.46 (s, 4H), 7.26-7.16 (m, 6H), 7.04 (d, J = 7.5 Hz, 4H), 6.92 – 6.76 (m, 
8H), 4.08 (s, 8H), 3.91 (s, 8H); 13C NMR (75 MHz, CDCl3) δ 158.07, 141.53, 139.56, 128.93, 128.65, 
127.66, 126.55, 122.17, 119.25, 116.43, 52.51, 52.00; HRMS (ESI): m/z calcd for C44H46N4O4 [M+H]+: 





 1H NMR of SCR022 (300 MHz, 25° C) in CDCl3. 
 
 13C NMR of SCR022 (75 MHz, 25° C) in CDCl3. 
 
 HR-MS of SCR022. 
Synthesis of 3,3',3'',3'''-((([1,1'-biphenyl]-3,3',5,5'-
tetrayltetrakis(methylene))tetrakis(azanediyl))tetrakis(methylene))tetraphenol (SCR023). Following 
the General Procedure, SCR023 was synthesized from 1 and 3-hydroxybenzaldehyde and purified by 





1H NMR (800 MHz, CD2Cl2) δ 7.52 (s, 4H), 7.27 (s, 2H), 7.18 (t, J = 7.6 Hz, 4H), 6.85 (s, 4H), 6.81 (d, J 
= 7.1 Hz, 4H), 6.74 (d, J = 7.4 Hz, 4H), 3.83 (s, 8H), 3.77 (s, 8H).; 13C NMR (200 MHz, CD2Cl2) δ = 
157.16, 141.01, 140.74, 140.14, 129.56, 127.77, 126.01, 119.65, 115.06, 114.34, 52.60, 52.49; HRMS 
(ESI): m/z calcd for C44H46N4O4 [M+H]+: 695.3592, found 695.3586. 
 
 1H NMR of SCR023 (800 MHz, 25° C) 4% MeOD in CD2Cl2. 
 
 13C NMR of SCR023 (200 MHz, 25° C) 4% MeOD in CD2Cl2. 
 




1.2. Electrospray Ionization (ESI)-Mass Spectrometry Analysis of Receptor-Glycan Binding 
General methods. A Bruker ultra-high resolution maXis-II / ETD ESI-q-TOF system was used to study 
receptor-glycan complex formation. All experimental parameters have been adjusted to preserve receptor-
glycan non-covalent interactions. The samples of the hosts and the glycans were prepared in 1 mM 
concentration in CH2Cl2, diluted to 1 µM with 40% dichloromethane in MeCN. The samples of host+glycan 
for complex mass screening were prepared using the aforementioned diluted solutions and mixed in a one-
to-one fashion. All samples were analyzed via direct infusion into the spectrometer with a syringe pump. 
Theoretical isotopic distributions were calculated using the Chemistry tool in Bruker’s Compass Data 
Analysis software. Glycans used in the ESI-MS studies are abbrebiated as follows: octyl-β-D-
glucopyranoside (β-Glc), octyl-α-D-glucopyranoside (α-Glc), octyl-β-D-mannopyranoside (β-Man), octyl-





 A) ESI mass spectra of SCR001. B) ESI mass spectra of SCR001 with β-Glc. C) ESI mass 
spectra of SCR001 with α-Glc. D) ESI mass spectra of SCR001 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR002. B) ESI mass spectra of SCR002 with β-Glc. C) ESI mass 
spectra of SCR002 with α-Glc. D) ESI mass spectra of SCR002 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR003. B) ESI mass spectra of SCR003 with β-Glc. C) ESI mass 
spectra of SCR003 with α-Glc. D) ESI mass spectra of SCR003 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR004. B) ESI mass spectra of SCR004 with β-Glc. C) ESI mass 
spectra of SCR004 with α-Glc. D) ESI mass spectra of SCR004 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR005. B) ESI mass spectra of SCR005 with β-Glc. C) ESI mass 
spectra of SCR005 with α-Glc. D) ESI mass spectra of SCR005 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR006. B) ESI mass spectra of SCR006 with β-Glc. C) ESI mass 
spectra of SCR006 with α-Glc. D) ESI mass spectra of SCR006 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR007. B) ESI mass spectra of SCR007 with β-Glc. C) ESI mass 
spectra of SCR007 with α-Glc. D) ESI mass spectra of SCR007 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR012. B) ESI mass spectra of SCR012 with β-Glc. C) ESI mass 
spectra of SCR012 with α-Glc. D) ESI mass spectra of SCR012 with β-Man. E) ESI mass spectra of 




 A) Top: ESI mass spectrum of a 1:1 mixture (0.5 µM, 40%:60% v/v CH2Cl2:CH3CN) of 
SCR019 and β-Man. Bottom: ESI mass spectrum of SCR019 alone (1.0 µM, 40%:60% v/v 
CH2Cl2:CH3CN). B) Top: ESI mass spectrum of a 1:1 mixture (0.5 µM, 40%:60% v/v CH2Cl2:CH3CN) of 
SCR020 and α-Man. Bottom: ESI mass spectrum of SCR020 alone (1.0 µM, 40%:60% v/v 





 A) ESI mass spectra of SCR017. B) ESI mass spectra of SCR017 with β-Glc. C) ESI mass 
spectra of SCR017 with α-Glc. D) ESI mass spectra of SCR017 with β-Man. E) ESI mass spectra of 




 A) ESI mass spectra of SCR018. B) ESI mass spectra of SCR018 with β-Glc. C) ESI mass 
spectra of SCR018 with α-Glc. D) ESI mass spectra of SCR018 with β-Man. E) ESI mass spectra of 





 A) ESI mass spectra of SCR019. B) ESI mass spectra of SCR019 with β-Glc. C) ESI mass 
spectra of SCR019 with α-Glc. D) ESI mass spectra of SCR019 with β-Man. E) ESI mass spectra of 





 A) ESI mass spectra of SCR020. B) ESI mass spectra of SCR020 with β-Glc. C) ESI mass 
spectra of SCR020 with α-Glc. D) ESI mass spectra of SCR020 with β-Man. E) ESI mass spectra of 





 A) ESI mass spectra of SCR021. B) ESI mass spectra of SCR021 with β-Glc. C) ESI mass 
spectra of SCR021 with α-Glc. D) ESI mass spectra of SCR021 with β-Man. E) ESI mass spectra of 





 A) ESI mass spectra of SCR022. B) ESI mass spectra of SCR022 with β-Glc. C) ESI mass 
spectra of SCR022 with α-Glc. D) ESI mass spectra of SCR022 with β-Man. E) ESI mass spectra of 





 A) ESI mass spectra of SCR023. B) ESI mass spectra of SCR023 with β-Glc. C) ESI mass 
spectra of SCR023 with α-Glc. D) ESI mass spectra of SCR023 with β-Man. E) ESI mass spectra of 
SCR023 with α-Man. F) ESI mass spectra of SCR023 with β-Gal. 
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1.3. NMR Titrations and Peak Shift Fittings 
1H NMR titrations were performed in CD2Cl2 at a field strength of either 600, 700 or 800 MHz at 298 K. 
The 1H NMR resonances corresponding to both pyranoside and host were assigned through 1H-1H COSY 
and 1H-1H NOESY experiments. The experimental temperatures were verified through calibration with a 
100% methanol standard.3 Glycans used in the titrations are abbrebiated as follows: octyl-β-D-
glucopyranoside (β-Glc), octyl-α-D-glucopyranoside (α-Glc), octyl-β-D-mannopyranoside (β-Man), octyl-
α-D-mannopyranoside (α-Man), and octyl-β-D-galactopyranoside (β-Gal). 
1.3.1. Models for 1H NMR Titration Fittings  
The addition of receptor to a CD2Cl2 pyranoside solution or vice versa resulted in the perturbation of the 
chemical shifts (δ) corresponding to resonances of both receptor and pyranoside. This is the result of an 
exchange process involving receptor (H) and pyranoside (G) equilibria products interchanging fast on the 
NMR timescale, resulting in the averaging of chemical shits of protons in differing chemical environments. 
Accordingly, equilibrium constants can be quantified by first defining a model that includes the correct set 
of equilibria, calculating the hypothetical concentrations of equilibrium species and the corresponding 
chemical shifts, and finally fitting the resulting data to the experimental results. For the 2:1 association 
between SCR001 and β-Man, fitting was carried out as previously described.[1] 
NMR Titrations and Peak Shift Fittings 1H NMR titrations were performed in CD2Cl2, unless otherwise 
noted, at a field strength of either 700 or 800 MHz at 298 K. The pyranosides’ 1H NMR peak assignments 
were previously reported[2]. The experimental temperatures were verified through calibration with a 100% 
methanol standard[4]. The addition of pyranoside to a SCR CD2Cl2 solution or vice versa resulted in the 
perturbation of the chemical shifts (δ) corresponding to resonances of both SCR and pyranoside. This is the 
result of an exchange process involving SCR (H) and pyranoside (G) equilibria products interchanging fast 
on the NMR timescale, resulting in the averaging of chemical shits of protons in differing chemical 
environments. Accordingly, equilibrium constants (K) can be quantified by first defining a model that 
includes the correct set of equilibria, calculating the hypothetical concentrations of equilibrium species and 
the corresponding chemical shifts, and finally fitting the resulting data to the experimental results. For the 
2:1 association of SCR022•β-Man and the 1:2 association of SCR017•β-Glc, SCR021•β-Glc, SCR019•β-
Man, SCR020•α-Man, fitting was carried out as previously described.4  
 
The equilibria involved in a CD2Cl2 mixture of β-Man and receptor are Kdimer, K1, which are expressed by 
the following relationships:  










Likewise, mass balance equations relating the known total concentrations of receptor ([H]t) and pyranoside 
([G]t) with their corresponding equilibrium concentrations can be derived:  
 (3) [𝐻𝐻]𝑡𝑡  =  [𝐻𝐻]  +  2[𝐻𝐻2]  +  [𝐻𝐻𝐻𝐻] 
 (4) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + [𝐻𝐻𝐻𝐻] 
 Combining equations (1) through (4) yields the following relationships:  
 (5) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]2 + 𝐾𝐾1[𝐻𝐻][𝐻𝐻] 
 (6) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + 𝐾𝐾1[𝐻𝐻][𝐻𝐻] 
Combining equations (5) and (6) yields equation (7) which can be solved for [G] to give equation (8) or 
[H] for equation (9)  
 (7) [𝐻𝐻]𝑡𝑡 − 2[𝐻𝐻]𝑡𝑡 = [𝐻𝐻] − 2[𝐻𝐻] − 4𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]2 − 𝐾𝐾1[𝐻𝐻][𝐻𝐻]  








Plugging equations (8) and (9) back into equations (6) and (5) respectively yields equation series (10) and 
(11): 













Taking the root of equations (10) and (11) respectively yields polynomial series (12) and (13): 
(12) 0 = 2𝐾𝐾1𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]3 + (𝐾𝐾1 + 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)[𝐻𝐻]2 + ([𝐻𝐻]𝑡𝑡𝐾𝐾1 − [𝐻𝐻]𝑡𝑡𝐾𝐾1 + 1)[𝐻𝐻] − [𝐻𝐻]𝑡𝑡 
(13) 0 = (𝐾𝐾12[𝐻𝐻]3 + �−[𝐻𝐻]𝑡𝑡𝐾𝐾𝑡𝑡2 + [𝐻𝐻]𝑡𝑡𝐾𝐾12 + 𝐾𝐾1 − 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑�[𝐻𝐻]2 + (−[𝐻𝐻]𝑡𝑡𝐾𝐾1 + 4𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]𝑡𝑡)[𝐻𝐻] −
2[𝐻𝐻]𝑡𝑡
2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑) 
All observable SCR and pyranoside peaks were simultaneously fitted by minimizing the total sum of 
squared residuals (the differences between experimental values and fitted values) using the binding 
constants (K1) and individual chemical shifts (δH) as fitting parameters. The binding constant describing the 
dimerization process, Kdimer, was determined through 1H NMR dilution experiments and was held constant 
throughout the fitting process. 
The equilibria involved in a CD2Cl2 mixture of β-Man and receptor are Kdimer, K1, which are expressed by 
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the following relationships:  








Likewise, mass balance equations relating the known total concentrations of receptor ([H]t) and pyranoside 
([G]t) with their corresponding equilibrium concentrations can be derived:  
 (3) [𝐻𝐻]𝑡𝑡  =  [𝐻𝐻]  +  2[𝐻𝐻2]  +  [𝐻𝐻𝐻𝐻] 
 (4) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + [𝐻𝐻𝐻𝐻] 
Combining equations (1) through (4) yields the following relationships:  
 (5) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]2 + 𝐾𝐾1[𝐻𝐻][𝐻𝐻]  
 (6) [𝐻𝐻]𝑡𝑡 = [𝐻𝐻] + 𝐾𝐾1[𝐻𝐻][𝐻𝐻]  
Combining equations (5) and (6) yields equation (7) which can be solved for [G] to give equation (8) or 
[H] for equation (9)  
 (7) [𝐻𝐻]𝑡𝑡 − 2[𝐻𝐻]𝑡𝑡 = [𝐻𝐻] − 2[𝐻𝐻] − 4𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]2 − 𝐾𝐾1[𝐻𝐻][𝐻𝐻]  








Plugging equations (8) and (9) back into equations (6) and (5) respectively yields equation series (10) and 
(11): 













Taking the root of equations (10) and (11) respectively yields polynomial series (12) and (13): 
(12) 0 = 2𝐾𝐾1𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]3 + (𝐾𝐾1 + 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)[𝐻𝐻]2 + ([𝐻𝐻]𝑡𝑡𝐾𝐾1 − [𝐻𝐻]𝑡𝑡𝐾𝐾1 + 1)[𝐻𝐻] − [𝐻𝐻]𝑡𝑡 
(13) 0 = (𝐾𝐾12[𝐻𝐻]3 + �−[𝐻𝐻]𝑡𝑡𝐾𝐾𝑡𝑡2 + [𝐻𝐻]𝑡𝑡𝐾𝐾12 + 𝐾𝐾1 − 2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑�[𝐻𝐻]2 + (−[𝐻𝐻]𝑡𝑡𝐾𝐾1 +
4𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑[𝐻𝐻]𝑡𝑡)[𝐻𝐻] − 2[𝐻𝐻]𝑡𝑡
2𝐾𝐾𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑) 
All observable host and guest peaks were simultaneously fitted by minimizing the total sum of squared 
residuals (the differences between experimental values and fitted values) using the binding constants (K1) 
and individual chemical shifts (δH) as fitting parameters. The binding constant describing the dimerization 
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process, Kdimer, was determined through 1H NMR dilution experiments and was held constant throughout 
the fitting process. 





f Hh Ha Hb 
6.56E-05 6.042 6.748 7.332 7.496 
1.97E-04 6.042 6.748 7.330 7.495 
3.87E-04 6.042 6.747 7.329 7.493 
5.73E-04 6.043 6.747 7.327 7.492 
7.52E-04 6.043 6.746 7.325 7.490 
9.26E-04 6.043 6.745 7.324 7.489 
1.72E-03 6.044 6.744 7.318 7.484 
3.57E-03 6.045 6.742 7.304 7.474 
5.56E-03 6.047 6.740 7.296 7.466 
1.25E-02 6.055 6.733 7.257 7.452 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR001 in CD2Cl2. 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.0
[SCR001] = 6.6E-05 M 
[SCR001] = 1.3E-02 M 
[SCR001] = 3.6E-03 M 
[SCR001] = 1.7E-03 M 
[SCR001] = 9.3E-04 M 
[SCR001] = 5.7E-04 M 
[SCR001] = 4.8E-04 M 
[SCR001] = 3.9E-04 M 
[SCR001] = 2.0E-04 M 






















5 H2 H1 
0.00E+00 1.00E-03 3.315 3.398 4.325 
1.97E-04 9.84E-04 3.243 3.366 4.305 
3.88E-04 9.69E-04 3.180 3.340 4.287 
4.81E-04 9.62E-04 3.152 3.329 4.279 
5.73E-04 9.54E-04 3.126 3.318 4.271 
7.52E-04 9.40E-04 3.081 3.299 4.258 
9.26E-04 9.26E-04 3.043 3.284 4.247 
1.72E-03 8.62E-04 2.921 3.235 4.212 
3.57E-03 7.14E-04 2.794 3.182 4.172 
5.56E-03 5.56E-04 2.747 3.156 4.155 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 










7 H4 H3 H1 
0.00E+00 1.00E-03 3.481 3.530 3.702 4.870 
1.97E-04 9.84E-04 3.471 3.509 3.688 4.862 
3.88E-04 9.69E-04 3.466 3.491 3.676 4.849 
4.81E-04 9.62E-04 3.462 3.482 3.670 4.844 
5.73E-04 9.54E-04 3.458 3.472 3.664 4.843 
7.52E-04 9.40E-04 3.453 3.459 3.655 4.832 
9.26E-04 9.26E-04 3.447 3.447 3.647 4.825 
1.72E-03 8.62E-04 3.428 3.396 3.613 4.797 
3.57E-03 7.14E-04 3.396 3.322 3.564 4.754 
5.56E-03 5.56E-04 3.376 3.278 3.537 4.728 
8.82E-03 2.94E-04 3.356 3.238 3.519 4.699 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 










5 H3 H7 H4 H6 H1 
0.00E+00 1.00E-03 3.380 3.597 3.666 3.812 3.895 4.663 
2.48E-04 9.92E-04 3.335 3.552 3.648 3.660 3.862 4.639 
4.92E-04 9.84E-04 3.304 3.531 3.648 3.531 3.832 4.619 
7.32E-04 9.77E-04 3.271 3.498 3.640 3.447 3.807 4.603 
9.69E-04 9.69E-04 3.249 3.479 3.634 3.380 3.787 4.589 
1.20E-03 9.62E-04 3.232 3.464 3.628 3.331 3.770 4.578 
1.43E-03 9.54E-04 3.214 3.449 3.621 3.288 3.751 4.564 
1.66E-03 9.47E-04 3.211 3.446 3.619 3.281 3.747 4.560 
1.88E-03 9.40E-04 3.207 3.443 3.617 3.276 3.743 4.557 
2.10E-03 9.33E-04 3.205 3.441 3.616 3.274 3.740 4.555 
2.31E-03 9.26E-04 3.203 3.440 3.614 3.274 3.737 4.552 
7.50E-03 7.60E-04 3.207 3.443 3.615 3.287 3.740 4.554 
1.65E-02 4.73E-04 3.217 3.451 3.616 3.320 3.746 4.558 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 
























7 H3 H7’ H1 
0.00E+00 1.00E-03 3.433 3.618 3.702 4.835 
3.88E-04 9.69E-04 3.410 3.580 3.679 4.802 
4.81E-04 9.62E-04 3.406 3.572 3.675 4.796 
5.73E-04 9.54E-04 3.402 3.565 3.671 4.790 
7.52E-04 9.40E-04 3.395 3.554 3.664 4.780 
9.26E-04 9.26E-04 3.389 3.553 3.658 4.772 
1.72E-03 8.62E-04 3.370 3.521 3.640 4.745 
3.57E-03 7.14E-04 3.346 3.494 3.618 4.714 
5.56E-03 5.56E-04 3.334 3.488 3.608 4.702 
8.82E-03 2.94E-04 3.325 3.485 3.601 4.693 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 













0.00E+00 1.00E-03 4.268 
1.97E-04 9.84E-04 4.257 
3.88E-04 9.69E-04 4.248 
4.81E-04 9.62E-04 4.242 
5.73E-04 9.54E-04 4.238 
7.52E-04 9.40E-04 4.230 
9.26E-04 9.26E-04 4.223 
1.72E-03 8.62E-04 4.195 
3.57E-03 7.14E-04 4.155 
5.56E-03 5.56E-04 4.131 
8.82E-03 2.94E-04 4.109 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 







 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 
1H NMR titration of SCR001 with A) β-Glc, B) α-Glc, D) α-Man and E) β-Gal, and C) a 2:1 receptor-sugar 







e Hc Hf Ha Hh Hb 
1.97E-04 3.841 3.870 6.240 7.321 7.418 7.503 
3.88E-04 3.841 3.870 6.240 7.321 7.418 7.503 
4.81E-04 3.841 3.869 6.240 7.321 7.418 7.504 
5.73E-04 3.841 3.869 6.240 7.321 7.417 7.503 
7.52E-04 3.841 3.869 6.240 7.321 7.418 7.504 
9.26E-04 3.841 3.870 6.240 7.321 7.418 7.504 
1.72E-03 3.841 3.870 6.240 7.321 7.417 7.503 
3.57E-03 3.841 3.870 6.240 7.321 7.418 7.504 
5.56E-03 3.842 3.870 6.240 7.321 7.418 7.504 
8.82E-03 3.842 3.870 6.241 7.322 7.418 7.505 
1.25E-02 3.843 3.871 6.241 7.323 7.419 7.506 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 























5 H2 H4 H1 
0.00E+00 1.00E-03 3.315 3.399 3.583 4.326 
1.97E-04 9.84E-04 3.311 3.396 3.579 4.324 
3.88E-04 9.69E-04 3.306 3.393 3.576 4.322 
4.81E-04 9.62E-04 3.303 3.392 3.574 4.321 
5.73E-04 9.54E-04 3.301 3.391 3.572 4.320 
7.52E-04 9.40E-04 3.297 3.387 3.564 4.318 
9.26E-04 9.26E-04 3.292 3.384 3.563 4.316 
1.72E-03 8.62E-04 3.273 3.373 3.558 4.308 
3.57E-03 7.14E-04 3.237 3.349 3.548 4.292 
5.56E-03 5.56E-04 3.206 3.328 3.540 4.279 
8.82E-03 2.94E-04 3.170 3.302 3.529 4.262 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 






















7 H4 H3 H1 
0.00E+00 1.00E-03 3.448 3.528 3.701 4.871 
1.97E-04 9.84E-04 3.457 3.529 3.701 4.870 
3.88E-04 9.69E-04 3.453 3.527 3.700 4.869 
4.81E-04 9.62E-04 3.453 3.527 3.700 4.868 
5.73E-04 9.54E-04 3.452 3.526 3.699 4.868 
7.52E-04 9.40E-04 3.451 3.524 3.698 4.867 
9.26E-04 9.26E-04 3.450 3.523 3.697 4.866 
1.72E-03 8.62E-04 3.444 3.517 3.693 4.862 
3.57E-03 7.14E-04 3.433 3.503 3.685 4.854 
5.56E-03 5.56E-04 3.422 3.490 3.677 4.845 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 























5 H7 H4 H1 
0.00E+00 1.00E-03 3.284 3.572 3.713 4.561 
1.97E-04 9.84E-04 3.282 3.571 3.712 4.559 
3.88E-04 9.69E-04 3.281 3.570 3.710 4.558 
4.81E-04 9.62E-04 3.280 3.569 3.709 4.558 
5.73E-04 9.54E-04 3.280 3.569 3.709 4.557 
7.52E-04 9.40E-04 3.278 3.568 3.707 4.556 
9.26E-04 9.26E-04 3.277 3.568 3.706 4.555 
1.72E-03 8.62E-04 3.271 3.564 3.699 4.549 
3.57E-03 7.14E-04 3.259 3.557 3.686 4.538 
5.56E-03 5.56E-04 3.248 3.551 3.674 4.528 
8.82E-03 2.94E-04 3.233 3.543 3.658 4.515 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 






















7 H3 H7’ H1 
0.00E+00 1.00E-03 3.432 3.616 3.700 4.835 
1.97E-04 9.84E-04 3.430 3.613 3.699 4.832 
3.88E-04 9.69E-04 3.429 3.610 3.698 4.831 
4.81E-04 9.62E-04 3.428 3.609 3.697 4.829 
5.73E-04 9.54E-04 3.427 3.607 3.696 4.828 
7.52E-04 9.40E-04 3.426 3.605 3.695 4.827 
9.26E-04 9.26E-04 3.424 3.602 3.693 4.824 
1.72E-03 8.62E-04 3.418 3.592 3.687 4.816 
3.57E-03 7.14E-04 3.407 3.574 3.677 4.801 
5.56E-03 5.56E-04 3.397 3.559 3.669 4.788 
8.82E-03 2.94E-04 3.385 3.542 3.659 4.772 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 























7 H5 H1 
0.00E+00 1.00E-03 3.456 3.563 4.267 
1.97E-04 9.84E-04 3.459 3.563 4.267 
3.88E-04 9.69E-04 3.458 3.560 4.266 
4.81E-04 9.62E-04 3.458 3.559 4.266 
5.73E-04 9.54E-04 3.458 3.559 4.265 
7.52E-04 9.40E-04 3.458 3.557 4.264 
9.26E-04 9.26E-04 3.458 3.556 4.263 
1.72E-03 8.62E-04 3.458 3.554 4.259 
3.57E-03 7.14E-04 3.458 3.555 4.259 
5.56E-03 5.56E-04 3.456 3.546 4.245 
8.82E-03 2.94E-04 3.454 3.537 4.232 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 



















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 





[H]t        
mol L-1 H
c He Hf,g Hh Ha Hb 
6.63E-05 3.928 4.061 6.986 7.262 7.355 7.532 
1.97E-04 3.928 4.061 6.986 7.259 7.355 7.532 
3.88E-04 3.928 4.062 6.986 7.262 7.355 7.532 
5.73E-04 3.928 4.061 6.986 7.259 7.355 7.532 
7.52E-04 3.928 4.062 6.986 7.259 7.355 7.532 
9.26E-04 3.928 4.062 6.986 7.262 7.355 7.532 
1.72E-03 3.928 4.062 6.986 7.262 7.355 7.532 
3.57E-03 3.928 4.062 6.986 7.262 7.355 7.532 
5.56E-03 3.928 4.062 6.986 7.262 7.356 7.533 
1.25E-02 3.929 4.063 6.987 7.263 7.357 7.534 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR003. 
[SCR003] = 6.6E-05 M 
[SCR003] = 1.3E-02 M 
[SCR003] = 3.6E-03 M 
[SCR003] = 1.7E-03 M 
[SCR003] = 9.3E-04 M 
[SCR003] = 5.7E-04 M 
[SCR003] = 4.8E-04 M 
[SCR003] = 3.9E-04 M 
[SCR003] = 2.0E-04 M 






















5 H2 H3,7 H1 
0.00E+00 1.00E-03 3.315 3.399 3.559 4.337 
1.97E-04 9.84E-04 3.313 3.398 3.555 4.336 
3.88E-04 9.69E-04 3.309 3.395 3.558 4.333 
4.81E-04 9.62E-04 3.309 3.395 3.558 4.334 
5.73E-04 9.54E-04 3.308 3.394 3.556 4.333 
7.52E-04 9.40E-04 3.306 3.393 3.556 4.333 
9.26E-04 9.26E-04 3.304 3.392 3.555 4.332 
1.72E-03 8.62E-04 3.296 3.386 3.541 4.328 
3.57E-03 7.14E-04 3.276 3.372 3.532 4.311 
5.56E-03 5.56E-04 3.261 3.354 3.524 4.308 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 






















7 H4 H5 H3 H1 
0.00E+00 1.00E-03 3.467 3.532 3.652 3.704 4.876 
1.97E-04 9.84E-04 3.467 3.530 3.651 3.702 4.876 
3.88E-04 9.69E-04 3.467 3.529 3.651 3.701 4.875 
4.81E-04 9.62E-04 3.466 3.529 3.650 3.701 4.875 
5.73E-04 9.54E-04 3.466 3.528 3.650 3.701 4.874 
7.52E-04 9.40E-04 3.466 3.527 3.649 3.700 4.874 
9.26E-04 9.26E-04 3.467 3.526 3.649 3.700 4.870 
1.72E-03 8.62E-04 3.465 3.523 3.646 3.698 4.867 
3.57E-03 7.14E-04 3.462 3.515 3.647 3.693 4.862 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 























5 H7 H4 H1 
0.00E+00 1.00E-03 3.284 3.571 3.715 4.561 
1.97E-04 9.84E-04 3.283 3.571 3.712 4.560 
3.88E-04 9.69E-04 3.282 3.571 3.711 4.559 
4.81E-04 9.62E-04 3.282 3.570 3.711 4.559 
5.73E-04 9.54E-04 3.281 3.570 3.711 4.558 
7.52E-04 9.40E-04 3.280 3.569 3.710 4.557 
9.26E-04 9.26E-04 3.278 3.569 3.710 4.556 
1.72E-03 8.62E-04 3.274 3.566 3.719 4.552 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 























0.00E+00 1.00E-03 3.432 4.835 
1.97E-04 9.84E-04 3.431 4.832 
3.88E-04 9.69E-04 3.429 4.831 
4.81E-04 9.62E-04 3.428 4.830 
5.73E-04 9.54E-04 3.427 4.828 
7.52E-04 9.40E-04 3.426 4.827 
9.26E-04 9.26E-04 3.425 4.825 
3.57E-03 7.14E-04 3.411 4.806 
5.56E-03 5.56E-04 3.408 4.775 
8.82E-03 2.94E-04 3.406 4.774 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 
























0.00E+00 1.00E-03 3.455 4.268 
1.97E-04 9.84E-04 3.459 4.267 
3.88E-04 9.69E-04 3.459 4.267 
4.81E-04 9.62E-04 3.458 4.266 
5.73E-04 9.54E-04 3.458 4.266 
7.52E-04 9.40E-04 3.458 4.265 
9.26E-04 9.26E-04 3.458 4.265 
1.72E-03 8.62E-04 3.458 4.262 
3.57E-03 7.14E-04 3.457 4.256 
5.56E-03 5.56E-04 3.457 4.269 
8.82E-03 2.94E-04 3.456 4.267 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 



















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 


















6.63E-05 7.360 7.524 
1.97E-04 7.360 7.525 
3.88E-04 7.360 7.525 
5.73E-04 7.360 7.526 
7.52E-04 7.360 7.526 
9.26E-04 7.356 7.526 
1.72E-03 7.355 7.526 
3.57E-03 7.355 7.527 
1.25E-02 7.355 7.527 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR004. 
[SCR004] = 6.6E-05 M 
[SCR004] = 1.3E-02 M 
[SCR004] = 3.6E-03 M 
[SCR004] = 1.7E-03 M 
[SCR004] = 9.3E-04 M 
[SCR004] = 5.7E-04 M 
[SCR004] = 4.8E-04 M 
[SCR004] = 3.9E-04 M 
[SCR004] = 2.0E-04 M 






















5 H2 H3 H7 H1 
0.00E+00 1.00E-03 3.315 3.399 3.557 3.570 4.337 
1.97E-04 9.84E-04 3.276 3.365 3.527 3.539 4.313 
3.88E-04 9.69E-04 3.243 3.338 3.494 3.523 4.293 
4.81E-04 9.62E-04 3.231 3.329 3.472 3.517 4.286 
5.73E-04 9.54E-04 3.219 3.318 3.460 3.511 4.279 
7.52E-04 9.40E-04 3.199 3.302 3.439 3.501 4.267 
9.26E-04 9.26E-04 3.185 3.290 3.425 3.493 4.258 
1.72E-03 8.62E-04 3.133 3.248 3.392 3.466 4.227 
3.57E-03 7.14E-04 3.081 3.206 3.345 3.438 4.196 
5.56E-03 5.56E-04 3.060 3.195 3.327 3.427 4.184 
8.82E-03 2.94E-04 3.049 3.185 3.339 3.424 4.177 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 






















2 H4 H1 
0.00E+00 1.00E-03 3.452 3.531 4.876 
1.97E-04 9.84E-04 3.439 3.508 4.862 
3.88E-04 9.69E-04 3.427 3.492 4.852 
4.81E-04 9.62E-04 3.421 3.485 4.848 
5.73E-04 9.54E-04 3.413 3.475 4.842 
7.52E-04 9.40E-04 3.401 3.460 4.832 
9.26E-04 9.26E-04 3.392 3.447 4.825 
3.57E-03 7.14E-04 3.357 3.403 4.797 
5.56E-03 5.56E-04 3.312 3.347 4.761 
8.82E-03 2.94E-04 3.289 3.317 4.741 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 





















5 H3 H7 H1 
0.00E+00 1.00E-03 3.282 3.500 3.583 4.559 
1.97E-04 9.84E-04 3.270 3.493 3.574 4.546 
3.88E-04 9.69E-04 3.260 3.484 3.567 4.536 
4.81E-04 9.62E-04 3.256 3.481 3.564 4.532 
5.73E-04 9.54E-04 3.252 3.478 3.561 4.528 
7.52E-04 9.40E-04 3.244 3.472 3.555 4.520 
9.26E-04 9.26E-04 3.237 3.466 3.550 4.512 
3.57E-03 7.14E-04 3.213 3.448 3.533 4.487 
5.56E-03 5.56E-04 3.180 3.423 3.507 4.451 
8.82E-03 2.94E-04 3.164 3.407 3.490 4.429 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 























0.00E+00 1.00E-03 3.444 4.834 
1.97E-04 9.84E-04 3.426 4.809 
3.88E-04 9.69E-04 3.413 4.793 
4.81E-04 9.62E-04 3.408 4.786 
5.73E-04 9.54E-04 3.404 4.780 
7.52E-04 9.40E-04 3.397 4.771 
9.26E-04 9.26E-04 3.391 4.763 
3.57E-03 7.14E-04 3.373 4.741 
5.56E-03 5.56E-04 3.352 4.720 
8.82E-03 2.94E-04 3.341 4.712 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 
























0.00E+00 1.00E-03 3.563 4.279 
1.97E-04 9.84E-04 3.549 4.268 
3.88E-04 9.69E-04 3.535 4.259 
4.81E-04 9.62E-04 3.529 4.254 
5.73E-04 9.54E-04 3.524 4.250 
7.52E-04 9.40E-04 3.516 4.243 
9.26E-04 9.26E-04 3.513 4.237 
3.57E-03 7.14E-04 3.480 4.212 
5.56E-03 5.56E-04 3.447 4.178 
8.82E-03 2.94E-04 3.411 4.158 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 


















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 







f He Hg Ha Hb Hd 
6.56E-05 6.541 6.545 6.923 7.283 7.487 8.237 
1.97E-04 6.544 6.548 6.922 7.272 7.473 8.235 
3.87E-04 6.547 6.551 6.921 7.259 7.458 8.234 
5.73E-04 6.550 6.553 6.921 7.250 7.448 8.233 
7.52E-04 6.551 6.555 6.921 7.246 7.442 8.232 
9.26E-04 6.552 6.556 6.921 7.243 7.439 8.231 
1.72E-03 6.555 6.559 6.921 7.238 7.434 8.229 
3.57E-03 6.561 6.565 6.920 7.234 7.428 8.224 
5.56E-03 6.564 6.568 6.920 7.234 7.428 8.219 
1.25E-02 6.565 6.569 6.918 7.219 7.406 8.218 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR005. 
 
[SCR005] = 6.6E-05 M 
[SCR005] = 1.3E-02 M 
[SCR005] = 3.6E-03 M 
[SCR005] = 1.7E-03 M 
[SCR005] = 9.3E-04 M 
[SCR005] = 5.7E-04 M 
[SCR005] = 4.8E-04 M 
[SCR005] = 3.9E-04 M 
[SCR005] = 2.0E-04 M 






















5 H2 H3 H1 
0.00E+00 1.00E-03 3.316 3.400 3.559 4.326 
1.97E-04 9.84E-04 3.260 3.353 3.495 4.261 
3.88E-04 9.69E-04 3.216 3.315 3.446 4.208 
4.81E-04 9.62E-04 3.189 3.291 3.415 4.174 
5.73E-04 9.54E-04 3.176 3.280 3.400 4.157 
7.52E-04 9.40E-04 3.139 3.247 3.357 4.110 
9.26E-04 9.26E-04 3.114 3.225 3.328 4.077 
1.72E-03 8.62E-04 2.990 3.106 3.178 3.901 
3.57E-03 7.14E-04 2.932 3.050 3.103 3.811 
5.56E-03 5.56E-04 2.922 3.038 3.089 3.793 
8.82E-03 2.94E-04 2.914 3.028 3.078 3.778 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 






















2 H4 H3 
0.00E+00 1.00E-03 3.429 3.528 3.701 
1.97E-04 9.84E-04 3.391 3.488 3.670 
3.88E-04 9.69E-04 3.334 3.435 3.630 
4.81E-04 9.62E-04 3.308 3.411 3.612 
5.73E-04 9.54E-04 3.289 3.393 3.598 
7.52E-04 9.40E-04 3.248 3.354 3.569 
9.26E-04 9.26E-04 3.203 3.311 3.536 
1.72E-03 8.62E-04 3.077 3.187 3.442 
3.57E-03 7.14E-04 3.010 3.118 3.393 
5.56E-03 5.56E-04 2.991 3.099 3.381 
8.82E-03 2.94E-04 2.984 3.092 3.379 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 





















5  H7 H4 H6’ H7’ H2 H1 
0.00E+00 1.00E-03 3.280 3.571 3.720 3.892 3.925 3.982 4.558 
1.97E-04 9.84E-04 3.261 3.555 3.678 3.872 3.910 3.966 4.538 
3.88E-04 9.69E-04 3.240 3.538 3.631 3.852 3.894 3.950 4.516 
4.81E-04 9.62E-04 3.228 3.528 3.605 3.841 3.885 3.941 4.503 
5.73E-04 9.54E-04 3.217 3.520 3.582 3.831 3.876 3.932 4.492 
7.52E-04 9.40E-04 3.201 3.507 3.546 3.817 3.864 3.920 4.475 
9.26E-04 9.26E-04 3.190 3.497 3.519 3.807 3.855 3.911 4.463 
1.72E-03 8.62E-04 3.154 3.464 3.434 3.776 3.824 3.884 4.424 
3.57E-03 7.14E-04 3.129 3.439 3.371 3.754 3.800 3.866 4.396 
5.56E-03 5.56E-04 3.122 3.431 3.357 3.748 3.793 3.860 4.387 
8.82E-03 2.94E-04 3.119 3.427 3.356 3.746 3.788 3.859 4.383 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 





















0.00E+00 1.00E-03 3.433 3.927 
1.97E-04 9.84E-04 3.422 3.912 
3.88E-04 9.69E-04 3.412 3.898 
4.81E-04 9.62E-04 3.406 3.891 
5.73E-04 9.54E-04 3.403 3.887 
7.52E-04 9.40E-04 3.396 3.879 
9.26E-04 9.26E-04 3.389 3.871 
1.72E-03 8.62E-04 3.371 3.850 
3.57E-03 7.14E-04 3.355 3.835 
5.56E-03 5.56E-04 3.345 3.830 
8.82E-03 2.94E-04 3.343 3.831 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 





















5 H3 H1 
0.00E+00 1.00E-03 3.594 4.004 4.269 
1.97E-04 9.84E-04 3.527 3.919 4.234 
3.88E-04 9.69E-04 3.492 3.807 4.188 
4.81E-04 9.62E-04 3.473 3.758 4.168 
5.73E-04 9.54E-04 3.422 3.722 4.151 
7.52E-04 9.40E-04 3.396 3.660 4.127 
9.26E-04 9.26E-04 3.374 3.612 4.107 
1.72E-03 8.62E-04 3.308 3.474 4.049 
3.57E-03 7.14E-04 3.271 3.397 4.017 
5.56E-03 5.56E-04 3.258 3.370 4.006 
8.82E-03 2.94E-04 3.251 3.357 4.000 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 



















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 
1H NMR titration of SCR005 with A) β-Glc, B) α-Glc, C) β-Man, D) α-Man and E) β-Gal at 298 K. 
 















Concentration of Host (M)


















Concentration of Host (M)




















Concentration of Host (M)



























Concentration of Host (M)























c Hf He Ha 
6.63E-05 4.833 6.534 6.835 7.317 
1.97E-04 4.833 6.534 6.835 7.317 
3.88E-04 4.832 6.534 6.835 7.317 
5.73E-04 4.833 6.534 6.835 7.317 
7.52E-04 4.833 6.534 6.835 7.317 
9.26E-04 4.833 6.534 6.835 7.317 
1.72E-03 4.833 6.534 6.835 7.317 
3.57E-03 4.833 6.534 6.835 7.317 
1.25E-02 4.833 6.536 6.835 7.318 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR006. 
[SCR006] = 6.6E-05 M 
[SCR006] = 1.3E-02 M 
[SCR006] = 3.6E-03 M 
[SCR006] = 1.7E-03 M 
[SCR006] = 9.3E-04 M 
[SCR006] = 5.7E-04 M 
[SCR006] = 4.8E-04 M 
[SCR006] = 3.9E-04 M 
[SCR006] = 2.0E-04 M 






















5 H7 H4 H7’ H1 
0.00E+00 1.00E-03 3.329 3.573 3.817 3.906 4.346 
1.97E-04 9.84E-04 3.313 3.555 3.803 3.886 4.335 
3.88E-04 9.69E-04 3.312 3.553 3.802 3.885 4.334 
4.81E-04 9.62E-04 3.311 3.552 3.801 3.884 4.333 
5.73E-04 9.54E-04 3.310 3.551 3.801 3.883 4.332 
7.52E-04 9.40E-04 3.308 3.549 3.800 3.882 4.331 
9.26E-04 9.26E-04 3.307 3.548 3.799 3.880 4.329 
1.72E-03 8.62E-04 3.302 3.541 3.794 3.875 4.323 
3.57E-03 7.14E-04 3.289 3.528 3.785 3.862 4.309 
5.56E-03 5.56E-04 3.279 3.515 3.777 3.850 4.295 
8.82E-03 2.94E-04 3.265 3.496 3.768 3.822 4.276 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 























0.00E+00 1.00E-03 3.464 3.532 
1.97E-04 9.84E-04 3.462 3.529 
3.88E-04 9.69E-04 3.461 3.528 
4.81E-04 9.62E-04 3.461 3.528 
5.73E-04 9.54E-04 3.460 3.527 
7.52E-04 9.40E-04 3.459 3.526 
9.26E-04 9.26E-04 3.458 3.525 
1.72E-03 8.62E-04 3.454 3.522 
3.57E-03 7.14E-04 3.445 3.514 
5.56E-03 5.56E-04 3.437 3.507 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 























5 H7 H4 H6 H2 H1 
0.00E+00 1.00E-03 3.283 3.584 3.714 3.917 3.983 4.560 
1.97E-04 9.84E-04 3.282 3.582 3.713 3.915 3.983 4.558 
3.88E-04 9.69E-04 3.280 3.581 3.713 3.914 3.982 4.557 
4.81E-04 9.62E-04 3.279 3.580 3.713 3.913 3.981 4.556 
5.73E-04 9.54E-04 3.279 3.579 3.713 3.913 3.981 4.555 
7.52E-04 9.40E-04 3.277 3.578 3.713 3.911 3.980 4.553 
9.26E-04 9.26E-04 3.276 3.576 3.713 3.910 3.979 4.552 
1.72E-03 8.62E-04 3.270 3.570 3.714 3.903 3.975 4.545 
3.57E-03 7.14E-04 3.258 3.558 3.717 3.885 3.966 4.533 
5.56E-03 5.56E-04 3.247 3.546 3.719 3.874 3.960 4.521 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 























0.00E+00 1.00E-03 3.627 3.713 
1.97E-04 9.84E-04 3.623 3.710 
3.88E-04 9.69E-04 3.620 3.708 
4.81E-04 9.62E-04 3.619 3.706 
5.73E-04 9.54E-04 3.617 3.705 
7.52E-04 9.40E-04 3.614 3.703 
9.26E-04 9.26E-04 3.614 3.703 
1.72E-03 8.62E-04 3.597 3.691 
3.57E-03 7.14E-04 3.580 3.673 
5.56E-03 5.56E-04 3.566 3.660 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 























6 H7’ H3 
0.00E+00 1.00E-03 3.862 3.930 4.002 
1.97E-04 9.84E-04 3.864 3.929 4.002 
3.88E-04 9.69E-04 3.860 3.928 4.000 
4.81E-04 9.62E-04 3.858 3.927 3.999 
5.73E-04 9.54E-04 3.857 3.927 3.998 
7.52E-04 9.40E-04 3.856 3.926 3.996 
9.26E-04 9.26E-04 3.855 3.925 3.995 
1.72E-03 8.62E-04 3.850 3.918 3.988 
3.57E-03 7.14E-04 3.840 3.910 3.974 
5.56E-03 5.56E-04 3.831 3.900 3.962 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 




















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 
1H NMR titration of SCR006 with A) β-Glc, B) α-Glc, C) β-Man, D) α-Man and E) β-Gal at 298 K. 
 

















Concentration of Host (M)



















Concentration of Host (M)


















Concentration of Host (M)

















Concentration of Host (M)




















c Hf Ha He Hg Hb Hd 
6.63E-05 4.839 7.122 7.307 7.383 7.445 7.518 8.541 
1.97E-04 4.838 7.121 7.305 7.382 7.444 7.516 8.541 
3.88E-04 4.838 7.122 7.305 7.383 7.444 7.516 8.541 
5.73E-04 4.838 7.122 7.305 7.383 7.445 7.516 8.541 
7.52E-04 4.838 7.122 7.305 7.383 7.445 7.516 8.541 
9.26E-04 4.838 7.122 7.306 7.383 7.445 7.516 8.541 
1.72E-03 4.838 7.122 7.305 7.383 7.445 7.516 8.541 
3.57E-03 4.838 7.122 7.305 7.383 7.445 7.516 8.541 
1.25E-02 4.839 7.122 7.307 7.383 7.445 7.518 8.541 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR007. 
 
[SCR007] = 6.6E-05 M 
[SCR007] = 1.3E-02 M 
[SCR007] = 3.6E-03 M 
[SCR007] = 1.7E-03 M 
[SCR007] = 9.3E-04 M 
[SCR007] = 5.7E-04 M 
[SCR007] = 3.9E-04 M 
[SCR007] = 2.0E-04 M 





















5 H3,7 H4 H6,6’,7’ H1 
0.00E+00 1.00E-03 3.315 3.557 3.808 3.888 4.337 
1.97E-04 9.84E-04 3.314 3.556 3.803 3.887 4.337 
3.88E-04 9.69E-04 3.314 3.555 3.803 3.887 4.336 
5.73E-04 9.54E-04 3.313 3.555 3.803 3.886 4.335 
7.52E-04 9.40E-04 3.312 3.554 3.802 3.886 4.335 
9.26E-04 9.26E-04 3.311 3.553 3.802 3.886 4.334 
1.72E-03 8.62E-04 3.309 3.552 3.801 3.885 4.332 
3.57E-03 7.14E-04 3.302 3.547 3.798 3.881 4.325 
5.56E-03 5.56E-04 3.301 3.542 3.796 3.875 4.319 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 






















0.00E+00 1.00E-03 3.532 3.703 
1.97E-04 9.84E-04 3.530 3.702 
3.88E-04 9.69E-04 3.529 3.702 
5.73E-04 9.54E-04 3.529 3.701 
7.52E-04 9.40E-04 3.529 3.701 
9.26E-04 9.26E-04 3.528 3.701 
1.72E-03 8.62E-04 3.527 3.700 
3.57E-03 7.14E-04 3.523 3.699 
5.56E-03 5.56E-04 3.520 3.698 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 






















5 H7 H4 H2 H1 
0.00E+00 1.00E-03 3.283 3.584 3.714 3.982 4.560 
1.97E-04 9.84E-04 3.282 3.583 3.713 3.984 4.559 
3.88E-04 9.69E-04 3.282 3.582 3.713 3.983 4.558 
5.73E-04 9.54E-04 3.281 3.581 3.713 3.983 4.557 
7.52E-04 9.40E-04 3.280 3.581 3.713 3.982 4.557 
9.26E-04 9.26E-04 3.280 3.581 3.714 3.982 4.556 
1.72E-03 8.62E-04 3.277 3.578 3.713 3.979 4.553 
3.57E-03 7.14E-04 3.274 3.573 3.711 3.974 4.548 
5.56E-03 5.56E-04 3.270 3.568 3.710 3.971 4.543 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 





















7 H3 H7’ H2 
0.00E+00 1.00E-03 3.444 3.627 3.713 3.840 
1.97E-04 9.84E-04 3.442 3.625 3.712 3.837 
3.88E-04 9.69E-04 3.441 3.624 3.710 3.836 
5.73E-04 9.54E-04 3.439 3.623 3.709 3.836 
7.52E-04 9.40E-04 3.438 3.621 3.708 3.836 
9.26E-04 9.26E-04 3.436 3.619 3.706 3.832 
1.72E-03 8.62E-04 3.432 3.616 3.702 3.832 
3.57E-03 7.14E-04 3.425 3.610 3.698 3.831 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 






















5 H6 H3 H1 
0.00E+00 1.00E-03 3.562 3.861 4.002 4.278 
1.97E-04 9.84E-04 3.563 3.864 4.003 4.279 
3.88E-04 9.69E-04 3.562 3.861 4.002 4.278 
5.73E-04 9.54E-04 3.562 3.860 4.002 4.278 
7.52E-04 9.40E-04 3.561 3.860 4.001 4.277 
9.26E-04 9.26E-04 3.561 3.860 4.001 4.277 
1.72E-03 8.62E-04 3.559 3.857 3.997 4.275 
3.57E-03 7.14E-04 3.554 3.855 3.989 4.270 
5.56E-03 5.56E-04 3.547 3.833 3.983 4.264 
 
 1H NMR (600 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 






















a Hb Hc Hu Hd 
6.56E-05 3.598 3.765 3.776 3.792 4.586 
1.97E-04 3.597 3.764 3.777 3.792 4.586 
3.88E-04 3.597 3.763 3.776 3.793 4.587 
4.81E-04 3.597 3.763 3.776 3.793 4.587 
5.73E-04 3.597 3.761 3.776 3.793 4.586 
7.52E-04 3.597 3.760 3.776 3.793 4.586 
9.26E-04 3.596 3.759 3.774 3.792 4.584 
1.72E-03 3.595 3.756 3.772 3.790 4.582 
3.57E-03 3.593 3.752 3.768 3.787 4.578 
1.25E-02 3.590 3.747 3.764 3.783 4.574 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 
concentration of SCR012. 
 
[SCR012] = 6.6E-05 M 
[SCR012] = 1.3E-02 M 
[SCR012] = 3.6E-03 M 
[SCR012] = 1.7E-03 M 
[SCR012] = 9.3E-04 M 
[SCR012] = 5.7E-04 M 
[SCR012] = 4.8E-04 M 
[SCR012] = 3.9E-04 M 
[SCR012] = 2.0E-04 M 






































0.00E+00 1.00E-03 3.318 4.336 
1.95E-04 9.76E-04 3.246 4.310 
3.81E-04 9.52E-04 3.189 4.290 
4.71E-04 9.41E-04 3.164 4.280 
7.27E-04 9.09E-04 3.144 4.288 
8.89E-04 8.89E-04 3.115 4.279 
1.60E-03 8.00E-04 3.034 4.258 
3.08E-03 6.15E-04 2.960 4.238 
4.45E-03 4.45E-04 2.944 4.233 
6.32E-03 2.11E-04 2.930 4.230 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Glc in CD2Cl2 























0.00E+00 1.00E-03 3.450 4.876 
1.95E-04 9.76E-04 3.419 4.849 
3.81E-04 9.52E-04 3.396 4.831 
4.71E-04 9.41E-04 3.384 4.820 
5.58E-04 9.30E-04 3.376 4.812 
7.27E-04 9.09E-04 3.364 4.803 
8.89E-04 8.89E-04 3.353 4.795 
1.60E-03 8.00E-04 3.333 4.786 
3.08E-03 6.15E-04 3.333 4.786 
4.45E-03 4.45E-04 3.292 4.767 
6.32E-03 2.11E-04 3.289 4.762 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Glc in CD2Cl2 























5 H2 H1 
0.00E+00 1.00E-03 3.394 4.084 4.664 
2.42E-04 9.69E-04 3.372 4.067 4.649 
4.70E-04 9.40E-04 3.355 4.055 4.637 
6.84E-04 9.12E-04 3.343 4.046 4.628 
8.87E-04 8.87E-04 3.332 4.039 4.621 
1.26E-03 8.39E-04 3.317 4.029 4.611 
1.59E-03 7.96E-04 3.307 4.023 4.603 
3.05E-03 6.10E-04 3.283 4.010 4.586 
4.39E-03 4.39E-04 3.272 4.007 4.577 
6.20E-03 2.07E-04 3.265 4.002 4.571 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 






















0.00E+00 1.00E-03 3.431 4.833 
1.95E-04 9.76E-04 3.413 4.814 
3.81E-04 9.52E-04 3.400 4.800 
4.71E-04 9.41E-04 3.405 4.804 
5.58E-04 9.30E-04 3.401 4.800 
7.27E-04 9.09E-04 3.395 4.794 
8.89E-04 8.89E-04 3.390 4.789 
1.60E-03 8.00E-04 3.377 4.775 
3.08E-03 6.15E-04 3.359 4.758 
4.45E-03 4.45E-04 3.354 4.752 
6.04E-03 2.45E-04 3.354 4.751 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of α-Man in CD2Cl2 
























0.00E+00 1.00E-03 4.279 
1.95E-04 9.76E-04 4.265 
3.81E-04 9.52E-04 4.253 
4.71E-04 9.41E-04 4.247 
5.58E-04 9.30E-04 4.242 
7.27E-04 9.09E-04 4.235 
8.89E-04 8.89E-04 4.230 
1.60E-03 8.00E-04 4.217 
3.08E-03 6.15E-04 4.198 
4.45E-03 4.45E-04 4.188 
6.32E-03 2.11E-04 4.181 
 
 1H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Gal in CD2Cl2 



















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 






H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 














[H]t [G]t H7 H6 H1 
0.00E+00 1.60E-02 3.37693 3.86502 4.34693 
3.48E-04 1.04E-02 3.34006 3.83897 4.33536 
4.44E-04 8.89E-03 3.32689 3.82963 4.33191 
6.15E-04 6.15E-03 3.30256 3.81131 4.32594 
7.62E-04 3.81E-03 3.28862 3.79775 4.32376 
8.89E-04 1.78E-03 3.28364 3.78843 4.3242 
9.41E-04 9.41E-04 3.28358 3.78713 4.3241 
9.52E-04 7.62E-04 3.2838 3.78707 4.32426 
9.64E-04 5.78E-04 3.28388 3.78693 4.32431 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR017 in 




















[H]t [G]t H4 H6' 
0.00E+00 1.25E-02 3.53743 3.70707 
2.94E-04 8.82E-03 3.524376 3.698074 
3.85E-04 7.69E-03 3.523174 3.697238 
5.56E-04 5.56E-03 3.516955 3.693119 
7.14E-04 3.57E-03 3.513094 3.690589 
8.62E-04 1.72E-03 3.509814 3.688501 
9.26E-04 9.26E-04 3.50854 3.687738 
9.40E-04 7.52E-04 3.507829 3.687021 
9.54E-04 5.73E-04 3.507627 3.686921 
9.62E-04 4.81E-04 3.507452 3.686737 
9.69E-04 3.88E-04 3.507246 3.686535 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR017 in 
CD2Cl2 upon incremental addition of α-Glc. 
 



















[H]t [G]t H5 H3 H7' H4 H2 H1 
9.84E-04 1.97E-04 3.24621 3.46468 3.55231 3.67511 3.94699 4.52682 
9.69E-04 3.88E-04 3.24604 3.46464 3.55202 3.67534 3.94706 4.52685 
9.54E-04 5.73E-04 3.24587 3.46479 3.55181 3.67572 3.94702 4.52685 
9.40E-04 7.52E-04 3.24606 3.46504 3.55197 3.67662 3.94728 4.52693 
9.26E-04 9.26E-04 3.24594 3.46515 3.55179 3.67742 3.94729 4.52696 
8.62E-04 1.72E-03 3.24629 3.46637 3.55168 3.68418 3.94818 4.52742 
7.14E-04 3.57E-03 3.24346 3.47111 3.55027 3.70683 3.95091 4.52638 
5.56E-04 5.56E-03 3.23472 3.48045 3.54614 3.74289 3.95527 4.52236 
3.85E-04 7.69E-03 3.22296 3.49631 3.53996 3.78603 3.96298 4.51668 






H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR017 in 
















[H]t [G]t H7' H6 
2.94E-04 8.82E-03 3.67367 3.9011 
3.85E-04 7.69E-03 3.67408 3.88996 
5.56E-04 5.56E-03 3.67571 3.86129 
7.14E-04 3.57E-03 3.67927 3.81636 
8.62E-04 1.72E-03 3.68571 3.75283 
9.26E-04 9.26E-04 3.689 3.74165 
9.40E-04 7.52E-04 3.68987 3.74184 
9.54E-04 5.73E-04 3.69067 3.74281 
9.62E-04 4.81E-04 3.69091 3.74344 
9.69E-04 3.88E-04 3.69123 3.75278 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR017 in 


















[H]t [G]t H6' H3 
0.00E+00 1.60E-02 3.85457 4.00457 
3.48E-04 1.04E-02 3.85017 3.99503 
4.44E-04 8.89E-03 3.84911 3.99261 
6.15E-04 6.15E-03 3.84696 3.9886 
7.62E-04 3.81E-03 3.84523 3.9861 
8.89E-04 1.78E-03 3.84372 3.98377 
9.41E-04 9.41E-04 3.83357 3.98312 
9.52E-04 7.62E-04 3.8334 3.98307 
9.64E-04 5.78E-04 3.8333 3.98288 
9.76E-04 3.90E-04 3.8332 3.98289 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR017 in 


















 Fitting of experimental data (circles) with the 2:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR017 with A) α-Man, B) β-Glc, C) α-Glc at 298 K.  

















Concentration of Guest (M)


















Concentration of Guest (M)
























 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 

















[H]t [G]t H5 H3,7' H4 H1 
9.88E-04 1.98E-04 3.375346 3.537085 3.760612 4.311278 
9.76E-04 3.90E-04 3.374983 3.536904 3.760523 4.311082 
9.70E-04 4.85E-04 3.374909 3.53689 3.760511 4.311044 
9.64E-04 5.78E-04 3.374671 3.536767 3.760479 4.310846 
9.52E-04 7.62E-04 3.374215 3.536681 3.760484 4.310643 
9.41E-04 9.41E-04 3.373772 3.536361 3.760514 4.310347 
8.89E-04 1.78E-03 3.370319 3.535071 3.760676 4.308303 
7.62E-04 3.81E-03 3.347101 3.537407 3.764909 4.300287 








H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR018 in 




















[H]t [G]t H2 H4 H7 H6' H6 H1 
0.00E+00 1.25E-02 3.45891 3.53743 3.70707 3.75249 3.83122 4.8729 
2.94E-04 8.82E-03 3.44581 3.52262 3.6988 3.74721 3.82603 4.86634 
3.85E-04 7.69E-03 3.44149 3.51877 3.69668 3.7455 3.82427 4.86406 
5.56E-04 5.56E-03 3.43452 3.51079 3.69178 3.74134 3.82255 4.86248 
7.14E-04 3.57E-03 3.43007 3.50503 3.68859 3.73869 3.82172 4.86062 
8.62E-04 1.72E-03 3.42465 3.49737 3.68303 3.73404 3.81875 4.85693 
9.26E-04 9.26E-04 3.42443 3.49535 3.68158 3.73334 3.81895 4.85645 
9.40E-04 7.52E-04 3.42828 3.49695 3.68174 3.7343 3.81795 4.85786 
9.54E-04 5.73E-04 3.42742 3.49649 3.68118 3.73446 3.81899 4.85704 
9.62E-04 4.81E-04 3.42714 3.49646 3.68104 3.73428 3.8182 4.85706 
9.69E-04 3.88E-04 3.42559 3.49647 3.68096 3.73402 3.81739 4.85765 






H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR018 in 


















[H]t [G]t H5 H3 H7' H4 H1 
9.88E-04 1.98E-04 3.26954 3.475472 3.561893 3.686243 4.544918 
9.76E-04 3.90E-04 3.268886 3.475241 3.561663 3.686388 4.544253 
9.70E-04 4.85E-04 3.268634 3.475255 3.56154 3.686602 4.54398 
9.64E-04 5.78E-04 3.268374 3.475267 3.561441 3.686802 4.543731 
9.52E-04 7.62E-04 3.267671 3.475044 3.561077 3.687378 4.542972 
9.41E-04 9.41E-04 3.26695 3.474916 3.560645 3.688073 4.542203 
8.89E-04 1.78E-03 3.263585 3.474664 3.558628 3.694335 4.538551 
7.62E-04 3.81E-03 3.252739 3.478211 3.552752 3.721877 4.528953 
6.15E-04 6.15E-03 3.240579 3.488298 3.546312 3.759898 4.520594 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR018 in 

















[H]t [G]t H3 H7' 
9.88E-04 1.98E-04 3.614591 3.687933 
9.76E-04 3.90E-04 3.612408 3.686571 
9.70E-04 4.85E-04 3.611177 3.685871 
9.64E-04 5.78E-04 3.609712 3.684994 
9.52E-04 7.62E-04 3.607375 3.68356 
9.41E-04 9.41E-04 3.604437 3.681761 
8.89E-04 1.78E-03 3.582408 3.673241 
7.62E-04 3.81E-03 3.56351 3.664397 
6.15E-04 6.15E-03 3.552693 3.662643 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR018 in 

















[H]t [G]t H2 H1 
0.00E+00 1.60E-02 3.55766 4.27641 
3.48E-04 1.04E-02 3.54103 4.2657 
6.15E-04 6.15E-03 3.53418 4.26273 
7.62E-04 3.81E-03 3.52895 4.26126 
8.89E-04 1.78E-03 3.52794 4.26023 
9.41E-04 9.41E-04 3.52464 4.26023 
9.52E-04 7.62E-04 3.52377 4.26008 
9.64E-04 5.78E-04 3.52324 4.2602 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR018 in 




















 Fitting of experimental data (circles) with the 1:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR018 with A) β-Man, B) α-Man at 298 K. 


















Concentration of Guest (M)


























 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 















[H]t [G]t H2 H7,6,6' H7,6,6' H1 
0.00E+00 1.60E-02 3.37693 3.86502 3.88604 4.33747 
3.48E-04 1.04E-02 3.331712 3.823352 3.870179 4.309092 
4.44E-04 8.89E-03 3.316705 3.81287 3.866606 4.301791 
6.15E-04 6.15E-03 3.288331 3.790043 3.863528 4.292537 
7.62E-04 3.81E-03 3.275539 3.779187 3.868003 4.29413 
8.89E-04 1.78E-03 3.275186 3.773715 3.882722 4.302932 
9.41E-04 9.41E-04 3.276703 3.772929 3.885304 4.305528 
9.52E-04 7.62E-04 3.277077 3.772907 3.885545 4.305882 
9.64E-04 5.78E-04 3.27758 3.77293 3.885697 4.306261 
9.70E-04 4.85E-04 3.277854 3.772976 3.88576 4.306449 
9.76E-04 3.90E-04 3.278072 3.773011 3.885784 4.306585 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR019 in 






















[H]t [G]t H4 H7 H6' H6 H1 
0.00E+00 1.25E-02 3.53743 3.70707 3.75249 3.83122 4.8729 
2.94E-04 8.82E-03 3.52047 3.69613 3.74853 3.82126 4.86614 
3.85E-04 7.69E-03 3.51683 3.69408 3.74759 3.81869 4.86437 
5.56E-04 5.56E-03 3.5118 3.69201 3.74809 3.82044 4.86734 
7.14E-04 3.57E-03 3.50509 3.688 3.74728 3.81849 4.8656 
8.62E-04 1.72E-03 3.49855 3.68396 3.74522 3.81425 4.86225 
9.26E-04 9.26E-04 3.49612 3.68266 3.74433 3.81151 4.862 
9.40E-04 7.52E-04 3.49191 3.68012 3.74371 3.8091 4.86076 
9.54E-04 5.73E-04 3.49119 3.67971 3.7434 3.80863 4.86095 
9.62E-04 4.81E-04 3.49064 3.67946 3.74348 3.80853 4.85712 
9.69E-04 3.88E-04 3.49008 3.67911 3.74312 3.80811 4.86058 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR019 in 

















[H]t [G]t H5 H7' H4 H1 
9.88E-04 1.98E-04 3.241356 3.685392 3.764799 4.52439 
9.76E-04 3.90E-04 3.238691 3.685328 3.773134 4.522789 
9.64E-04 5.78E-04 3.237915 3.675684 3.774857 4.52167 
9.52E-04 7.62E-04 3.237679 3.6765 3.776089 4.521057 
9.41E-04 9.41E-04 3.236688 3.677954 3.776491 4.520191 
8.89E-04 1.78E-03 3.23489 3.686512 3.779796 4.517782 
7.62E-04 3.81E-03 3.224527 3.719689 3.796949 4.508856 
6.15E-04 6.15E-03 3.213577 3.76203 3.8473 4.501859 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR019 in 

















[H]t [G]t H3 H2,4,6' 
9.88E-04 2.00E-04 3.592822 3.879269 
9.76E-04 3.95E-04 3.587522 3.879953 
9.64E-04 5.85E-04 3.584839 3.879346 
9.52E-04 7.71E-04 3.582657 3.878514 
9.41E-04 9.52E-04 3.580146 3.877225 
8.89E-04 1.80E-03 3.571888 3.877673 
7.62E-04 3.85E-03 3.544364 3.882252 
6.15E-04 6.22E-03 3.5329 3.888999 
4.44E-04 8.99E-03 3.526138 3.900959 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR019 in 
















[H]t [G]t H2 H7 H3 H1 
0.00E+00 1.60E-02 3.59859 3.85457 4.00457 4.27641 
3.48E-04 1.04E-02 3.57968 3.84472 3.98819 4.25958 
6.15E-04 6.15E-03 3.57212 3.84137 3.9808 4.26062 
7.62E-04 3.81E-03 3.56933 3.84113 3.97831 4.26289 
8.89E-04 1.78E-03 3.56079 3.83362 3.96963 4.25638 
9.41E-04 9.41E-04 3.55986 3.83299 3.96853 4.25611 
9.52E-04 7.62E-04 3.55966 3.83289 3.9683 4.25608 
9.64E-04 5.78E-04 3.55942 3.83344 3.96798 4.25601 
9.70E-04 4.85E-04 3.55919 3.83302 3.96771 4.25593 
9.76E-04 3.90E-04 3.55921 3.8336 3.96764 4.25599 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR019 in 



















 Fitting of experimental data (circles) with the 2:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR019 with A) β-Man, B) α-Man at 298 K.  

















Concentration of Guest (M)























 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 














[H]t [G]t H5 H7,6,6' H1 
0.00E+00 1.60E-02 3.37693 3.86502 4.33747 
3.48E-04 1.04E-02 3.326623 3.819723 4.30511 
6.15E-04 6.15E-03 3.276029 3.790844 4.287722 
7.62E-04 3.81E-03 3.254721 3.774501 4.280818 
8.89E-04 1.78E-03 3.250647 3.769623 4.27982 
9.41E-04 9.41E-04 3.252433 3.77008 4.280915 
9.52E-04 7.62E-04 3.25323 3.770348 4.281385 
9.64E-04 5.78E-04 3.253652 3.770493 4.28166 
9.70E-04 4.85E-04 3.25408 3.770628 4.281896 
9.76E-04 3.90E-04 3.254596 3.770809 4.282162 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR020 in 



















[H]t [G]t H7' H4 
0.00E+00 1.25E-02 3.46929 3.53743 
2.94E-04 8.82E-03 3.45148 3.52557 
3.85E-04 7.69E-03 3.44913 3.52338 
5.56E-04 5.56E-03 3.44559 3.5195 
7.14E-04 3.57E-03 3.44227 3.51625 
8.62E-04 1.72E-03 3.43988 3.51376 
9.26E-04 9.26E-04 3.43886 3.51286 
9.40E-04 7.52E-04 3.4391 3.51289 
9.54E-04 5.73E-04 3.43893 3.5127 
9.62E-04 4.81E-04 3.43879 3.51267 
9.69E-04 3.88E-04 3.43888 3.51255 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR020 in 

















[H]t [G]t H5 H3 H4 
9.88E-04 2.00E-04 3.256423 3.466281 3.674043 
9.76E-04 3.95E-04 3.256028 3.466147 3.67429 
9.70E-04 4.85E-04 3.255658 3.466026 3.674261 
9.64E-04 5.85E-04 3.255577 3.466102 3.674457 
9.52E-04 7.71E-04 3.255375 3.466244 3.675231 
9.41E-04 9.52E-04 3.254929 3.466199 3.675821 
8.89E-04 1.80E-03 3.253698 3.467279 3.68208 
7.62E-04 3.85E-03 3.24952 3.47373 3.70739 
6.15E-04 6.22E-03 3.241942 3.487061 3.7486 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR020 in 

















[H]t [G]t H3 H1 
9.88E-04 2.00E-04 3.592166 4.791717 
9.76E-04 3.95E-04 3.579043 4.791092 
9.70E-04 4.85E-04 3.577776 4.790583 
9.64E-04 5.85E-04 3.576578 4.790106 
9.52E-04 7.71E-04 3.574932 4.789557 
9.41E-04 9.52E-04 3.572652 4.78893 
8.89E-04 1.80E-03 3.567882 4.788639 
7.62E-04 3.85E-03 3.545188 4.796604 
6.15E-04 6.22E-03 3.537665 4.806361 
4.44E-04 8.99E-03 3.532873 4.8146 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR020 in 



















[H]t [G]t H5 H3 H4 
9.88E-04 2.00E-04 3.256423 3.466281 3.674043 
9.76E-04 3.95E-04 3.256028 3.466147 3.67429 
9.70E-04 4.85E-04 3.255658 3.466026 3.674261 
9.64E-04 5.85E-04 3.255577 3.466102 3.674457 
9.52E-04 7.71E-04 3.255375 3.466244 3.675231 
9.41E-04 9.52E-04 3.254929 3.466199 3.675821 
8.89E-04 1.80E-03 3.253698 3.467279 3.68208 
7.62E-04 3.85E-03 3.24952 3.47373 3.70739 
6.15E-04 6.22E-03 3.241942 3.487061 3.7486 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR020 in 


















 Fitting of experimental data (circles) with the 1:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR020 with A) β-Man at 298 K; and 2:1 receptor sugar model 









 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 















[H]t [G]t H5 H7,6,6' 
0.00E+00 1.60E-02 3.376927 3.865024 
3.48E-04 1.04E-02 3.357588 3.849901 
4.44E-04 8.89E-03 3.349806 3.8434 
6.15E-04 6.15E-03 3.331803 3.828346 
7.62E-04 3.81E-03 3.312301 3.812062 
8.89E-04 1.78E-03 3.304854 3.800531 
9.41E-04 9.41E-04 3.305428 3.800058 
9.52E-04 7.62E-04 3.305444 3.799935 
9.64E-04 5.78E-04 3.305594 3.799895 
9.70E-04 4.85E-04 3.305862 3.800002 
9.76E-04 3.90E-04 3.306133 3.80008 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR021 in 



















[H]t [G]t H7' H4 H5 H3 H7 H6 H1 
0.00E+00 1.25E-02 3.45891 3.53743 3.64823 3.70707 3.75249 3.83122 4.8729 
2.94E-04 8.82E-03 3.45929 3.53298 3.64964 3.70431 3.75339 3.83152 4.87186 
3.85E-04 7.69E-03 3.4592 3.53303 3.64938 3.7043 3.75324 3.8313 4.87173 
5.56E-04 5.56E-03 3.45865 3.53086 3.65081 3.70274 3.75429 3.83264 4.8745 
7.14E-04 3.57E-03 3.45863 3.52998 3.65158 3.70207 3.75482 3.83317 4.87442 
8.62E-04 1.72E-03 3.4587 3.52957 3.65189 3.70177 3.75506 3.83395 4.87478 
9.26E-04 9.26E-04 3.45874 3.52955 3.65224 3.70173 3.75563 3.83415 4.87458 
9.40E-04 7.52E-04 3.45905 3.52979 3.65259 3.70168 3.75572 3.83418 4.87487 
9.54E-04 5.73E-04 3.45922 3.52991 3.6527 3.70175 3.75573 3.83434 4.87512 
9.62E-04 4.81E-04 3.45929 3.52995 3.65282 3.70178 3.75588 3.83438 4.8751 
9.69E-04 3.88E-04 3.45929 3.52995 3.65281 3.70176 3.75585 3.8344 4.87511 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR021 in 

















[H]t [G]t H5 H3 H7' H2 H1 
9.88E-04 2.16E-04 3.276005 3.488809 3.558098 3.687844 4.545871 
9.76E-04 4.27E-04 3.273211 3.487708 3.558353 3.688797 4.545655 
9.64E-04 6.32E-04 3.276767 3.487227 3.558332 3.689217 4.545668 
9.52E-04 8.33E-04 3.276431 3.487978 3.558407 3.689746 4.545357 
9.41E-04 1.03E-03 3.275828 3.487883 3.557659 3.69068 4.545072 
8.89E-04 1.94E-03 3.27351 3.489312 3.556585 3.698343 4.543441 
7.62E-04 4.17E-03 3.256807 3.499114 3.549972 3.73985 4.534566 
6.15E-04 6.73E-03 3.243109 3.511417 3.541305 3.783511 4.52461 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR021 in 
















[H]t [G]t H3 H7' 
9.88E-04 2.00E-04 3.616055 3.698389 
9.76E-04 3.95E-04 3.616055 3.698389 
9.64E-04 5.85E-04 3.613125 3.697502 
9.52E-04 7.71E-04 3.612457 3.697192 
9.41E-04 9.52E-04 3.611013 3.696506 
8.89E-04 1.80E-03 3.592159 3.69107 
7.62E-04 3.85E-03 3.568949 3.680287 
6.15E-04 6.22E-03 3.554858 3.675585 
4.44E-04 8.99E-03 3.554858 3.675585 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR021 in 


















[H]t [G]t H2 H3 H1 
0.00E+00 1.60E-02 3.55766 4.00457 4.27641 
3.48E-04 1.04E-02 3.55982 4.0052 4.27582 
6.15E-04 6.15E-03 3.55384 3.99524 4.269 
7.62E-04 3.81E-03 3.55479 3.99464 4.26966 
8.89E-04 1.78E-03 3.55526 3.99487 4.2702 
9.41E-04 9.41E-04 3.55593 3.99545 4.27075 
9.52E-04 7.62E-04 3.55621 3.99573 4.27105 
9.64E-04 5.78E-04 3.55624 3.99565 4.27101 
9.70E-04 4.85E-04 3.55622 3.99558 4.27103 
9.76E-04 3.90E-04 3.55629 3.99564 4.27106 




H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR021 in 



















 Fitting of experimental data (circles) with the 2:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR021 with A) β-Glc, B) β-Man, and C) α-Man a 1:1 receptor 
sugar model at 298 K. 



















Concentration of Guest (M)
A 


















Concentration of Guest (M)
B 



























 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally increasing 















[H]t [G]t H2 H3,7' H7,6,6' 
9.88E-04 1.98E-04 3.298735 3.555258 3.789557 
9.76E-04 3.90E-04 3.298917 3.555321 3.789379 
9.70E-04 4.85E-04 3.298769 3.555058 3.789541 
9.64E-04 5.78E-04 3.299194 3.555516 3.789495 
9.52E-04 7.62E-04 3.298555 3.554782 3.78935 
9.41E-04 9.41E-04 3.298812 3.554998 3.789925 
8.89E-04 1.78E-03 3.299582 3.555756 3.790351 
7.62E-04 3.81E-03 3.306028 3.561404 3.797443 
6.15E-04 6.15E-03 3.322247 3.575222 3.813033 
4.44E-04 8.89E-03 3.338099 3.587616 3.827579 
3.48E-04 1.04E-02 3.34489 3.593 3.83379 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR022 in 


















[H]t [G]t H4 H5 H3 H7 H6 H1 
0.00E+00 1.25E-02 3.53743 3.64823 3.70707 3.75249 3.83122 4.8729 
2.94E-04 8.82E-03 3.530841 3.649402 3.703191 3.753451 3.830745 4.871517 
3.85E-04 7.69E-03 3.530396 3.64973 3.702869 3.753641 3.83069 4.871262 
5.56E-04 5.56E-03 3.530042 3.650124 3.702491 3.7539 3.833286 4.871033 
7.14E-04 3.57E-03 3.52944 3.650999 3.701892 3.75435 3.83368 4.870808 
8.62E-04 1.72E-03 3.529066 3.651446 3.7015 3.754646 3.834381 4.870481 
9.26E-04 9.26E-04 3.528578 3.651356 3.701048 3.754691 3.833807 4.870483 
9.40E-04 7.52E-04 3.528976 3.65194 3.701212 3.755055 3.83448 4.87056 
9.54E-04 5.73E-04 3.528994 3.652028 3.701209 3.75522 3.83458 4.870699 
9.62E-04 4.81E-04 3.528984 3.652024 3.701177 3.755147 3.834636 4.870506 
9.69E-04 3.88E-04 3.528967 3.652051 3.701158 3.755197 3.834653 4.87054 
9.84E-04 1.97E-04 3.528965 3.652132 3.701162 3.755652 3.834767 4.870628 
 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR022 in 


















[H]t [G]t H5 H3 H7' H4 H1 
9.88E-04 1.98E-04 3.28824 3.503941 3.57744 3.706506 4.564114 
9.76E-04 3.90E-04 3.28802 3.503541 3.577282 3.707482 4.564027 
9.70E-04 4.85E-04 3.288019 3.503612 3.577224 3.707922 4.563983 
9.64E-04 5.78E-04 3.28791 3.503514 3.577144 3.708337 4.563965 
9.52E-04 7.62E-04 3.287567 3.503819 3.577138 3.709424 4.56388 
9.41E-04 9.41E-04 3.287394 3.503687 3.576893 3.710543 4.563709 
8.89E-04 1.78E-03 3.285431 3.504585 3.576026 3.717827 4.562741 
7.62E-04 3.81E-03 3.273247 3.512671 3.57029 3.753379 4.555132 
6.15E-04 6.15E-03 3.262517 3.525005 3.562209 3.794672 4.544927 
4.44E-04 8.89E-03 3.251587 3.53628 3.555786 3.824159 4.537199 
3.48E-04 1.04E-02 3.247475 3.542168 3.552619 3.835442 4.534122 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR022 in 



















[H]t [G]t H3 H7' 
9.88E-04 1.98E-04 3.635138 3.706092 
9.76E-04 3.90E-04 3.634268 3.706252 
9.70E-04 4.85E-04 3.634222 3.706225 
9.64E-04 5.78E-04 3.633965 3.706198 
9.52E-04 7.62E-04 3.632296 3.705562 
9.41E-04 9.41E-04 3.631082 3.705009 
8.89E-04 1.78E-03 3.614461 3.700093 
7.62E-04 3.81E-03 3.588467 3.688821 
6.15E-04 6.15E-03 3.572574 3.683549 
4.44E-04 8.89E-03 3.563532 3.680727 
3.48E-04 1.04E-02 3.560337 3.67979 
 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR022 in 

















[H]t [G]t H2 H6' H3 H1 
0.00E+00 1.60E-02 3.55766 3.84482 4.00457 4.27641 
3.48E-04 1.04E-02 3.558339 3.846891 4.00441 4.275316 
6.15E-04 6.15E-03 3.560111 3.847909 4.001806 4.275535 
7.62E-04 3.81E-03 3.554999 3.842689 3.995185 4.270049 
8.89E-04 1.78E-03 3.555604 3.843646 3.994921 4.270597 
9.41E-04 9.41E-04 3.55578 3.844102 3.994829 4.270749 
9.52E-04 7.62E-04 3.555959 3.844411 3.994789 4.270901 
9.64E-04 5.78E-04 3.555928 3.844507 3.994513 4.270853 
9.70E-04 4.85E-04 3.555854 3.844503 3.994207 4.270809 
9.76E-04 3.90E-04 3.555859 3.844572 3.994157 4.270791 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR022 in 

















 Fitting of experimental data (circles) with the 2:1 receptor sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR022 with A) β-Man, B) α-Man, and C) β-Glc a 1:2 receptor 
sugar model at 298 K. 
 


















Concentration of Guest (M)


















Concentration of Guest (M)





















Concentration of Guest (M)
C 





[H]t Hc He Hj Hh Hf Hi Hb 
1.00E-03 3.80088 3.85576 6.75276 6.82714 6.91373 7.20014 7.28684 
9.62E-04 3.80259 3.85726 6.75286 6.82861 6.91602 7.20022 7.28743 
9.26E-04 3.80289 3.85755 6.75294 6.82864 6.91636 7.20029 7.28755 
8.62E-04 3.80328 3.85792 6.75318 6.82883 6.91698 7.20054 7.28788 
7.14E-04 3.80425 3.85889 6.75367 6.82929 6.91837 7.20104 7.28858 
5.56E-04 3.80528 3.8599 6.75416 6.82979 6.91986 7.20161 7.28929 
3.85E-04 3.80664 3.86122 6.75472 6.83043 6.92173 7.20228 7.29023 
2.94E-04 3.80711 3.86162 6.75505 6.83067 6.92272 7.20229 7.29056 
2.50E-04 3.80794 3.86225 6.7554 6.83117 6.92381 7.20291 7.29105 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of an incrementally decreasing 
concentration of SCR023 in 4%CD3OD in CD2Cl2.  
 
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
[SCR023] = 1.0E-03 M 
[SCR023] = 2.5E-04 M 
[SCR023] = 2.9E-04 M 
[SCR023] = 3.8E-04 M 
[SCR023] = 7.1E-04 M 
[SCR023] = 8.6E-04 M 
[SCR023] = 9.3E-04 M 
[SCR023] = 9.6E-04 M 






[H]t [G]t Hc He Hj Hh Hf Hi Hb 
0.001 0 3.90324 3.95805 6.85253 6.93097 7.01611 7.30234 7.38824 
9.88E-04 1.98E-04 3.90345 3.95789 6.85278 6.93103 7.01652 7.30247 7.38824 
9.76E-04 3.90E-04 3.90386 3.95782 6.85287 6.93104 7.01689 7.30256 7.38812 
9.70E-04 4.85E-04 3.90402 3.95774 6.85479 6.93108 7.01722 7.30261 7.38813 
9.64E-04 5.78E-04 3.90425 3.95771 6.85302 6.93108 7.01749 7.30265 7.38812 
9.52E-04 7.62E-04 3.90458 3.95756 6.85327 6.93111 7.01795 7.30274 7.38806 
9.41E-04 9.41E-04 3.90440 3.95692 6.85286 6.93059 7.01784 7.30228 7.38747 
8.89E-04 1.78E-03 3.90596 3.95635 6.85345 6.93077 7.01983 7.30269 7.38724 
7.62E-04 3.81E-03 3.90969 3.95495 6.85512 6.93119 7.02460 7.30364 7.38688 
6.15E-04 6.15E-03 3.91447 3.95368 6.85709 6.93182 7.03044 7.30483 7.38680 
4.44E-04 8.89E-03 3.92220 3.95021 6.86019 6.93297 7.03928 7.30665 7.38821 






H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR023 in 4% 




















[H]t [G]t Hc He Hj Hh Hf Hi Hb 
0.001 0 3.90372 3.95833 6.85266 6.93086 7.01678 7.30234 7.38837 
9.88E-04 1.98E-04 3.90412 3.95853 6.85484 6.93107 7.01733 7.30259 7.38867 
9.76E-04 3.90E-04 3.90434 3.95852 6.85307 6.93113 7.01767 7.30267 7.38876 
9.70E-04 4.85E-04 3.90452 3.95858 6.85312 6.93112 7.01785 7.30269 7.38875 
9.64E-04 5.78E-04 3.90472 3.95864 6.85323 6.93113 7.01807 7.30271 7.38882 
9.52E-04 7.62E-04 3.90493 3.95864 6.85332 6.93116 7.01835 7.30276 7.38889 
9.41E-04 9.41E-04 3.90470 3.95816 6.85284 6.93062 7.01806 7.30226 7.38836 
8.89E-04 1.78E-03 3.90557 3.95820 6.85332 6.93089 7.01921 7.30256 7.38876 
7.62E-04 3.81E-03 3.90752 3.95837 6.85422 6.93135 7.02147 7.30313 7.38947 
6.15E-04 6.15E-03 3.90988 3.95858 6.85520 6.93192 7.02409 7.30377 7.39031 
4.44E-04 8.89E-03 3.91333 3.95924 6.85653 6.93262 7.02764 7.30461 7.39161 





H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR023 in 4% 


















[H]t [G]t Hc He Hj Hh Hf Hi Hb 
0.001 0 3.90324 3.95825 6.85247 6.93098 7.01593 7.30233 7.38843 
9.88E-04 1.98E-04 3.90324 3.95825 6.85247 6.93098 7.01593 7.30233 7.38843 
9.76E-04 3.90E-04 3.90362 3.95819 6.85462 6.93101 7.01646 7.30246 7.38867 
9.70E-04 4.85E-04 3.90376 3.95818 6.85276 6.93103 7.01667 7.30250 7.38875 
9.64E-04 5.78E-04 3.90385 3.95813 6.85282 6.93102 7.01689 7.30248 7.38879 
9.52E-04 7.62E-04 3.90405 3.95812 6.85480 6.93107 7.01714 7.30258 7.38893 
9.41E-04 9.41E-04 3.90419 3.95805 6.85484 6.93107 7.01734 7.30256 7.38902 
8.89E-04 1.78E-03 3.90485 3.95770 6.85315 6.93120 7.01833 7.30273 7.38953 
7.62E-04 3.81E-03 3.90608 3.95693 6.85379 6.93152 7.02047 7.30316 7.39066 
6.15E-04 6.15E-03 3.90723 3.95599 6.85435 6.93167 7.02261 7.30345 7.39166 
4.44E-04 8.89E-03 3.90968 3.95551 6.85677 6.93164 7.02414 7.30361 7.39276 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR023 in 4% 

















[H]t [G]t Hc He Hj Hh Hf Hi Hb 
0.001 0 3.95851 6.8546 6.93105 7.01639 7.30246 7.38874 7.66828 
9.88E-04 1.98E-04 3.95851 6.85468 6.93101 7.01664 7.30249 7.38881 7.66825 
9.76E-04 3.90E-04 3.95852 6.85482 6.93109 7.01700 7.30259 7.389 7.6685 
9.70E-04 4.85E-04 3.95855 6.85487 6.93111 7.01719 7.30263 7.38908 7.66856 
9.64E-04 5.78E-04 3.95868 6.85494 6.93113 7.01734 7.3027 7.38911 7.66852 
9.52E-04 7.62E-04 3.95869 6.85507 6.93118 7.01765 7.30274 7.38925 7.66861 
9.41E-04 9.41E-04 3.95857 6.85512 6.93114 7.01779 7.3027 7.3893 7.66862 
8.89E-04 1.78E-03 3.95861 6.85624 6.93191 7.02019 7.30354 7.39099 7.66843 
7.62E-04 3.81E-03 3.95893 6.85699 6.93224 7.02198 7.30398 7.39208 7.66821 
6.15E-04 6.15E-03 3.96265 6.85798 6.93271 7.02415 7.30463 7.39343 7.66835 
4.44E-04 8.89E-03 3.96265 6.85812 6.93241 7.02465 7.30443 7.39384 7.66783 





H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR023 in 4% 


















[H]t [G]t Hc He Hj Hh Hf Hi Hb 
0.001 0 3.80067 3.85528 6.75003 6.82860 6.91383 7.19995 7.28555 
9.88E-04 1.98E-04 3.80089 3.85536 6.75207 6.82858 6.91411 7.19998 7.28561 
9.76E-04 3.90E-04 3.80118 3.85547 6.75031 6.82855 6.91446 7.19998 7.28563 
9.70E-04 4.85E-04 3.80133 3.85553 6.75040 6.82860 6.91474 7.20004 7.28578 
9.64E-04 5.78E-04 3.80143 3.85556 6.75042 6.82856 6.91486 7.20003 7.28576 
9.52E-04 7.62E-04 3.80167 3.85562 6.75050 6.82860 6.91527 7.20009 7.28590 
9.41E-04 9.41E-04 3.80190 3.85569 6.75067 6.82860 6.91553 7.20012 7.28597 
8.89E-04 1.78E-03 3.80308 3.85620 6.75114 6.82873 6.91690 7.20035 7.28646 
7.62E-04 3.81E-03 3.80676 3.85810 6.75285 6.82928 6.92064 7.20115 7.28810 
6.15E-04 6.15E-03 3.80778 3.85895 6.75517 6.83027 6.92608 7.20238 7.29057 
4.44E-04 8.89E-03 3.80808 3.86507 6.76044 6.83225 6.93562 7.20453 7.29556 




H NMR (700 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of SCR023 in 4% 




















 Fitting of experimental data (circles) with the 1:1 receptor sugar model (dashed line) 










5 H2 H1 
0.00E+00 1.00E-03 3.394 4.084 4.664 
2.00E-04 1.00E-03 3.372 4.067 4.649 
5.00E-04 9.00E-04 3.355 4.055 4.637 
7.00E-04 9.00E-04 3.343 4.046 4.628 
9.00E-04 9.00E-04 3.332 4.039 4.621 
1.30E-03 8.00E-04 3.317 4.029 4.611 
1.60E-03 8.00E-04 3.307 4.023 4.603 
3.00E-03 6.00E-04 3.283 4.010 4.586 
4.40E-03 4.00E-04 3.272 4.007 4.577 
6.20E-03 2.00E-04 3.266 4.002 4.571 
 
 1H NMR (800 MHz, 298 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 




















6 H2 H1 
0.00E+00 1.00E-03 3.272 3.982 4.560 
1.97E-04 9.84E-04 3.254 3.963 4.542 
3.88E-04 9.69E-04 3.237 3.951 4.531 
4.81E-04 9.62E-04 3.230 3.947 4.526 
5.73E-04 9.54E-04 3.224 3.943 4.522 
7.52E-04 9.40E-04 3.214 3.936 4.515 
9.26E-04 9.26E-04 3.206 3.931 4.509 
1.72E-03 8.62E-04 3.180 3.915 4.490 
3.57E-03 7.14E-04 3.155 3.900 4.471 
5.56E-03 5.56E-04 3.145 3.893 4.463 
 
 1H NMR (700 MHz, 293 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 




















6 H2 H1 
0.00E+00 1.00E-03 3.275 3.982 4.558 
1.97E-04 9.84E-04 3.245 3.958 4.535 
3.88E-04 9.69E-04 3.224 3.944 4.521 
4.81E-04 9.62E-04 3.216 3.939 4.516 
5.73E-04 9.54E-04 3.210 3.935 4.511 
7.52E-04 9.40E-04 3.199 3.928 4.504 
9.26E-04 9.26E-04 3.190 3.922 4.498 
1.72E-03 8.62E-04 3.165 3.908 4.480 
3.57E-03 7.14E-04 3.144 3.896 4.465 
5.56E-03 5.56E-04 3.137 3.892 4.458 
 
 1H NMR (700 MHz, 288 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 



















6 H2 H1 
0.00E+00 1.00E-03 3.273 3.982 4.555 
1.97E-04 9.84E-04 3.234 3.952 4.527 
3.88E-04 9.69E-04 3.211 3.937 4.510 
4.81E-04 9.62E-04 3.202 3.931 4.505 
5.73E-04 9.54E-04 3.195 3.927 4.500 
7.52E-04 9.40E-04 3.183 3.920 4.492 
9.26E-04 9.26E-04 3.174 3.915 4.487 
1.72E-03 8.62E-04 3.152 3.903 4.472 
3.57E-03 7.14E-04 3.137 3.895 4.460 
5.56E-03 5.56E-04 3.132 3.892 4.455 
 
 1H NMR (700 MHz, 283 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 





















6 H2 H1 
0.00E+00 1.00E-03 3.252 3.981 4.539 
1.97E-04 9.84E-04 3.209 3.937 4.504 
3.88E-04 9.69E-04 3.182 3.918 4.486 
4.81E-04 9.62E-04 3.172 3.912 4.481 
5.73E-04 9.54E-04 3.165 3.909 4.477 
7.52E-04 9.40E-04 3.155 3.903 4.471 
9.26E-04 9.26E-04 3.147 3.901 4.467 
1.72E-03 8.62E-04 3.135 3.897 4.460 
3.57E-03 7.14E-04 3.131 3.897 4.456 
5.56E-03 5.56E-04 3.131 3.897 4.454 
 
 1H NMR (700 MHz, 273 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 


















 Fitting of experimental data (circles) with the 1:1 model (dashed line) corresponding to the 









5 H3 H1 
0.00E+00 1.00E-03 3.291 3.580 4.560 
1.97E-04 9.84E-04 3.244 3.569 4.534 
3.88E-04 9.69E-04 3.200 3.559 4.512 
4.81E-04 9.62E-04 3.192 3.556 4.504 
5.73E-04 9.54E-04 3.179 3.551 4.495 
7.52E-04 9.40E-04 3.174 3.550 4.492 
9.26E-04 9.26E-04 3.160 3.545 4.483 
1.72E-03 8.62E-04 3.128 3.532 4.459 
3.57E-03 7.14E-04 3.102 3.516 4.433 
5.56E-03 5.56E-04 3.095 3.508 4.421 
 
 1H NMR (700 MHz, 293 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 








5 H3 H1 
0.00E+00 1.00E-03 3.283 3.575 4.558 
1.97E-04 9.84E-04 3.222 3.561 4.523 
3.88E-04 9.69E-04 3.172 3.549 4.496 
4.81E-04 9.62E-04 3.156 3.545 4.486 
5.73E-04 9.54E-04 3.139 3.540 4.477 
7.52E-04 9.40E-04 3.134 3.538 4.473 
9.26E-04 9.26E-04 3.120 3.534 4.464 
1.72E-03 8.62E-04 3.090 3.521 4.441 
3.57E-03 7.14E-04 3.078 3.506 4.419 
5.56E-03 5.56E-04 3.077 3.498 4.410 
 
 1H NMR (700 MHz, 288 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 








5 H3 H1 
0.00E+00 1.00E-03 3.282 3.556 4.556 
1.97E-04 9.84E-04 3.196 3.539 4.511 
3.88E-04 9.69E-04 3.132 3.526 4.478 
4.81E-04 9.62E-04 3.109 3.521 4.468 
5.73E-04 9.54E-04 3.085 3.517 4.458 
7.52E-04 9.40E-04 3.080 3.515 4.455 
9.26E-04 9.26E-04 3.067 3.511 4.446 
1.72E-03 8.62E-04 3.047 3.499 4.426 
3.57E-03 7.14E-04 3.054 3.485 4.409 
5.56E-03 5.56E-04 3.064 3.479 4.401 
 
 1H NMR (700 MHz, 283 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 








5 H3 H1 
0.00E+00 1.00E-03 3.271 3.542 4.547 
1.97E-04 9.84E-04 3.147 3.522 4.488 
3.88E-04 9.69E-04 3.052 3.508 4.447 
4.81E-04 9.62E-04 3.031 3.504 4.436 
5.73E-04 9.54E-04 3.015 3.500 4.427 
7.52E-04 9.40E-04 3.011 3.498 4.424 
9.26E-04 9.26E-04 3.004 3.495 4.417 
1.72E-03 8.62E-04 3.006 3.485 4.405 
3.57E-03 7.14E-04 3.019 3.472 4.395 
5.56E-03 5.56E-04 3.042 3.465 4.391 
 
 1H NMR (700 MHz, 273 K) chemical shifts (ppm) of a 1 mM solution of β-Man in CD2Cl2 







 Fitting of experimental data (circles) with 2:1 receptor-sugar model (dashed line) 
corresponding to the 1H NMR titration of SCR001 with β-Man at A) 298 K, B) 293 K, C) 288 K, D) 283 
K and E) 273 K. 
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1.4. Complete Table of Binding Constants 
Table S1. Complete table of association (Ka) and dimerization (Kd) constants of the receptors (SCR001- SCR007, SCR012) with the 
pyranosides determined from NMR titrations in in CD2Cl2 at different temperatures.[a,b] 
Receptor Temp.(K) 
β−Glc α−Glc β−Man α−Man β−Gal Dilution 
K1 (M−1) K2 (M−1) K1 (M−1) K1 (M−1) K2 (M−1) K1 (M−1) K2 (M−1) K1 (M−1) Kd (M−1) 
SCR001 298 1.3 x 103 — 3.6 x 102 1.2 x 103 3.0 x 101 c 1.4 x 103 —g 3.5 x 102 1.4 x 101 
SCR001 293 —h —h —h 1.5 x 103 3.5 x 101 c —h —h —h —h 
SCR001 288 —h —h —h 2.2 x 103 4.1 x 101 c —h —h —h —h 
SCR001 283 —h —h —h 1.8 x 104 4.7 x 101 c —h —h —h —h 
SCR001 273 —h —h —h 2.1 x 104 6.3 x 101 c —h —h —h —h 
SCR002 298 9.6 x 101 —g —e 5.4 x 101 —g 1.1 x 102 —g —e —e 
SCR003 298 4.8 x 101 —g —e —e — 1.4 x 102 —g —e —e 
SCR004 298 2.3 x 103 —g 6.8 x 102 5.9 x 102 —g 4.4 x 103 —g 5.5 x 102 —e 
SCR005 298 1.7 x 103 —g 2.7 x 103 2.4 x 103 —g 3.0 x 103 —g 4.2 x 103 1.9 x 103 
SCR006 298 1.1 x 102 —g 1.1 x 102 3.7 x 101 —g 2.0 x 102 —g 3.0 x 101 —e 
SCR007 298 —f — —f —f — —f — —f —e 
SCR012 298 2.6 x 103 —g 8.1 x 103 1.7 x 103 — 2.6 x 103 —g 1.8 x 103 —f 
SCR012 293 —h —h —h 2.4 x 103 —h —h — —h —h 
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SCR012 288 —h —h —h 5.6 x 103 —h —h — —h —h 
SCR012 283 —h —h —h 1.4 x 104 —h —h — —h —h 
SCR012 273 —h —h —h 1.2 x 105 —h —h — —h —h 
SCR017 298 1.2 x 10
0
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SCR021 298 2.7 x 10
0













SCR022 298 1.2 x 10
2



























[a] Titrations were done in triplicate for SCR012•β-Man, and the standard deviation of Ka was 3.2 x 102 M−1 (15% error). [b] All Kas are based on 1:1 
binding models that also consider Kd when appropriate. [c] Kas involving a 2:1 SCR•glycan binding model where K1 and K2 correspond to 1:1 and 
2:1 SCR•glycan association constants, respectively. [d] Kas involving a 1:2 SCR•glycan binding model where K1 and K2 correspond to 1:1 and 1:2 
SCR•glycan association constants, respectively. [e] No detectable binding/dimerization above the threshold of Ka = 3.0 x 101 M‒1. [f] No NMR peak 




1.5. Van’t Hoff Analysis 
 
  Van’t Hoff plot for binding of β-Man to SCR001. 
 
 
 Van’t Hoff plot for binding of β-Man to SCR012. 
  
y = 10.844x - 29.457
R² = 0.8416














ΔHo = ‒21.6 (kcal mol‒1)
ΔSo = ‒58.5 (e.u.)
K2
ΔHo = ‒4.8 (kcal mol‒1)
ΔSo = ‒9.4 (e.u.)

















 ΔHo = ‒28.45 (kcal mol‒1) 
 ΔSo = ‒81.28 (e.u.) 
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1.6. 2D NMR Experiments 
To identify the protons of the guest involved in binding, 1H‒1H COSY NMR was taken for β-Man alone.  
1H‒1H COSY NMR was also taken for the SCR012•β-Man to assign the protons of the guest as there were 
some shift in the chemical shift for some protons.  
 
 1H‒1H 2D DQF COSY spectrum (700 MHz, CD2Cl2, 268 K) of β-Man (5.6 mM) showing 




 1H‒1H 2D DQF COSY spectrum (800 MHz, CD2Cl2, 298 K) of β-Man (5.6 mM) showing 
the protons assigned. 
 
 1H‒1H 2D DQF COSY spectrum (700 MHz, CD2Cl2, 268 K) of SCR012 (5.6 mM) showing 




 1H‒1H 2D DQF COSY spectrum (800 MHz, CD2Cl2, 298 K) of SCR012 (5.6 mM) showing 
the protons assigned.  
 
 1H‒1H 2D DQF COSY spectrum (800 MHz, CD2Cl2, 268 K) of 1:1 mixture of SCR012 




 1H‒1H 2D DQF COSY spectrum (700 MHz, CD2Cl2, 298 K) of 1:1 mixture of SCR012 
(5.6 mM) and β-Man (5.6 mM) showing the protons assigned.  
 
The SCR012•β-Man complex geometry was analyzed by 2D NOESY with a mixing time of 300 
ms showing the contacts between SCR012 (5.6 mM) and β-Man (5.6 mM). Residual solvent signal 




 1H‒1H 2D NOESY full spectrum (700 MHz, CD2Cl2, 263 K) of SCR012 (5.6 mM) 
showing the intramolecular contacts between the host protons. 
 
 1H‒1H 2D NOESY full spectrum (700 MHz, CD2Cl2, 298 K) of SCR012 (5.6 mM) 





 700 MHz 2D 1H‒1H NOESY partial spectra of SCR012 (5.6 mM in CD2Cl2) and β-Man 
(5.6 mM in CD2Cl2) with expanded spectral regions showing the intermolecular contacts between host and 

































































 Schematic representation of 1H-1H NOESY intermolecular contacts of SCR012 (5.6 mM 




Table S2. 700 MHz 1H‒1H NOE interactions for SCR012•β-Man complex at 268 K. 
 Intensity 
Qualifier From To 
Weak 21630 58120 
Medium 58120 94610 
Strong 94610 131100 
 
SCR012 SCR012 Intensity   SCR012 β-Man Intensity SCR012 SCR012 Intensity 
Hc Hd Strong   Ha H1 Strong Hc Hd Strong 
Hm,v Hl,u Strong   Hb H1 Strong Hm,v Hl,u N/A 
Hj,s Ho,x Strong   Hm,v H1 Medium Hj,l,s,u Ho,x N/A 
Hl,u Ho,x Strong   Hn,w H1 Medium Hr Hs N/A 
Hr Hs Strong   Ho,x H1 Strong Hg Hj N/A 
Hg Hj Strong   Hr H1 Weak Hq Hs N/A 
Hq Hs Strong   Hq H1 Weak Hi Hj N/A 
Hi Hj Strong   Hi H1 Weak Hd He Strong 
Hd He Strong   He H1 Weak He Hf Strong 
He Hf Strong   Ha H2 Strong Hf Hg Strong 
Hf Hg Strong   Hb H2 Strong Hf Hh Strong 
Hf Hh Strong   Ho,x H2 Strong Ho,x Hn,w  Strong 
Ho,x Hn,w  Strong   Hg H2 Weak    
    Hr H2 Strong    
    Hq H2 Strong    
    Hi H2 Medium    
    Hm,v H6’ Strong    
    Hn,w H6’ Strong    
    Ho,x H6’ Strong    
    Hg H6’ Strong    
    He H6’ Strong    
    Hm,v H4,6 Strong    
    Hn,w H4,6 Strong    
    Ho,x H4,6 Strong    
    He H4,6 Strong    
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    Hi H3,7 Strong    
    Ha H5 Strong    
    Hn,w H5 Weak    
    Ho,x H5 Strong    
    Hg H5 Weak    
    Hr H5 Medium    
    Hh,q H5 Strong    
    Hi H5 Strong    
 
2.4.8. Computational Modelling Data 
The initial screening of the guest-host conformational space has been carried out with Maestro 
software.5 The mixed torsional/low-mode sampling algorithm augmented with torsional mutation has been 
employed. The calculations have been done using Amber* force field in a medium with dielectric constant 
of 4.8 to account for the non-polar solvent. Extended cutoffs of 8.0 Å, 20.0 Å and 4.0 Å for van der Waals, 
electrostatic and hydrogen-bond potentials, respectively, have been used. A window of 50 kJ/mol and 
maximum atom deviation of 0.5 Å to eliminate redundant conformers were set to collect resulting 
structures. A probability of 0.5 for a torsional angle mutation during a structure generation was set. 
The screening has been done twice for unconstrained complex and once for constrained search where 
additional restraints derived from the 2D NMR study were added. In details, we set restraining force of 
200.0 kcal/(mol*Å2) at a distance of 4.0 Å between following hydrogen pairs: 
H1-Ha, H2-Hb, H4-Hr. All structures resulting from these searches have been exported and clustered with a 
RMSD cutoff between heavy atoms of 0.2 Å to yield 117 unique structures. Furthermore, two additional 
searches starting from a structure selected from these 117 conformers that featured closest H1/H2-Ha/Hb 
contacts were carried out. We performed one unconstrained and one constrained search using the same 
setup as in the previous search.  
Next, the resulting structures were clustered and RMS distance between closest hydrogen atoms involved 
in each contact visible in the 2D NMR study was calculated. From both searches, we selected 20 structures 
that yielded the smallest RMS distance. These structures were added to other 117 unique conformations 
and subjected to density-functional calculations in FHI-aims code.6 
The geometry optimizations were performed using PBE exchange-correlation functional7 augmented with 
long-range dispersion-correction vdWTS 8 in light basis set settings. The calculations were carried out in a 
gas-phase using loose 0.005 eV/Å maximum force convergence criterion for geometry optimization. The 





For the receptor itself, we performed one unconstrained search using the same settings as for the complex. 
The resulting 367 structures were clustered (RMSD=0.2Å cutoff) and 67 unique structures were subjected 
to geometry optimization in FHI-aims using same setup. The lowest energy structure was more stable by 
27 kJ/mol than the following conformer. All graphics have been prepared with PyMol software.9 
Table S3. Intermolecular H−H distances (Å) calculated for the lowest energy structure of SCR012•β-
Man complex. 
  Ha Hb Hc Hd He Hg Hh Hi Hq Hr Ho,x Hm,v Hn 
H1 7.89 6.89 7.08 8.91 7.83 4.94 5.40 3.15 4.39 6.26 2.87 5.03 5.21 
H2 5.79 4.61 5.19 7.33 6.56 5.60 4.10 3.56 2.22 4.89 4.22 7.02 6.51 
H3 6.92 5.09 4.62 6.25 5.11 3.64 3.12 3.73 3.01 5.63 5.07 7.56 6.78 
H4 8.43 6.25 6.38 6.42 7.01 5.65 5.82 6.37 5.14 3.76 2.48 4.92 4.84 
H5 9.19 7.52 7.18 8.31 7.32 3.70 5.48 4.25 5.34 6.43 4.55 6.03 6.21 
H6 10.93 8.81 8.36 8.39 8.19 4.84 7.11 6.74 7.20 6.55 2.67 6.14 5.14 




1.7. Theoretical Modeling.  
The search protocol for finding the minimum-energy binding structures involved the following steps: 
1.7.1. The initial sampling of the conformational space has been performed using a replica-exchange 
molecular dynamics10 (REMD) protocol implemented in Gromacs-2018.2.11 First, the 
parameters for 8 SCRs and 5 sugars were derived from a CHARMM36 force field12 using the 
charmm-gui web-interface13 and combined into 40 SCR•glycan complexes. Initial hand-
generated conformations were first equilibrated in the gas phase for 1 ns at 300 K, controlled 
by a v-rescaling thermostat,14 and the final structure was used as a starting geometry for REMD 
simulations. Each complex involved 16 replicas distributed in 300-400 K temperatures 
according to the Monte-Carlo criteria.15 The temperatures were chosen to yield an exchange 
rate of 0.65. The trajectories were simulated for a 500 ns each, with a 1 fs time step and an 
attempted exchange between trajectories neighboring in temperature space every 10 ps.  
1.7.2. Each 300 K trajectory was subsampled every 100 ps to generate a set of initial structures visited 
during the simulations. The structures were then clustered using a single linkage algorithm with 
a loose 2.5 Å cutoff for root means square deviations (RMSD) between all atoms. In several 
cases in which the supramolecular complex was found dissociated at 300 K, we restarted the 
REMD from a different equilibrated structure. The clustering unraveled that some complexes 
(for instance SCR018•β-Man or SCR019•β-Gal) occupy only several conformational basins, 
while other (SCR022•α-Man or SCR020•α-Glc) visit numerous lowly populated states. The 
overall distribution of cluster sizes and RMSD of the 20 most abundant clusters for each 
complex is shown in Figure S197. For each system we collected central structures of the 20 
most abundant clusters, which were used as starting geometries for subsequent density-
functional theory calculations.  
1.7.3. The central structures of the most abundant complexes were next geometry-optimized using 
dispersion-corrected Generalized-Gradient Approximation DFT, PBE+vdWTS 7-8 and light 
settings for a basis set, as implemented in FHI-aims numerical atomic orbitals code.6 Although 
the PBE functional, placed on the second rung of the Jacob’s ladder, does not include the exact-
exchange term in the functional form, as for instance B3LYP, it provides significant 
computational speed-up over more popular hybrid DFT methods suitable for screening of the 
molecular conformational space. Furthermore, the vdWTS parameter-free dispersion correction 
has been successfully applied to bioorganic systems that require delicate balance between 
dispersion and electrostatic interactions.16-18 The potential energy of the geometry-optimized 




1.7.4. To account for the solvent effects, we computed each conformer’s solvation energies in CH2Cl2 
using the SMD continuous solvation model19 available in Gaussian16 rev.D01 code.20 This 
model computes solvation energy from electrostatic interactions and appends it by dispersion 
and entropic terms. It has been shown to yield excellent solvation energies of small molecules 
in aqueous solution21 and best performance among other implicit in non-aqueous solvents22 The 
single-point energy of a complex in a gas-phase and in a solvent model were computed using 
PBE1PBE+D3/def2-SVP level of theory. The difference between these two values was adopted 
as a conformational-dependent solvation energy correction and added to the PBE+vdWTS 
potential energy.  
To evaluate whether sampling of the trajectory using REMD limited to 20 largest cluster is sufficient, 
we compared the lowest DFT-energy of five SCR•β-Man complexes (SCR018-022) with the lowest energy 
structures found among 638 conformations generated from low-mode dynamics, as implemented in 
MAESTRO5 Macromodel software, and reoptimized them at the respective DFT level of theory. The 
lowest-energy conformers found during REMD sampling were, after DFT-optimizations, on average 5.7 
kcal mol-1 more stable than those found in low-mode dynamics, which confirms that the REMD protocol 
appropriately samples the conformational space. The same search strategy was applied to derive solvation-
corrected energies of free receptors. The most stable structures of free receptors were dominated by 
compact, dispersion-stabilized conformers that featured symmetry elements. For carbohydrates, the 4C1 
ring-puckering, is the most stable conformations in a gas phase, and a fully extended C1-octyloxy chain 
was assumed. Finally, for the analysis we defined binding energy (ΔE) as a difference between energy of 
the complex (Ecomplex) and energies of relaxed SCR (E°SCR) and glycan (E°G): 
ΔE = Ecomplex – E°SCR – E°G 
 
In addition, we defined interaction energy between two sugars (ΔEsug-sug) as a difference between energy of 
the two sugars in the binding geometry (Ess) and the energy of each sugar individually (Es1, Es2):  





































1.8. Anti Zika Studies 
1.8.1. Zika reporter virus particles  
The codon optimized version of ZIKV C-prM-E construct has been described previously23 and was 
synthesized using the complete ZIKV sequence available from the current outbreak in Americas (accession 
number KU312312.1).24 The C-prM-E variant lacking the E-glycosylation site N154Q was constructed by 
site directed mutagenesis using forward primer 5'-agcggcatgatcgtccaggacaccggccacgag-3' and reverse 
primer 5'-ctcgtggccggtgtcctggacgatcatgccgct-3' using the Quick Change II XL site directed mutagenesis kit 
(Stratagene). The entire C-PrM-E region was sequenced to verify the presence of the mutations and 
authenticity of insert.  ZIKV RVPs were generated using the protocol described below. 293T cells stably 
expressing the Zika virus CprME (293T-CPrME-F6) and described previously23 were transfected with the 
plasmid containing the sub-genomic GFP expressing replicon derived from lineage II strain of WNV.25 For 
generation of N154Q RVPs, 293T cells were transfected with plasmids C-PrME-N154Q and sub-genomic 
GFP replicon at a ratio of 1:1. Transfections were performed using the Turbofect transfection reagent 
(ThermoFisher) strictly following the manufacturer’s recommendations. The RVPs were harvested 48 h 
post-transfection, aliquoted, and stored for future use.  
1.8.2. Titration of RVPs 
Vero cells were plated in 96 well, clear bottom black plates at 5,000 cells per well. Serial 2-fold dilutions 
of RVPS were prepared in DMEM-10 medium and added to Vero cells starting with the highest dose of 50 
µl/well. For each RVP dilution, infections were conducted in duplicates/triplicates and cells incubated with 
RVPs for 72 h. Thereafter, the plates were fixed with 4% formalin/PBS and images of whole wells acquired 
using the Cytation 5 imaging system (BioTek). The number of GFP+ cells were counted using the Gen5 
imaging software which provides a read out of the number of GFP-positive cells per well. The optimal virus 
dose for infection experiments was then determined from the titration curves.  
1.8.3. Inhibition of Zika infection using synthetic carbohydrate receptors 
Vero and HeLa cells were obtained from ATCC, and cultured in DMEM supplemented with 10% FBS and 
Penicillin, streptomycin, and Glutamine. Cells were plated in 96 well, clear bottom black plates at 5,000 
cells per well. Stock solutions of the compounds were made in DMSO at 10 mM concentration. Further 
dilutions of the compounds were made in cell culture media. Different compounds were added at the 
indicated concentrations in duplicates/triplicates and cells incubated with the compounds for 30 min at 
room temperature.  Thereafter, a predetermined amount of Zika RVPs that yields up to 1000 GFP+ cells per 




the compounds and infected with Zika RVPs, were used as normalization control for determination of 100% 
infection. Plates were incubated for 72 h at 37 °C, after which images acquired using the Cytation5 imaging 
system (BioTek). The experiment was repeated 3 times and inhibition curves were generated for each 
experiment using the Sigma plot software and 50% inhibitory concentration (IC50) value for each compound 
were determined.  
1.8.4. Inhibition studies with infectious ZIKV, PRVABC59  
The ZIKV isolate PRVABC59 derived from a human serum specimen from Puerto Rico in December 2015 
was obtained from ATCC and propagated in Vero cells following the manufacturer’s recommendations. The 
virus stocks were titrated in Vero cells using fluorescent microscopy. Briefly, Vero cells were infected with 
serial dilutions of the virus stocks and cells fixed with 4% formaldehyde/PBS 48 hr post infection. 
Subsequently cells were stained using 4G2 antibody (MAB10216, Millipore) followed by Alexa 488 
conjugated secondary antibody (Invitrogen). Images for the whole wells were acquired on Cytation 5 
imaging reader and number of GFP+ cells per well quantified using Gen5 Software. For subsequent 
experiments, a predetermined amount of virus that yields ~2000-3000 GFP+ cells per well was used. 
For compound inhibition studies with infectious virus, Vero cells were plated in 96 well, clear bottom black 
plates at 7,500 cells per well. Cells were incubated with different concentrations of the SCRs for 30 min at 
room temperature as indicated above. Cells were then infected with a pre-determined amount of ZIKV 
PRVABC59 isolate that yields ~2000-3000 GFP+ cells per well determined from titration curves above. 
Thereafter, cells were fixed and number of infected cells determined via 4G2 antibody staining followed 
by Cytation5 imaging as above. The experiment was conducted in triplicate wells and the entire experiment 
was repeated.  
1.8.5. Determination of cellular toxicity  
Vero or HeLa cells were plated in 96 well clear bottom white plates at 5,000 cells per well. Different 
compounds were added at the indicated concentrations in duplicates, and the cells were incubated for 72 h 
at 37 °C. Cellular toxicity was measured using the CellTiter- Glo (Promega) luminescent viability assay 
that is based on quantitation of the ATP in cells, an indicator of metabolically active cells. Data was 
normalized to cells treated with DMSO as being 100% viable. Toxicity curves were generated using the 
Sigma plot software by fitting curves using Sigmoidal logistic 4 Parameter non-linear regression and TC50 




1.8.6. Time of addition experiments  
ZIKV virus RVP inhibition assays in Vero cells were conducted as described above, with slight 
modification. Cells were infected with a pre-determined amount of ZIKV RVPs in a volume of 95 µl and 
the compounds were added either 30 min prior to infection or 4 h or 24 h post-infection in a volume of 5 
µl. The plates were fixed 72 h post infection, and the number of GFP+ cells per well were determined using 
the Cytation5 imaging system. 
 
 SCR-mediated inhibition of Zika infection and toxicity in Vero cells. (A) Vero cells 
were treated with the indicated SCRs for 30 min at room temperature followed by infection with Zika RVPs. 
The number of GFP positive cells per well was quantified after imaging of whole wells via the Cytation5 
imager. (B) Toxicity of SCRs in Vero cells. Vero cells were treated with the indicated SCRs and the cells 
were incubated for 72 h at 37 °C. Cellular toxicity was measured using the CellTiter- Glo (Promega) 
luminescent viability assay. Data are mean of duplicate observations. One representative of three 





 SCR-mediated inhibition of Zika infection and toxicity in HeLa cells. (A) HeLa cells 
were treated with the indicated SCRs for 30 min at room temperature followed by infection with Zika RVPs. 
The number of GFP positive cells per well was quantified after imaging of whole wells via the Cytation5 
imager. (B) Toxicity of SCRs in HeLa cells. HeLa cells were treated with the indicated SCRs and the cells 
were incubated for 72 h at 37 °C. Cellular toxicity was measured using the CellTiter- Glo (Promega) 
luminescent viability assay. Data are mean of duplicate observations. One representative of three 
independent experiments is shown. 
 
 Titration of infectious Zika virus-RPVABC59 in Vero cells. Vero cells were infected 
with serial dilutions of the virus stocks and cells were fixed 48 hrs post infection. Subsequently, cells were 
stained using 4G2 antibody. Images for the whole wells were acquired on Cytation 5 imaging reader and 






1. Rieth, S.; Miner, M. R.; Chang, C. M.; Hurlocker, B.; Braunschweig, A. B., Saccharide receptor 
achieves concentration dependent mannoside selectivity through two distinct cooperative binding 
pathways. Chem. Sci. 2013, 4, 357-367. 
2. Feng, Y.; Li, J.; Jiang, L.; Gao, Z.; Huang, W.; Jiang, F.; Luo, N.; Han, S.; Zeng, R.; Yang, D., 
Efficient Syntheses and Complexation Studies of Diacetylene-Containing Macrocyclic Polyethers. Eur. J. 
Org. Chem. 2011, 2011, 562-568. 
3. Ammann, C.; Meier, P.; Merbach, A., A simple multinuclear NMR thermometer. Journal of 
Magnetic Resonance (1969) 1982, 46, 319-321. 
4. Palanichamy, K.; Bravo, M. F.; Shlain, M. A.; Schiro, F.; Naeem, Y.; Marianski, M.; 
Braunschweig, A. B., Binding Studies on a Library of Induced‐Fit Synthetic Carbohydrate Receptors with 
Mannoside Selectivity. Chem.: Eur. J. 2018, 24, 13971-13982. 
5. Schrödinger Release 2019-4: MacroModel, S., LLC, New York, NY, 2019. 
6. Blum, V.; Gehrke, R.; Hanke, F.; Havu, P.; Havu, V.; Ren, X.; Reuter, K.; Scheffler, M., Ab initio 
molecular simulations with numeric atom-centered orbitals. Comput. Phys. Commun. 2009, 180, 2175-
2196. 
7. Perdew, J. P.; Burke, K.; Ernzerhof, M., Generalized Gradient Approximation Made Simple. Phys. 
Rev. Lett. 1996, 77, 3865-3868. 
8. Tkatchenko, A.; Scheffler, M., Accurate Molecular Van Der Waals Interactions from Ground-State 
Electron Density and Free-Atom Reference Data. Phys. Rev. Lett. 2009, 102, 073005. 
9. Schrödinger, L., The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC (2017). 
Google Scholar There is no corresponding record for this reference. 
10. van der Spoel, D.; Seibert, M. M., Protein Folding Kinetics and Thermodynamics from Atomistic 
Simulations. Phys. Rev. Lett. 2006, 96, 238102. 
11. Abraham, M. J.; Murtola, T.; Schulz, R.; Páll, S.; Smith, J. C.; Hess, B.; Lindahl, E., GROMACS: 
High performance molecular simulations through multi-level parallelism from laptops to supercomputers. 
SoftwareX 2015, 1-2, 19-25. 
12. Guvench, O.; Mallajosyula, S. S.; Raman, E. P.; Hatcher, E.; Vanommeslaeghe, K.; Foster, T. J.; 
Jamison, F. W.; MacKerell, A. D., CHARMM Additive All-Atom Force Field for Carbohydrate Derivatives 
and Its Utility in Polysaccharide and Carbohydrate–Protein Modeling. J. Chem. Theory Comput. 2011, 7, 
3162-3180. 
13. Lee, J.; Cheng, X.; Swails, J. M.; Yeom, M. S.; Eastman, P. K.; Lemkul, J. A.; Wei, S.; Buckner, 
J.; Jeong, J. C.; Qi, Y.; Jo, S.; Pande, V. S.; Case, D. A.; Brooks, C. L.; MacKerell, A. D.; Klauda, J. B.; 




CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. J. Chem. Theory Comput. 
2016, 12, 405-413. 
14. Bussi, G.; Donadio, D.; Parrinello, M., Canonical sampling through velocity rescaling. J. Chem. 
Phys. 2007, 126, 014101. 
15. Patriksson, A.; van der Spoel, D., A temperature predictor for parallel tempering simulations. 
PCCP 2008, 10, 2073-2077. 
16. Tkatchenko, A.; Rossi, M.; Blum, V.; Ireta, J.; Scheffler, M., Unraveling the Stability of 
Polypeptide Helices: Critical Role of van der Waals Interactions. Phys. Rev. Lett. 2011, 106, 118102. 
17. Marom, N.; Tkatchenko, A.; Rossi, M.; Gobre, V. V.; Hod, O.; Scheffler, M.; Kronik, L., 
Dispersion Interactions with Density-Functional Theory: Benchmarking Semiempirical and Interatomic 
Pairwise Corrected Density Functionals. J. Chem. Theory Comput. 2011, 7, 3944-3951. 
18. Marianski, M.; Supady, A.; Ingram, T.; Schneider, M.; Baldauf, C., Assessing the Accuracy of 
Across-the-Scale Methods for Predicting Carbohydrate Conformational Energies for the Examples of 
Glucose and α-Maltose. J. Chem. Theory Comput. 2016, 12, 6157-6168. 
19. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G., Universal Solvation Model Based on Solute 
Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and 
Atomic Surface Tensions. J. Phys. Chem. B 2009, 113, 6378-6396. 
20. Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; Cheeseman, J. R.; 
Scalmani, G.; Barone, V.; Petersson, G. A.; Nakatsuji, H.; Li, X.; Caricato, M.; Marenich, A. V.; Bloino, 
J.; Janesko, B. G.; Gomperts, R.; Mennucci, B.; Hratchian, H. P.; Ortiz, J. V.; Izmaylov, A. F.; Sonnenberg, 
J. L.; Williams; Ding, F.; Lipparini, F.; Egidi, F.; Goings, J.; Peng, B.; Petrone, A.; Henderson, T.; 
Ranasinghe, D.; Zakrzewski, V. G.; Gao, J.; Rega, N.; Zheng, G.; Liang, W.; Hada, M.; Ehara, M.; Toyota, 
K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.; Nakai, H.; Vreven, T.; 
Throssell, K.; Montgomery Jr., J. A.; Peralta, J. E.; Ogliaro, F.; Bearpark, M. J.; Heyd, J. J.; Brothers, E. 
N.; Kudin, K. N.; Staroverov, V. N.; Keith, T. A.; Kobayashi, R.; Normand, J.; Raghavachari, K.; Rendell, 
A. P.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Millam, J. M.; Klene, M.; Adamo, C.; Cammi, 
R.; Ochterski, J. W.; Martin, R. L.; Morokuma, K.; Farkas, O.; Foresman, J. B.; Fox, D. J. Gaussian 16 
Rev. D.01, Wallingford, CT, 2016. 
21. Marenich, A. V.; Cramer, C. J.; Truhlar, D. G., Performance of SM6, SM8, and SMD on the 
SAMPL1 Test Set for the Prediction of Small-Molecule Solvation Free Energies. J. Phys. Chem. B 2009, 
113, 4538-4543. 
22. Zhang, J.; Zhang, H.; Wu, T.; Wang, Q.; van der Spoel, D., Comparison of Implicit and Explicit 
Solvent Models for the Calculation of Solvation Free Energy in Organic Solvents. J. Chem. Theory Comput. 




23. Garg, H.; Sedano, M.; Plata, G.; Punke, E. B.; Joshi, A., Development of Virus-Like-Particle 
Vaccine and Reporter Assay for Zika Virus. J. Virol. 2017, 91, e00834-00817. 
24. Enfissi, A.; Codrington, J.; Roosblad, J.; Kazanji, M.; Rousset, D., Zika virus genome from the 
Americas. The Lancet 2016, 387, 227-228. 
25. Pierson, T. C.; Sánchez, M. D.; Puffer, B. A.; Ahmed, A. A.; Geiss, B. J.; Valentine, L. E.; 
Altamura, L. A.; Diamond, M. S.; Doms, R. W., A rapid and quantitative assay for measuring antibody-
mediated neutralization of West Nile virus infection. Virology 2006, 346, 53-65. 
 
